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CHAPTER 1: INTRODUCTION
Conventional imaging modalities, such as radiography, ultrasound, computed
tomography (CT), and magnetic resonance imaging (MRI) have been used for years to
identify and characterize many diseases, including cancer, based on anatomic
differences in tissue density, their shape, size, and water content(1). Recently, with the
advent of functional imaging modalities, clinicians have been able to characterize
diseases based on changes at the molecular level(1). Positron emission tomography
(PET) imaging is used clinically and for translational research to study these molecular
mechanisms. In the clinic, PET has shown utility in diagnosing and staging cancer,
assisting in radiotherapy treatment planning, and monitoring chemotherapy(2).
Preclinically, PET has been used in small animal research where new molecular probes
are employed to target, detect, and visualize processes associated with cancer.
1.1 Overview of Positron Emission Tomography (PET)
PET is a non-invasive imaging modality where a small mass of radioactive tracer
is injected into the patient, and through a series of reconstruction algorithms, an image
portraying specific tissue uptake of the tracer is displayed. First, a probe (a small
molecule, antibody, or peptide) with an affinity for the molecular target is labeled with a
positron emitting radioisotope. A table of common isotopes and their half-lives can be
found in Table 1. Matching the physical and biological half-lives of the PET nuclide and
the target probe, respectively, ensures that the probe accumulates in the tumor before
the radioactivity decays and allows clearance from normal tissues. In this regard,
enhanced signal-to-noise ratio – one of the primary considerations in diagnostic imaging
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– is achieved.
Isotope

Half-Life

O-15

122.24 s

N-13

9.97 m

C-11

20.4 m

F-18

110 m

Cu-64

12.7 h

Y-86

14.72 h

Br-76

16.2 h

Ga-68

68.1 h

Zr-89

78.4 h

I-124

4.18 d

Table 1. Possible PET radioisotopes and their half-lives.
A patient is injected with the probe, and as the radionuclide decays it emits
positrons that annihilate with electrons within the tissues producing two coincident
photons that emit energy at 511 keV. Ring detectors made of scintillation crystals
positioned around the subject pick up on the coincident photons and process their spatial
location, energy, and arrival time, and through a series of reconstruction algorithms a final
image is produced (Fig. 1)(3).
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Figure 1. Principles of PET imaging. Upon decay, the radionuclide emits positrons that
meet with electrons within the tissue that produces two gamma photons of 511 keV. This
research was originally published in Angewandte Chemie Internaltional Edition. Philip W.
Miller, Nicholas J. Long, Ramon Vilar, et al. Synthesis of 11C, 18F, 15O, and 13N
Radiolabels for Positron Emission Tomography. 2008;47(47):36.
Several tracers are currently approved by the Food and Drug Administration (FDA)
which target metabolism, proliferation, hypoxia, but the most common PET probe for
cancer is 18F-fludeoxyglucose (FDG). FDG is chemically known as 2-deoxy-2-(18F)fluoroD-glucose, which is an analog of glucose consumed by tissues in the body. Uptake of the
tracer marks tissues scavenging for glucose, which is abundant in proliferating tumors.
Since 2000, there has been a nine-fold increase in the number of FDG-PET scans
performed in the U.S., possibly driven by the enhanced sensitivity and specificity of PET
as compared to other imaging modalities(4). In 2011 it was estimated that 1.8 million
FDG-PET scans were performed, with 94% of the scans for cancer patients(1). It is
increasingly being used to assess therapeutic response and tumor biology, although a
disadvantage is its background uptake in normal, high glucose-consuming tissues (brain,
muscle), in situations where tumors lack metabolic activity, and lack of avidity for the
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tracer. Additionally, FDG-PET is a non-specific tracer, and is unable to stratify patients
who would benefit from a particular molecular treatment. Therefore, efforts have been
made to develop tracers that target intracellular and cell-surface receptors that are
uniquely expressed or overexpressed in cancer. In order to target these PET nuclides to
receptors present on tumors, carriers in the form of small molecules, peptides, or
antibodies must be linked to the nuclide and are employed to enhance the signal-to-noise
ratio of the target to background uptake.
The research described throughout this dissertation solely focuses on the use of
antibody-based tracers. The following section was adapted in full with permission from
the Journal of Labelled Compounds and Radiopharmaceuticals “89Zr-ImmunoPET
companion diagnostics and their impact in clinical drug development” by Brooke N.
McKnight and Nerissa T. Viola-Villegas, volume 61, issue 9(5).
1.1.1 ImmunoPET Tracer Development
Therapeutic monoclonal antibodies (mAbs) gained clinical utility in 1985 with the
first FDA approval of the biologic, muromonab-CD3 (Orthoclone OKT3), specific for
cluster of differentiation 3 (CD3), a co-receptor present on all T-cells(5). Since then,
applications in cancer have been exploited with the approval of rituximab (Rituxin®) in
1997(6) followed by trastuzumab (Herceptin®) in 1998(7). By 2016, there were 24
monoclonal antibodies (mAbs) and antibody drug conjugates (ADC) approved by the FDA
for cancer treatment. These mAbs are directed to a specific target ranging from tumor
and cell-surface associated antigens to biomarker signatures within the tumor
microenvironment. Despite their specificity and moderate safety profile, clinical efficacy
of these mAbs remains limited due to perpetuating factors, including but not limited to i)
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unpredictable tumor antigen density, ii) internalizing status of the mAb:antigen complex,
iii) the success at which the antibody reaches the target, iv) vascular penetration, and, v)
tissue distribution, which may impact adverse events (8–12). All of these factors
underscore the need for precision medicine, borne out of the intent of tailoring the disease
treatment and prevention by providing the right drug to the right patient at the appropriate
time and dose.
A logical approach to precision medicine explores non-invasive imaging tools that
can be repeatedly utilized to profile tumors at the molecular level, and to augment flaws
present in biopsies from tumor heterogeneity or poor sample quality. With this
perspective, antibody or immune-based positron emission tomography (immunoPET)
was developed to provide a direct readout of antigen density present within each lesion;
moreover, the pharmacokinetic and dosimetric properties of the mAb, in the case of
radioimmunotherapy, can be considered cognate when compared to the imaging tool(13).
Taken together, immunoPET has a high potential to influence and direct informed
decisions in drug design and development.
The development of immunoPET tracers relies on the following principles: i) the
biological and chemical properties of the mAb, ii) the radionuclide chosen iii) the chelate
selected, and iv) the stability of the linker between mAb and chelate. MAbs for patient
use are either humanized or made fully human to prevent human anti-mouse antibody
response (HAMA)(14). The size of full-length biologics (~150 kDa) prolongs their half-life
in the blood, which affects the time it takes to deliver to the tumor target and clearance
from healthy tissues. Thus, pairing mAbs with long-lived radionuclides
h),

86Y

(t1/2 ~ 14.7 h),

89Zr

(t1/2 ~ 78.4 h), and

124I

64Cu

(t1/2 ~ 12.7

(t1/2 ~ 100.3 h) is the most common
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strategy(15).
One limitation to using full mAbs specifically for imaging purposes is the long wait
times between tracer administration and imaging acquisition, as well as higher radiation
exposure of non-target organs. Tracer pharmacokinetics can be improved by decreasing
its size, effectively reducing circulation time, and minimizing dose exposure to the
patient(16). With this perspective, smaller fragment constructs are engineered offering
shorter blood residencies and faster tumor target delivery. These fragments mostly retain
the variable region where the antigen-binding site is primarily located. Suggested PET
radionuclide tags to complement mAb fragments are provided in Table 2. Moderatelysized fragments (i.e. F(ab)’2 (~100-110 kDa), minibody (~75 kDa), and diabody (~50
kDa)) may be appropriately labeled with

18F

(t1/2 ~ 109 min),

64Cu

(t1/2 ~ 12.7 h) and

86Y

(t1/2 ~ 14.7 h). Smaller-sized fragments like affibodies (~ 6 kDa), nanobodies or single
domain antibodies (~12-15 kDa) can be radiolabeled with shorter-lived isotopes like
and

68Ga

18F

(t1/2 ~ 68 min), which consequently decreases the radiation exposure of the

patient(17). The caveat herein lies in the overall rate of clearance and nuclide site delivery
of the mAb fragments.
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Antibody Fragments

Affibody (~7 kDa),
Nanobody (~12-15 kDa)

Recommended
PET Nuclide

References

68Ga
18F

(18–23)

64Cu

18F

Diabody (~55 kDa)

64Cu

(24–26)

89Zr

Minibody (~80 kDa)

64Cu

(27,28)

89Zr
64Cu

Fab’2 (~100-110 kDa)

89Zr

(29)

124I

Table 2. Different antibody fragments and recommended PET radionuclide for
companion diagnostic development
1.1.2 Zirconium-89 immunoPET tracers
Standardized production and commercial availability has made the development
of Zr-89 radiolabeled mAbs relatively straightforward(17). As a radiometal, Zr-89 requires
complexation to prevent random, non-specific binding to non-targeted tissue (usually the
bone), which consequently lowers contrast. To date, only desferrioxamine (DFO), a
known iron-sequestering siderophore with three hydroxamate groups is currently utilized
as a chelate despite reports of metal:complex in vivo instability(30,31). DFO
bioconjugation techniques were established either through non-specific attachment to
terminal lysines(32,33) and cysteines(34) or through a more discriminate glycan selective
labeling(35). A depiction of a mAb radiolabeled with
found in Figure 2.

89Zr

through a DFO linker can be

8

Figure 2. 89Zr labeled monoclonal antibody. mAbs are conjugated to DFO at the
terminal amine groups before undergoing radiolabeling with 89Zr. The figure only shows
one DFO conjugated to the antibody for clarity, but in reality there are often more DFO
molecules bound depending on the method of conjugation.
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Consequently, preclinical research flourished with many imaging probes
developed to target different oncogenic molecular signatures. A significant number of
these tracers were developed to target surface-bound biomarkers, such as i) members of
the epidermal growth factor receptor family (e.g. EGFR(36), HER2(37) and HER3(38)),
ii) prostate-specific membrane antigen (PSMA)(39), iii) prostate stem cell antigen
(PSCA)(28), iv) CD20(40), v) CD44(41), vi) programmed death receptor (PD1)(42) and
vii) programmed death ligand 1 (PD-L1)(43), to name a few. Imaging probes targeting
secreted

signaling

proteins

(e.g.

VEGF,

granzyme

B,

interferon-γ)(44–46),

antigen/receptors bound to T cells (e.g. CD3(47), CD8(48)) and shed antigens (e.g.
CA19.9(49), carcinoembryonic antigen or CEA(50)) were also investigated. With
substantial preclinical data, a number of these tracers have progressed to clinical trials.
The first study of a

89Zr-mAb

probe (89Zr-cmAb U36) targeting CD44v6 in patients with

head and neck cancer was reported in 2006(51). The number of 89Zr-based immunoPET
probes in the clinic tripled in 2013(30). As of this writing, to the best of our knowledge and
after extensive search at clinicaltrials.gov, there are ~46

89Zr-mAbs

that are currently

undergoing or have completed patient trials, none of which are FDA approved. An
overview of 89Zr-based immunoPET probes can be found in Table 3.
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ANTIBODY

Trastuzumab

Bevacizumab

TARGET

HER2

VEGF

INDICATIONS
Metastatic HER2+ Breast
cancer
Metastatic HER2+ Breast
cancer; to select patients
for T-DM1 treatment
Unsuspected HER2 Breast
Metastases
Trastuzumab-resistant
Breast Cancer; measure
HER2 post-treatment with
HSP90 inhibitor AUY922

Girentuximab

Cetuximab

Ipilimumab

PSMA

Carbonic
Anydrase
IX

EGFR

CTLA-4

NCT01420146
NCT01565200

PHASE AND
STATUS
Phase 1;
Completed
Phase 2;
Active, not
recruiting

NCT02286843

Recruiting

NCT01081600

Phase ½;
Completed

Esophagogastric cancer

NCI-201600986,
NCT02023996

Phase 1;
Recruiting

HER2+ primary
malignancy

NCT03109977

Breast Cancer

NCT02065609

Inflammatory Breast
Cancer
Pulmonary arterial
hypertension
Multiple Myeloma
Breast Cancer
Neuroendocrine Tumors
Renal Cell Carcinoma

NCT01859234
NCT01081613
NCT01338090
NCT01028638

Breast Cancer

NCT00991978

Prostate cancer
huJ591

CLINICAL
TRIALS
IDENTIFIER

NCT01894451
NCT03166306

NCT02693860

Metastatic prostate cancer

NCT01543659

Glioblastoma

NCT02410577

Renal cell carcinoma

NCT02883153

Clear cell renal carcinoma

NCT03556046

Stage IV cancer

NCT00691548

Colorectal cancer
Metastatic Colorectal
Cancer

NCT01691391

Melanoma

NCT03313323

NCT02117466

Phase 1;
Completed
Phase 1;
Completed
Phase 1;
not recruiting
Phase 1/2;
recruiting
Unknown
Completed
Completed
Completed
Phase 1;
Completed
Phase 1; active
not recruiting
Phase 1/2;
active not
recruiting
Completed
Phase 2/3,
Completed
Phase 1;
Recruiting
Phase 1;
Completed
Completed
Phase 1/2;
Recruiting
Phase 2;
Recruiting
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Fresolimumab
(GC1008)

TGF-β

Primary brain tumor

NCT01472731

Pertuzumab

HER2

HER2 positive malignancy

NCT03109977

Metastatic prostate cancer

NCT01923727

Prostate cancer, preprostatectomy

NCT02349022

Prostate Cancer

NCT03675451

IAb2M

PSMA

IAb22M2C

CD8

Rituximab

CD20

GSK3128349
(Albumin
domain
binding
antibody)

Albumin

MPDL3280

PD-L1

Non-Small Cell Lung
Cancer, Small Cell Lung
Cancer, Squamous Cell
Carcinoma Head and
Neck, Melanoma, Merkel
Cell Tumor, Renal,
Bladder, Hepatocellular,
Triple Negative Breast, or
Gastroesophageal Cancer,
Hodgkin’s Lymphoma
Lung disease, interstitial
pneumonitis

Phase 2;
Completed
Phase 1;
Completed
Phase 1/2,
Completed
Phase 2,
Completed
Phase 2;
Recruiting

NCT03107663

Phase 1;
Completed

NCT02251964

Phase 2/3;
Completed

Drug related side effects
and adverse reactions

NCT02829307

Phase 1;
completed

Breast cancer, bladder
cancer and non-small cell
lung cancer

NCT02453984

Phase 1;
recruiting

Non-small cell lung cancer

NCT03065764

Melanoma

NCT02760225

Solid tumors

NCT02345174

Pembrolizuma
b

PD-1

GSK2849330

HER3

AMG211

HER3

RO5479599

HER3

MMOT0530A

Mesothelin

MSTP2109A

STEAP1

Prostate cancer

NCT01774071

HuMab-5B1
(MVT-2163)

CA19.9

Pancreatic Cancer; tumors
that express CA19.9

NCT02687230

Advanced gastrointestinal
cancer
Metastatic and/or Locally
Advanced Malignant
HER3-Positive Solid
Tumors of Epithelial Cell
Origin
Unresectable pancreatic
cancer, platinum-resistant
ovarian cancer

NCT02760199

Phase 2; active
not recruiting
Recruiting
Phase 1;
Completed
Phase 1;
Completed

NCT01482377

Phase 1;
Completed

NCT01832116

Phase 1;
Completed
Phase 1/2; Ongoing but not
recruiting
Phase 1;
Recruiting
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KN035

PD-L1

Advanced solid tumors

NCT03638804

ABT806

EGFR VIII

Glioma

NCT03058198

Certolizumab

TNF-α

Rheumatoid Arthritis

NCT03546335

Avelumab

PD-L1

NSCLC

NCT03514719

RO5429083

CD44

Neoplasms

NCT01358903

DS-8895a

EphA2

Solid Tumors

NCT02252211

Not yet
recruiting
Recruiting
Phase 1;
Recruiting
Phase 1; Not
yet recruiting
Phase 1;
Completed
Phase 1

Table 3. List of 89Zr-immunoPET tracers that advanced to clinical trials
1.1.3 Clinical Impact of Companion Diagnostics
Understanding the molecular profile of a malignancy is necessary to determine
treatment indications. A standard clinical strategy obtains tumor specimens through
surgical or core needle biopsies in solid tumors for histopathological analyses. One can
also analyze blood, urine, sputum, or cerebrospinal fluid, for circulating biomarkers(52).
Biopsy-driven molecular profiling is often fraught with problems and limitations since
access to the tumor sites may be difficult, often requiring complicated invasive
procedures(53). Additionally, biopsies only sample a small portion of the global tumor,
and analysis could miss important tumor characterizations. Tumor heterogeneity renders
biopsies inconsistent, which can inadequately portray the presence and level of
expression of the molecular signature; thus, requiring more tests to accurately
characterize the tumor. Consequently, proper histopathological analysis of the
receptor/antigen density may not be reflected, potentially eliminating a patient from
benefiting from molecular-based treatments. Repeat biopsies are performed on patients
to pathologically confirm malignancy to direct treatment decisions, but secondary biopsy
results may not match the original pathology report(54). Moreover, multiple sequential
biopsies are deemed impractical, unethical, and unsafe(55). In this regard, using a PET
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probe to profile tumors could reduce cases of biopsy mismatch by looking at the entire
tumor in an unperturbed, non-invasive setting.
ImmunoPET may potentially provide an image-guided molecular diagnostic tool
where pathological results may not be able to confirm and identify true positive disease.
It detects the target antigen and quantitatively measures its expression. The imaging
agent

18F-FDG

has long been the standard PET tracer for detecting lesions, but it is

limited to visualizing tumor metabolism. Moreover, weak tumor avidity or probe
accumulation, non-specific tissue binding, and low metabolic lesions can pose problems,
hindering detection(56). Pandit-Taskar et al. conducted identification of metastatic bony
lesions using the anti-PSMA PET tracer, 89Zr-J591 and analyzed against lesions detected
by

18F-FDG,

89Zr-J591

bone scans (99mTc-medronic acid (MDP)) and computed tomography (CT).

was able to detect four occult lesions, which were undetected by FDG and other

imaging assays(57). Out of 21 lesions, 19 were PSMA-positive as identified by 89Zr-J591.
Of these select osseous lesions, two were biopsy-proven negative, but further
assessment using magnetic resonance imaging confirmed one of the lesions as
metastatic with a repeat biopsy confirming the malignancy.
Dose escalation studies using 89Zr-IAB2M (anti-PSMA minibody) in patients were
conducted with 10 mg, 20 mg, or 50 mg of IAB2M (Fig. 3)(58). Differences in
biodistribution were minor across all doses. Decreased blood pool activity coupled with
an increased liver and GI tract accumulation was observed over time. The highest lesion
uptake was seen in the 10-mg cohort with optimal biodistribution for imaging, as well as
improved delineation of bony metastatic sites. Of note, increased doses of the cold IAB2M

14
resulted in slower serum clearance due to mass effects, although a non-significant
decrease in liver uptake was noted in the 50 mg cohort.

Figure 3. Confirmation of malignancy Differences in lesion detection in a metastatic
prostate cancer patient using 99mTc‐MDP (bone scan) showed lesions in the ribs and
vertebrae (A), 18F‐FDG PET scan displayed uptake in the femur and in the vertebrae
(B), and 89Zr-IAB2M imaging identified more true‐positive lesions than 99mTc‐MDP and
18F‐FDG (C). A comparison of serum clearance (D) and lesion uptake (E) between
89Zr‐IAB2M (minibody) and 89Z-J591 (full length mAb cognate) over time. This research
was originally published at JNM Pandit-Taskar N,Donoghue JA, Ruan S, et al. First-in-Human
Imaging with 89Zr-Df- IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate
Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. J Nucl
Med.2016;57(12):1858-1864. © by the Society of Nuclear Medicine and Molecular Imaging,
Inc.
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Perhaps the most impact immunoPET has contributed can be gleaned from the
pioneering study investigating the biodistribution of

89Zr-trastuzumab

in patients with

metastatic BC (Fig. 4). Djikers et al. observed rapid hepatic excretion and low blood pool
levels of the tracer in breast cancer (BC) patients who are naïve to trastuzumab with
extensive HER2+ tumor mass in the liver; consequently, a false-negative readouts in
distal metastatic sites was exhibited(59). The hepatic “sink” and poor uptake in metastatic
lesions were attributed to slow extravasation of the drug through the vascular
compartment compared to fast pharmacokinetic clearance of the mAb at low dose levels.
In this study, a 10 mg and 50 mg loaded dose displayed terminal half-lives of 1.5 and 4.3
days respectively; in contrast, tumor penetration and accumulation of

89Zr-trastuzumab

occurred between 4-5 days. To gain perspective, administered therapeutic doses (4
mg/kg loading plus 2 mg/kg maintenance dose) reached an average terminal half-life of
~28.5 days when at steady state. Another important finding of this pivotal clinical trial was
the importance of drug receptor occupancy. The fast pharmacokinetics of low
trastuzumab doses led the authors to estimate drug/receptor occupancy by considering
the amount of HER2 per tumor cell and the liver mass of the patient. The mass (1.2 kg)
was obtained through image analysis of normalized PET/CT scans. The authors
rationalized that a 50 mg dose of trastuzumab, equivalent to 2.0×1017 trastuzumab
molecules (via conversion through Avogadro’s number) cannot fully saturate over a kg
(1.2 kg) of tumor tissue based on the following approximations. A gram of tumor tissue is
nearly comprised of ~1 × 109 cells. Each single cell, on average, possesses 2 million
HER2 receptor sites. Thus, in the patient’s case, there are ~2.4 × 1018 HER2 receptor
molecules present in the hepatic metastases, 10-fold higher than the 50 mg dose (1.2×103
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g tumor tissue × 1×109 cells/g × 2×106 HER2 receptors/cell)(60,61). The majority of the
dose (50 mg) accumulated in the extensive liver metastasis. This created the impetus to
vary doses in patients who are naïve to trastuzumab versus those receiving this treatment
with the former requiring more mAb administered (50 mg vs. 10 mg, respectively).

Figure 4. Receptor Occupancy. 89Zr‐trastuzumab PET biodistribution in patients given 10
mg of 89Zr‐trastuzumab (untreated) (A), 50‐mg 89Zr‐trastuzumab during concurrent
trastuzumab treatment (B), and 10‐mg 89Zr‐trastuzumab during concurrent trastuzumab
treatment (C) show different clearance rates in the blood pool (D), and should be considered
when dosing patients in the clinic. This research was originally published at Clin Pharmacol
Ther. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab
and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin
Pharmacol Ther. 2010;87(5):586-592.

Taken together, these pivotal biodistribution studies underscore the substantial
dependence of mAb-based therapies (e.g. ado-trastuzumab emtansine (T-DM1)(62),
pertuzumab(63), rituximab(64)) on pharmacokinetics for personalized dosing strategies.
Current clinical protocol relies on body weight to determine drug doses administered.
ImmunoPET CDx can potentially transform this practice by facilitating the assessment of
effective patient-tailored doses based on the extent of tumor burden and mAb
pharmacokinetics.
A clinical study assessing

89Zr-rituximab

as an imaging biomarker of CD20 in

patients with relapsed or refractory diffuse large B cell lymphoma was correlated against
pathologic findings (Fig. 5)(65). Biopsy-proven lesions (5/6 patients) showed
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concordance with the tumor uptake of

89Zr-rituximab.

A strong uniform staining of CD20

was correlated with a high SUVpeak of 12.8 while a moderate, heterogeneous CD20
expression corresponded to a tumor uptake of SUVpeak ~ 3.2-5.4. In certain cases, the
pathology may lead to discordance with the immunoPET data. One patient demonstrated
a biopsy-mismatch with CD20 PET displaying a positive tumor uptake (SUVpeak ~ 3.8) but
negative pathology. The lesion was conclusively assessed as a true positive.

Figure 5. ImmunoPET findings in relation to pathology. Concordance (A) and (B)
discordance of 89Zr‐rituximab‐PET/CT (left) with CD20 pathology via IHC (right). Arrows point
to lesions on the PET scan. This research was originally published at PLOS One Jauw YW,
Zijlstra JM, de Jong D, et al. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging
Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory
Diffuse Large B Cell Lymphoma. PLoS One. 2017;12(1):e0169828 and modified for use
under the creative commons license https://creativecommons.org/licenses/by/4.0/).
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Another concrete example was presented by Ulaner et al. investigating HER2-PET
in patients with HER2-negative primary BC (Fig. 6) (54). Of the 20 patients, 15% (3/20)
were identified by

89Zr-trastuzumab

as having unsuspected HER2-positive metastases

with proven pathologies. In this study, a patient who was diagnosed with ER+/HER2invasive ductal BC presented two years later with several bone lesions and was observed
HER2-PET avid. Biopsy of the right ilium (SUV~ 5.9) confirmed metastases but with an
ambiguous IHC score of 2+. Confirmation of the foci as true-positive was made using
MSK-IMPACT assay. Of note, the authors emphasized that the intensity of the PET tracer
on foci can indiscriminately assess true- from false-positive lesions. The study reported
~30% (6/20) of the patient population was conservatively categorized as false-negative
due to negative pathology even with foci avidity for the probe. The relatively high
incidence of false-positive lesions was attributed to non-specific uptake of free Zr-89,
particularly in osseous sites, which marginalizes the use of this nuclide for detecting bone
metastases.
Collectively, tumor heterogeneity can impact go/no-go treatment decisions with
standard biopsy results rendering ambiguity to some extent. In these cases, immunoPET
can reinforce and potentially resolve equivocal tumor pathology. However, confirmation
of true-positive or -negative lesions as visualized by immunoPET needs to be
meticulously validated.

19

Figure 6. PET readout gave true-positive results despite discordance with biopsy
findings. PET readout gave true‐positive results despite discordance with biopsy findings.
An ER+/HER2‐ invasive ductal BC patient with confirmed negative pathology in the primary
lesion (A) but presented with HER2‐PET positive disease 2 years after primary diagnosis (B).
Biopsy of the same site resulted in an ambiguous IHC score (2+) (C) Red arrow points to the
lesion. MSK‐IMPACT assay confirmed the foci as true‐positive (D). This research was
originally published in JNM. Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89ZrTrastuzumab PET/CT. Journal of Nuclear Medicine : official publication, Society of Nuclear
Medicine. 2016;57(10):1523-1528. ©by the Society of Nuclear Medicine and Molecular
Imaging, Inc.
A first-in-human study investigated by Lamberts et al. evaluated 89Zr-MMOT0530A
in pancreatic tumors and metastases expressing mesothelin (MSLN)(66). Pre-treatment
scans showed a mean SUVmax of 11.5 ± 5.6 lesions in the pancreas. Patients received
the antibody-drug conjugate DMOT4039A (MMOT0530A bound to MMAE) followed by
89Zr-MMOT0530A

PET, 4 days post injection of the tracer. After treatment, 9 out of 11

patients presented with stable disease, and two patients had progressive disease. Those
with progressive disease showed an uptake in liver metastasis with the PET tracer. This
suggests that 89Zr-MMOT0530A-PET can be used to visualize pancreatic cancer lesions,
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as well as guide individualized antibody-based treatment with the ADC DMOT4039A.
The landmark ZEPHIR study evaluated the predictive value of HER2 PET/CT in
combination with FDG PET prior to T-DM1 treatment in patients with metastatic breast
cancer (Fig. 7)(67). From the 55 patients enrolled, 16 (29%) were negative for HER2-PET
while 39 patients were categorically classified as positive for HER2-PET/CT, depending
on lesion heterogeneity. From the HER2-positive pool, 28 patients displayed an objective
response (OR) after 3 cycles of T-DM1. In combination with post-treatment (after 1 cycle
of T-DM1), a 100% positive predictive value (PPV) was achieved for HER2-PET imaging
(72% PPV) in combination with early treatment FDG-PET imaging based on RECIST 1.1.
Moreover, a time-to-treatment failure of ~ 11.2 months in the HER2-positive group and
~3.5 months for the HER2-negative group were identified. A negative predictive value of
88% in patients with low HER2-PET was deemed clinically significant. To date, this is the
first trial that used a three-prong strategy that employed imaging biomarkers for go/no go
treatment decisions in the clinic. In conclusion, these clinical trials highlighted the potential
of immunoPET to measure functional effects of targeted treatment, making this imaging
technique a conceivable predictive and prognostic biomarker.
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Figure 7. Predictive markers of treatment. Time‐to‐treatment failures were evaluated
based on HER2‐PET/CT (A), early FDGPET/CT (B) and combination of both HER2‐ and
FDG‐PET/CT (C). This research was originally published in Ann Oncol. Gebhart G, Lamberts
LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced
HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine
(T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619-624.
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1.1.4 Practical Considerations
While immunoPET CDx may seem straightforward, several aspects of using this
imaging technique need to be deliberated. The amount of dose administered and the
interval between tracer administration and imaging acquisition warrant investigation to
obtain an optimized contrast between lesions and background. In the case of

89Zr-

trastuzumab, the optimal imaging time for a ~37 MBq (50 mg) intravenous injection was
observed between 4-5 days after injection(59). At this period, low blood pool activity and
high tumor avidity was established. Imaging at longer periods >6 days can compromise
the spatial resolution and image quality(59). At higher activities (~185 MBq/50 mg)
administered,

89Zr-trastuzumab

still generated high quality spatial resolution in images

acquired between 5-6 days post-injection(68). The scan periods of 4-6 days depending
on the dose are typical for other full-length mAb tracers in clinical trials(54,65,68,69). For
smaller biologics-based tracers,

89Zr-IAB2M,

for example, demonstrated shorter interval

wait times with the best lesion to background ratio identified at 48 h p.i.(58) Safety profiles
of 89Zr-labeled mAbs require careful assessment to limit radiation-related toxicities. Whole
body effective doses reported in a number of early phase studies ranged from 0.41
mSv/MBq for

89Zr-IAB2M(58),

0.47 mSv/MBq for

0.87 ± 0.14 mSv/MBq for

89Zr-trastuzumab(71)

89Zr-ibritumomab

and 0.264 mSv/MBq for

tiuxetan(70),

89Zr-panitumumab(18)

whereas FDG-PET(72) had a reported mean effective dose of 0.0199 ± 0.0032 mSv/MBq.
Engagement of immunoPET CDx as predictive imaging biomarkers in the clinic
should continue to be explored in the clinical translational efforts toward precision
medicine. It has already shown success in accurately profiling lesions at the molecular
level when pathology is incorrect, discovering the density of targets available, and
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determining the biodistribution of therapy before treating the patient. Sequential imaging
in test-retest studies can provide a viable tool to appropriately dose patients, but should
be used with caution during treatment regimens. In a nutshell, immunoPET is still at its
early stages of clinical development and will most likely require further standardization
(i.e. streamlined SUV readout analysis, chemistry optimization) and validation through
other molecular profiling tools. Once harnessed, its benefits can provide a powerful
impact in patient management.
1.2 Overview of Breast Cancer and Selected Subtypes
Breast cancer (BC) is the most commonly diagnosed cancer in women, as well as
the leading cause of cancer-related deaths(73). BC is typically referred to as a single
disease, but it is clinically and molecularly heterogeneous, with many ways to categorize
tumors. Still, clinical decisions rely on the assessment of three markers: the expression
of the estrogen receptor (ER), progesterone receptor (PR) and the overexpression of the
human epidermal growth factor receptor 2 (HER2)(73). The accurate assessment of
these biomarkers assists in tumor classification and aids in appropriate treatment
decisions. This section will mainly discuss HER2 and EGFR, molecular therapeutic
strategies, and current diagnostic techniques.
1.2.1 HER family
The HER family is a group of transmembrane receptor tyrosine kinases (RTK) with
four members: EGFR, HER2, HER3, and HER4 (Fig. 8). They are deregulated in many
cancer subtypes, but are most commonly recognized in BC, lung cancers, and
glioblastoma. In breast cancer, the EGFR gene is amplified in up to 5% of cancer cases,
and the HER2 gene is amplified by up to 30%. They all share a common structure
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comprising of an extracellular domain, a single transmembrane domain, and an
intracellular domain with a conserved carboxyl terminal tail and catalytic kinase
domain(74). A key function of their activity is within the dimerization portion of the
extracellular domain(74). When a ligand binds the dimerization domain, it changes the
conformation of the receptor allowing for dimerization and inter-receptor interactions,
although HER2 is the exception, since it has no known ligand(74). Table 4 describes the
HER receptor binding combinations.
After dimerization, the receptors will phosphorylate their tails and activate
downstream signaling cascades, such as the phosphatidylinositol-3-kinase (PI3K)/Akt
pathway, the Janus kinase, and phospholipase C pathway; all which affect and promote
cell proliferation, survival, and adhesion(75). Additionally, the Src pathway responds to
upstream HER family signaling(75). The signaling potency of receptors is governed by
the particular dimer pair. For example, heterodimers are more active than homodimers,
with the heterodimer HER2-HER3 possessing the most signaling activity(76).

Figure 8. HER family members and ligands. EGFR, HER2, HER3, and HER4 are all
capable of dimerizing upon ligand binding and activation, except for HER2 which does not have
a known ligand.
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Dimers

Ligands

EGFR-EGFR

EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR

EGFR-HER2

EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR

EGFR-HER3

EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2

EGFR-HER4

EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg3, Nrg-4

HER2-HER2
HER2-HER3
HER3-HER3

None
Nrg-1, Nrg-2
Nrg-1, Nrg-2

HER3–HER4

BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4

HER4-HER4

BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4

Table 4. HER family member dimer pairs and activating ligands.
1.2.2 EGFR
The human epidermal growth factor receptor 1 (EGFR) or HER1 is a
transmembrane protein comprised of an extracellular ligand binding domain, a
transmembrane domain, and a cytoplasmic domain with kinase activity (Figure 9). When
its ligands, such as EGF, transforming growth factor α (TGFα), or amphiregulin (AR) binds
to the extracellular region, a conformational change on the EGF receptor is triggered that
allows dimerization with another EGFR molecule, or a heterodimer with another RTK(77).
Upon dimerization, EGFR kinase is activated, allowing for autophosphorylation and
transphosphorylation of the intercellular tails that serve as docking sites for downstream
proteins containing the Src Homology 2 (SH2) domain(77). The primary activated
pathways include the RAS/RAF/MEK/ERK, PI3K/AKT, and PLCγ/PKC pathways, but
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activation of Src tyrosine kinases have been documented(77). Additionally, EGFR can
signal from different compartments of the cell including the nucleus.
The nuclear EGFR (nEGFR) signaling network has recently been implicated in
cancer progression and response to EGFR-targeted therapies. nEGFR has been
detected in cancer cells of primary tumor specimens, as well as other highly proliferating
tissues(78–81). Additionally, high expression of nEGFR has been correlated with poor
clinical outcome in patients with breast cancer, in particular(82), as well as in many other
cancers(82,83). Due to the many pathways that EGFR functions within, EGFR as a
treatment target has been strongly pursued over the last 30 years(77).
1.2.3 EGFR expression in TNBC
Approximately 10-20% of global BC patients will be diagnosed with a tumor lacking the
three targetable biomarkers, ER, HER2, and PR, and are considered “triple negative”
(84). TNBC is a more aggressive BC subtype, disproportionately affecting premenopausal
African or Hispanic women, and accounts for 25% of BC deaths(85). TNBC patients have
a poorer outcome compared to other BC subtypes presenting with known molecular
targets, and many of these tumors must be treated with chemotherapy as the mainstay
in the neoadjuvant, adjuvant, and metastatic setting(85). Yet despite promising results,
there have been cases of increased toxicity without improvements to survival(86). This
may be in part due to the fact that BC is a heterogeneous disease with complex variances
in genes, epigenetics, and protein expression within each individual’s tumor(87). Due to
this complexity, efforts have been made to classify tumors into subgroups based on
homogeneous patterns of sensitivity to other therapies(88).
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Figure 9. EGFR trafficking to the nucleus. Upon ligand binding and activation, EGFR
homodimerizes and induces transautophosphoylation. This causes internalization to
endocytic vesicles. EGFR then undergoes translocation through the Golgi apparatus and
into the endoplasmic reticulum outside of the nucleus. EGFR then moves through the
outer and inner nuclear membranes through the nuclear pore complex. Finally, EGFR
interacts with Sec61 and is released from the ER into the nucleus.
Lehmann and colleagues have defined six new TNBC subtypes based on gene
expression profiles: basal-like 1, basal-like 2, mesenchymal, mesenchymal stem-like,
immunomodulatory, and luminal androgen receptor(89). Within these subtypes, there is
further stratification based on gene mutations, which lead to possible actionable

28
pathways, such as PARP inhibitors, anti-angiogenic antibodies and inhibitors, PI3K and
mTOR inhibitors, AKT inhibitors, and immunotherapy, to name a few(90). One of these
actionable pathways has been shown to be EGFR. In one study, EGFR was
overexpressed in 89.47% of cases of invasive BC(91). Similar results were also observed
in a study among 151 TNBCs where 27% of cases were scored as 3+ for EGFR and 37%
were scored as 2+ by IHC, confirming high EGFR expression(92). Therefore, targeting
EGFR in TNBC is a critical need.
1.2.4 EGFR targeted therapies in BC
To date, two successful approaches towards targeting EGFR in cancer therapies
have been explored. The first approach involves targeting the kinase activity of the
receptor through the use of tyrosine kinase inhibitors (TKIs) that bind to the ATP-binding
sites of the receptor. There are currently three FDA approved TKIs – erlotinib (Tarceva®),
gefitinib (Iressa®), and lapatinib(Tykerb®)(93). A second approach uses mAbs to target
the extracellular domain of EGFR and block natural ligand signaling and dimerization,
which are outlined in Table 5.
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Drug

Treatment
Type

Clinical
Trial

Breast
Panitumumab
(Vectibix®)

Cetuximab
(Erbitux®)

Laprituximab
emtansine
(IMGN-289)
Necitumumab
(Portrazza®)
SCT-200
Anti-EGFRimmunoliposomedox
Gefitinib
(Iressa®)

Poziotinib
Lapatinib
(Tykerb®)
Erlotinib
(Tarceva®)

Human
mAb

Malignant
neoplasm
of Breast
Metastatic
Breast

Phase/
clinicaltrials.gov
identifier
II/NCT02593175
II/NCT01036087
II/NCT01009983
II/NCT02876107

Notes
(M/ = approved)

M/2006 –
colorectal

II/NCT00894504

Chimeric
mAb

Breast

II/NCT00232505
II/NCT00275041
II/NCT00463788
II/NCT00633464
II/NCT00600249
I/NCT03319459
I/NCT02627274
I/NCT02124148

Chimeric
mAb

Solid
Tumors

I/NCT01963715
(terminated)

Conjugated to
drug DM1

Humanized
mAb
Humanized
mAb
EGFRtargeted
liopsome
Small
molecule
inhibitor
Small
molecule
inhibitor
Small
molecule
inhibitor
Small
molecule
inhibitor

Solid
Tumors

II/NCT01606748

M/2015 - NSCLC

Breast

II/NCT03692689

Breast

II/NCT02833766

Breast

II/NCT01732276
II/NCT00739063

Metastatic
Breast

II/NCT02544997

Breast

II/NCT00820924

M/2007 – HER2+
Breast

Breast

II/NCT00503841

M/2004 - NSCLC

Table 5. EGFR targeted treatments for BC.

M/2004 colorectal

M/2015 - NSCLC
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Cetuximab was FDA approved in 2006 for the treatment of colorectal cancers in
the metastatic setting(94). It is a chimeric monoclonal antibody that targets domain II of
EGFR with a higher binding affinity than natural ligands transforming growth factor (TGF)
and EGF, effectively blocking the ligand-binding domain and preventing dimerization(77).
Similarly to trastuzumab, cetuximab is capable of antibody-dependent cell-mediated
cytotoxicity (ADCC) and complement-dependent cytotoxicity(95,96). Cetuximab can also
block EGFR phosphorylation and promotes internalization of the receptor which reduces
proliferation(97). Upon cetuximab binding to EGFR, phosphorylation will be induced
which can trigger downstream responses such as aberrant growth signals or
apoptosis(98,99). Due to its efficacy, it has been combined with many other treatments
such as chemotherapy and radiotherapy, resulting in tumor depletion in mice, and
improved chemotherapy efficacy in humans(100). It has limited dose toxicities, with only
about 10% of patients reporting a severe toxicity(101).
Surprisingly, clinical trials focusing on EGFR-TKIs and mAbs in TNBC have been
disappointing, potentially due to resistance mechanisms(77). These pathways of
resistance

include

the

angiogenesis

pathway,

increased

EGFR

degradation,

dysregulation of EGFR internalization, oncogenic shift (increased expression of other
HER family members), constitutive activation, and increased expression of ligand growth
factors(77).
Cetuximab as a monotherapy has shown dismal response rates in TNBC(102). In
a phase II clinical trial, patients who received one or fewer chemotherapy regimens were
randomly assigned to cisplatin plus cetuximab, or cisplatin alone. While cetuximab alone
did not result in an increased overall response rate, its combination with cisplatin doubled
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objective response rate, suggesting there is hope for cetuximab in TNBC(102).
In another phase II clinical trial on metastatic TNBC patients, Carey et al. had
patients receive cetuximab alone or with carboplatin after progression. Overall response
rates were 6% with cetuximab alone, or 17% with combination therapy, and EGFR
expression as a single marker did not provide a significant correlation with clinical
response(103). Due to its failure to yield improved response rates using EGFR-targeting
mAbs without prior EGFR profiling, it has been suggested to stratify patients first by their
expression of target biomarkers before they undergo treatment, and has been explored
in colorectal cancer with some success.
Due to its success in other cancers, investigations have been made to find
biomarkers to better stratify patients and predict responses. Most obvious, EGFR
expression

levels

were

hypothesized

to

correlate

with

cetuximab

response.

Unfortunately, early clinical trials failed to find a correlation between EGFR expression
and clinical response to EGFR therapy in BC(104). This finding led to the belief that IHCbased EGFR measurements are not robust predictors for cetuximab therapy, and they
moved onto other methods, such as EGFR copy number and mutation status. So far, only
KRAS mutations(105), BRAF mutations(106), and IGF1R expression(107) status have
correlated with response to cetuximab therapy, which none of these biomarkers have
been implemented in TNBC, highlighting a need for an approved method to monitor
EGFR-therapy response rates. One notable resistance pathway to cetuximab treatment
in TNBC was highlighted as the subcellular localization of EGFR (108).
1.2.5 HER2-positive BC
The HER2 receptor is amplified or overexpressed in about 20% of all diagnosed
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BCs(109). Albeit significant efforts to develop anti-HER2 agents, there is still a significant
number of patients with HER2+ BC that progress within 5-10 years of treatment(109).
The value of HER2 as a prognostic factor is controversial. In 88% of early studies looking
at over 40,000 cancer patients, harboring the HER2 amplified gene or HER2 protein
overexpression was a negative prognostic factor for traditional chemotherapy,
independent of other prognostic variables(109). However, the advent of HER2 specific
treatments, such as the monoclonal antibody trastuzumab (Herceptin®), has improved
treatment outcomes for patients in the adjuvant and metastatic setting(102). Trastuzumab
has been tested in many major clinical trials for patients with HER2+ breast cancer, with
the median overall response rates ranging from 15.6-25.1 months(109).
1.2.6 Current companion diagnostics for HER2-positive BC
Due to the prognostic value of HER2-receptor presence and response to HER2targeted treatment, it is now recommended that all primary, metastatic, and recurrent BC
be tested for HER2(110,111). Currently, there are many FDA-approved in vitro
companion diagnostics for HER2 overexpression, including five immunohistochemistry
assays (IHC), three tests to quantify HER2 gene copy numbers through fluorescence in
situ hybridization (FISH), one chromogenic in situ hybridization (CISH), and a dual in situ
hybridization (ISH) assay(109). These in vitro diagnostic techniques require an invasive
procedure of collecting sample tissue from a patient. Due to tumor heterogeneity, the
sample collected may not fully represent the entire tumor microenvironment, potentially
yielding inconclusive results. Additionally, tissue can only be collected from a patient with
accessible tumors, limiting the utility for hard to access cancers.
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IHC staining is a semi-quantitative, but subjective, method for determining HER2
status, since HER2 is expressed in all breast epithelial cells. Results are scored from 0
to 3+, which measures the amount of HER2 protein present in the cell, with a score of 3+
called “HER2 positive”(112). Although IHC is an available, low cost, and easy method to
determine HER2 status, its interpretation is subject to reader bias(112). For example,
comparing HER2 overexpression measured by IHC on-site and HER2 amplification
measured by FISH at a reference lab revealed low concordance rates (66-87%)(112).
FISH, on the other hand, is more reliable and sensitive, but it requires special equipment
and training to appropriately perform the test(113). Additionally, HER2 expression can
vary between primary and metastatic sites, making it difficult to characterize each
individual lesion(114,115).
On the other hand, fluorescence in situ hybridization (FISH) testing is an
automated slide-based DNA-hybridization using fluorescent probes. It is a more objective
scoring system, although it is an expensive test and requires specialized microscopes.
Chromogenic in situ hybridization (CISH) is a similar test where instead of a fluorescent
probe, a chromogenic probe is used. These tests are binary, providing a “positive” or
“negative” HER2 score, and not a numeric value.
Since the advent of immunoPET, efforts have been made to use imaging as a
means to characterize breast lesions with trastuzumab as a tracer. In

a

study

by

Dehdashti et al., women with HER2+ and HER2- BC underwent a PET/CT scan after
administration of a 89Zr-labeled HER2-specific antibody (trastuzumab)(116). The PET/CT
uptake was correlated to HER2 status determined by IHC or FISH of a primary or
metastatic lesion. They found that 88.2% of HER2+ patients had a positive PET/CT scan,
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and 93.7% of HER2- patients had a negative PET/CT scan. This translated to a positivepredictive value of 83.3% and a negative predictive value of 50% in differentiating HER2
positive from negative tumors. They conclude that

89Zr-trastuzumab

has the potential to

characterize the complete tumor burden in BC patients for HER2 status, obviating the
need for multiple invasive tissue samples. Additionally, it addresses the issue of
interpatient heterogeneity of HER2, and can further aide in treatment decisions.
1.2.7 HER2-targeted treatment strategies
At time of writing, there are five FDA-approved targeted therapies for HER2+
disease, including monoclonal antibodies (mAb), antibody-drug conjugates (ADC), and
small molecule inhibitors (Table 6).
Drug
trastuzumab
(Herceptin®)(117)
pertuzumab
(Perjeta®)(118)
ado-trastuzumab
emtansine
(Kadcyla®)(119)
lapatinib
(Tykerb®)(120)
neratinib
(Nerlynx®)(121)

Type
mAb
mAb
Antibody-Drug
conjugate
Small molecule
inhibitor
Small molecule
inhibitor

Target
Juxtamembrane
domain IV
Dimerization
domain II
Juxtamembrane
domain IV
EGFR/HER2
EGFR, HER2,
HER4

Mechanism
Cell intrinsic effects
Antibody dependent cellmediated cytotoxicity
Binds to HER2 like
trastuzumab and delivers
emtansine
Bind to the ATP binding
cleft in tyrosine kinase
domain to block catalytic
activity

Table 6. FDA approved HER2-targeted treatments for HER2+ BC
Trastuzumab (Herceptin®) is a humanized monoclonal antibody targeted against
HER2. It was approved in 1998 for the treatment of metastatic HER2+ disease, and was
the first anti-HER2 agent on the market. In 1998, the “pivot trial”, a randomized phase III
trial testing chemotherapy alone versus chemotherapy and trastuzumab, showed a
median overall survival of 25.1 months in patients who received trastuzumab, and
impacted the FDA approval of trastuzumab for metastatic breast cancer that same
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year(109). It has radically improved outcomes in HER2+ breast cancer patients, with a
study in 2014 of 4,000 patients showed that adding trastuzumab to chemotherapy
improved overall survival from 75.2% to 84%, and is listed as an essential medicine by
the world health organization(122,123). Its mechanism of action is not fully understood,
but it is thought to evoke antibody-dependent cellular cytotoxicity (ADCC), disrupt
downstream signaling pathways, inhibit cell cycle progression, and act as an
antiangiogenic agent upon binding to HER2(124). Early clinical response rates ranged
from 12-68% response, with the best responders observed in patients with an IHC or
FISH score of 3+. The addition of trastuzumab to other therapies increased progression
free survival by 2-3 months(124). The success from these trials and the many others has
resulted in a 1 year-long cycle of adjuvant trastuzumab as standard of care for HER2+
tumors, as well as provided proof-of-concept that targeting HER2 would improve patient
outcomes.
The phase III study comparing lapatinib (Tykerb®), an oral TKI of HER2 and
EGFR, to capecitabine in patients with HER2+ metastatic breast cancer improved
progression free survival(125), and, therefore led to its FDA approval in 2007. Recently,
two antibody-based therapies and a small molecule TKI were FDA approved:
pertuzumab, TDM-1 and neratinib. Pertuzumab (Perjeta®) prevents the pairing of HER2
and HER3; the results from the phase III CLEOPATRA study demonstrated a synergistic
effect achieved when pertuzumab was combined with trastuzumab and docetaxel with
patients showing improved progression free survival(126). TDM-1 (Kadcyla®), approved
in 2013, links a cytotoxic agent to trastuzumab, specifically delivering emtansine to
HER2+ tumors. A randomized phase III EMILIA study demonstrated improved overall and
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progression free survival of TDM-1 compared to capecitabine plus lapatinib(127). Finally,
neratinib (Nerlynx®) is an oral TKI that inhibits EGFR, HER2, and HER4, approved in
HER2+ patients based on the exteNET phase III clinical trial(128). A phase III trial of
women with stage 1-3 HER2+ BC who previously completed trastuzumab therapy,
patients were randomized to neratinib (Nerlynx®) or placebo. Those who received
neratinib had significantly improved 2-year disease free survival.
More new HER2 agents or potential combination therapies either under preclinical
development or FDA-approved for other HER2+ cancers can be potential treatments in
BC in the future(129). HER2 antibodies MGAH22, MCLA-123, and ZW-25, and ADCs
SYD 985 and DS-8201 are all past phase I clinical trials. New TKIs tucatinib, poziotinib,
and pyrotinib (Nerlyxn®), are all through phase II trials.
Even with the diverse availability of treatments, because of HER2 mutations
(intrinsic and acquired) causing drug resistance, there are differences in sensitivity
between patients and therapies. Changes in downstream pathways or activation of
parallel oncogenic pathways can potentially contribute to resistance. Particular attention
should be given to identifying acquired resistance mechanisms to help optimize HER2
directed therapies(130).
1.3 Mechanisms of resistance to treatment in BC
In hormone receptor positive BC (ER+ and PR+), endocrine therapy is the
mainstay(131). Endocrine therapy includes the use of selective ER modulators (SERMS)
which act as tissue specific estrogen receptor agonists and antagonists. Selective ER
down regulators (SERDs) competitively bind ER with a greater affinity than SERMs, and
reduce transcription of ER regulated genes. Aromatase inhibitors block estrogen
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synthesis and prevent their growth-stimulating effects. Development of resistance is
thought to be due to genetic factors (ESR1, CCDC170 mutations, for example), loss of
ER expression, crosstalk between compensatory receptors (HER2, EGFR)

and

epigenetic factors(132). For TNBC, first line neoadjuvant platinum-based or taxane
chemotherapy is the mainstay, and comes with its own set of challenges. Most often,
resistance stems from an increase in the cell’s ability to efflux the drug, which results in
decrease net intracellular accumulation(133). In HER2+ BCs, resistance pathways can
develop after trastuzumab (Herceptin®) therapy from upregulation and compensation
from other HER family members, epitope masking, and enzymatic cleavage of the
trastuzumab binding site(134). Additionally, cells can develop adaptive responses by
down-regulating tumor suppressors PTEN and PI3K/Akt(135,136), or through alteration
of downstream pathway signaling, through the PTEN/PI3K/AKT/mTOR pathway, and
even the Src pathway(137).
1.3.1 Overview of Src
Src is expressed in all normal, mammalian cells and is classified as a protooncogene(138). The Src gene produces a protein produced called Src that is a member
of the Src family kinase (SFK) group, which is a group of non-receptor tyrosine
kinases(138). SFKs are involved in many cellular processes and their aberrant signaling
has been associated with tumor promoting events, such as cell proliferation and
survival(138). The most studied mechanism of Src function is its interaction with RTKs,
such as EGFR and HER2 through its SH2 and SH3 domains(139). Src also plays a role
in tumor metastasis, with roles in regulating the cytoskeleton, cell migration, cell-cell
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adhesions, and invasion (Fig. 10)(140).
Pre-clinically, Src appeared as a promising therapeutic for cancer, although
efficacy of single agent Src inhibitors in solid tumors has not shown promise in Phase II
clinical trials(139). This is in part due to its activation in many resistance pathways. In
particular, SFKs are an important component in chronic myelogenous leukemia (CML)
due to their direct interaction with BCR-ABL(141). Src is shown to be involved in steroid
receptor signaling and endocrine resistance(142). Src activation is observed in 40% of
ER-positive (143) and in up to 70% of primary human BC with concomitant HER2 or
EGFR expression(144). The synergism between EGFR, ER, and Src facilitates hormone
signaling and confers resistance to targeted therapies(145).

The mechanism of

resistance most important to this body of work is the interaction between Src and the
RTKs EGFR and HER2. It has been previously reported that in many cancers, targeting
SFK dramatically enhances the efficacy of anti-RTK therapies(146).
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Figure 10. Src signaling and downstream pathways. Src interacts with many RTKs
and facilitates their downstream signaling to promote cell survival. Major Src downstream
activation includes: (i) AKT activation and cell proliferation, (ii) stat3 activation and
transcription upregulation, (iii) disruption of cell-cell junctions through p120-catenin, and
(iv) stabilization of adhesion through FAK phosphorylation. This figure was reprinted with
permission from Trends in Pharmacological Sciences. Targeting Src family kinases in
anti-cancer therapies: turning promise into triumph, Siyuan Zhang and Dihua Yu.
2012;33(3):7.
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1.3.2 Src inhibitors
Due to its role in promoting tumorigenesis, there has been extensive developments
of small molecule inhibitors targeting Src dysregulation(138). Dasatinib (Sprycel™,
Bristol-Meyers Squibb) was the first FDA-approved Src/ABL inhibitor for the treatment of
CML(147). Other inhibitors include saracatinib (AZD0530, AstraZeneca) and bosutinib
(SKI-606, Wyeth)(148). Src inhibitors typically have low toxicity, but as a monotherapy
they have dismal response rates in solid tumors(139). Dasatinib in particular has shown
< 25% clinical benefit in phase II trials in BC, prostate cancer, and melanoma(149).
Additionally, targeting Src though dasatinib failed to show a significant clinical benefit in
metastatic colorectal(147) and small cell lung cancer(150). Saracatinib additionally failed
to show benefit in prostate(151), pancreatic, and metastatic head and neck cancer(95),
gastric adenocarcinoma(152), and ER/PR negative metastatic BC(153). Not surprisingly,
no Src inhibitors have been FDA-approved for treating solid tumors as a
monotherapy(139).
For the past 30 years, Src monotherapy has lacked efficacy, but recently, new
studies have provided a foundation for future clinical trials(139). One of the challenges in
developing Src inhibitors is the lack of biomarkers available for Src-targeted therapy,
making patient selection and stratification difficult. Previous clinical trials were performed
on patients unselected for Src activation. This led to poor treatment outcomes, warranting
re-examination of the Src activation pathway in the hopes of a target for subsequent
clinical trials. In a recent study of 23 colorectal cancer cell lines, Src pathways activation
was observed and correlated with enhanced sensitivity to Src inhibitor saracatinib,
supporting the hypothesis that looking into Src pathway activation is beneficial for
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improved treatment outcomes(154). In a trial of pancreatic cancer patients, Src activation
was observed and noted. They found that patients with Src activation were more sensitive
to dasatinib, as compared to their non-activated counterparts, and furthermore, those
patients with Src localized to the cytoplasm had increased survival(155). These results
highlight Src activation as a molecular target and are looked into more thoroughly in the
next sections.
1.3.3 Src hyperactivation and its role in trastuzumab-resistance in HER2+ BC
Despite its success in HER2+ BC, some patients who receive trastuzumab will
relapse. Some proposed mechanisms of resistance have included HER2 forming
heterodimers with other family members and effectively blocking trastuzumab binding, an
increase in expression of HER2, and shedding of the extracellular domain leaving the
form of the receptor (p95) which does not bind to trastuzumab but retains kinase
activity(156).
HER2 directly associates with Src as it activates its downstream signaling and
stability(157). It has been shown that Src signaling is up-regulated in trastuzumab
resistant tumors(157), as well as de novo trastuzumab-resistant cells(158). A particular
oncogenic variant, HER2Delta16, induces Src function and activates Src to confer
trastuzumab resistance(159). Src inhibition has been shown to sensitize trastuzumabresistant BC to trastuzumab(158). One study has shown that combination treatment with
saracatinib and an anti-HER2 antibody (clone H2-18) produces a greater antitumor effect
on trastuzumab-resistant (PTEN wt) breast cancer(160). An additional study has shown
that cells overexpressing wild-type Src were resistant to trastuzumab(158). Clinically,
there is a correlation between phosphorylation of Src at tyrosine reside 416 (Y416) and
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total Src abundance (p = 0.025), and patients with higher levels of phospho-Src in tumors
had a lower clinical response rate and progressive disease after trastuzumab(158).
1.3.4 Src and its role in EGFR-overexpressing cancers
Src activation has been shown to promote resistance in anti-EGFR therapies.
Particularly, Src is responsible for the full activation of EGFR(161), and it physically
associates with activated EGFR(162). Once Src binds to EGFR, EGFR undergoes a
conformational change. This leads to autophosphorylation at the tyrosine residue 416
(Y416) and subsequent transient activity, which leads to phosphorylation of downstream
targets, such as EGFR on tyrosine 845 (Y845)(144). Y845 is situated in a conserved
position within the activation loop of EGFR, and is necessary for full activity of the
receptor(163). It has been discovered that Src can directly phosphorylate EGFR on Y845,
strengthening the communication between the two proteins(164). This residue also acts
in concert with the redistribution of EGFR from the membrane to intracellular vesicles,
and has been suggested as a marker of drug response in NSCLC, breast, and colorectal
cancers(164).
EGFR and Src are shown to be upregulated in a majority of lung, colorectal, and
pancreatic cancers(165).

Additionally, Src is commonly activated in EGFR-

overexpressing cells and its activation enhances EGFR signaling of downstream PI3KAkt pathway(158). In one study, it was reported that cells with acquired cetuximab
resistance have increased Src activity, potentially due to its cooperation with EGFR and
resultant signaling to HER3 and PI3K/Akt. A decrease in HER3 phosphorylation and
PI3K/Akt signaling is observed when cetuximab-resistant cells are treated with dasatinib,
which was coupled with a decrease in proliferation and survival(166). In a different study
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of breast cancers expressing EGFR, HER2, and HER3, dasatinib treatment resulted in
apoptosis and growth inhibition in a dose dependent manner(167). This was
accompanied by decreased EGFR and Src phosphorylation, suggesting that these two
RTKs are prime targets for BC therapy. In non-small cell lung cancer (NSCLC) in
particular, Src is highly active and associated with cetuximab resistance(166). Most
notably, it has been shown in a non-small cell lung cancer cell line H226, that cetuximabresistance leads to overexpression of EGF, and concomitant nuclear translocation of
EGFR mediated by Src. Treatment of these resistant cells with dasatinib resulted in loss
of nuclear EGFR, increased membrane EGFR expression and cetuximab resensitization, further supporting the hypothesis that EGFR nuclear compartmentalization
impacts cetuximab efficacy(168). Additionally in colorectal cancer, dasatinib re-sensitized
cetuximab-resistant tumors to cetuximab(169).
EGFR localization, in particular, has been investigated as a potential resistance
mechanism in breast cancer. Extensive reports have shown EGFR family members being
shuttled from the plasma membrane to the nucleus, with nEGFR expression
demonstrating poor clinical outcomes in breast cancer(80,81,137,170). nEGFR acts as a
transcription factor, interacting with STAT3 and E2F1. When in the nucleus, EGFR is
associated with gene transcription, DNA repair, and radioresistance.
1.4 Immune oncology
Despite significant advances in BC chemo- and molecular therapies, a proportion
of patients with localized disease still remain refractory to treatment, or suffer relapse.
Furthermore, those with metastatic disease are rarely cured. In BC, it is believed that
immunosuppression

and

inflammation

become

induced

and

contribute

to
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progression(171). Particularly in TNBC, BC gene profiling has demonstrated patterns of
immune gene activation(172). In approximately 50% of HER2+ BCs inflammatory
signatures are observed which correlate with improved outcomes(173). Additionally, high
levels of tumor infiltrating lymphocytes (TILs) have been associated with improved
response to neoadjuvant chemotherapy(174). Due to these observations, recent
advances in immunotherapy highlight the potential to harness the immune system for
improved tumor responses in the adjuvant and monotherapeutic space (175).
The immune system can impact tumor growth and prevention through the
immunoediting process. This is comprised of three stages called elimination, equilibrium,
and escape. In the elimination phase, the tumor is destroyed by inflammation, infiltration
of effector cells, and production of tumor-inhibiting cytokines(176). The escape phase is
characterized by sustained inflammation comprised of immunosuppressive cells and
soluble molecules(177). In equilibrium, the tumor is neither proliferating nor dying off, and
can turn into the other two stages based on the immune response.
1.4.1 The immune pathway
The primary cells responsible for killing breast tumor cells are CD8+ CTLs and
natural killer (NK) cells. Induced CTLs target specific antigens expressed on BC cells,
and their infiltration into the tumor microenvironment has been associated with improved
outcomes, particularly in the TNBC or basal subtype(178). Combining immunotherapy
and chemotherapy has also been shown to enhance the activity of CTLs and is coupled
with enhanced antitumor effects(179), and the positive effect of vaccines has been shown
to be achieved through CTL-mediated recognition and destruction of breast cancer(180).
NK cells, on the other hand, are cells of the innate immune system that kill tumors cells

45
unrestricted by major histocompatibility complex (MHC) class(69). Decreased NK activity
has been observed in patients with familial breast cancer, stage IV breast cancer, and
during breast cancer progression. When profiling gene expression in breast cancerassociated stroma, it has been found that CTL and NK associated genes were enriched
and predictive of better outcomes. Overall, it has been suggested that CD8+ T cells and
NK have strong antitumor activity against BC(181).
It is now accepted that BCs have an infiltration of leukocytes, and this can either
promote tumorigenesis or elimination(182) (Fig. 11), and in BC these TILs have been
established as a putative biomarker of treatment prognosis(183). There have been many
retrospective studies published that suggest an association between pathologic complete
response to neoadjuvant treatment and the presence of TILs in solid tumors, potentially
representing a robust and reproducible predictive factor(184). Particularly, a decrease in
regulatory T cells confers response to treatment, and restores anticancer responses in
non-responders(184). This hypothesis has been supported by studies reporting that
some patients treated with high-dose interleukin-2 (IL-2) show durable responses and an
increase in response to TIL therapy, where others do not(185). More recently, the
inhibition of PD-1 alone results in response rates of 20-30% of patients, but upon
combination with CTLA-4 blockade, this response rate increases to 57%(186). The
varying response rates between patients has been hypothesized to be due to TILs
presence, with higher PD-1 responding patients having more CD8+ T cells in their tumor
bed(187). Therefore, ways to monitor presence of TILs before selecting a treatment type
is of upmost importance.
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Figure 11. TIL infiltration and its mechanism for eliminating tumors. Tumors in the
elimination phase (left) have an influx of active dendritic cells, NK cells, and T cells which
produce cytokines and signals to stop tumor proliferation. In the escape phase, these
infiltrates are now engaged with the tumor environment, and the tumor is able to
proliferate. This figure was reproduced with permission under the creative commons
license
from:
http://www.frontiersin.org/files/Articles/51138/fonc-03-00197HTML/image_m/fonc-03-00197-g001.jpg
1.4.2 FDA-approved and emerging immunotherapies
Cancer immunotherapy is defined as the utilization of naturally derived or
synthetically generated compounds to enhance or stimulate the immune system. The
main types of immunotherapy include adoptive T-cell transfer, viruses, monoclonal
antibodies, and cancer vaccines(175). During adoptive T-cell transfer, a patient’s own Tcells are genetically engineered to recognize cancer cells. Oncolytic viruses are
specifically modified viruses that avoid normal tissue and recognize a tumor associated
antigen. Once inside the cancer cell, the virus will replicate and then rupture the tumor
cell. As of writing, talimogene laherparepvec (T-VEC) is the only approved treatment of
this kind, for melanoma(188). Monoclonal antibodies are immune cell manufactured
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proteins that specifically recognize an antigen on a target cell. These antibodies will
suppress the activity of a cancer-associated protein, or kill the cancer cell entirely(189).
Finally, vaccines will expose the immune system to a specific antigen for prevention
(prophylactic) or treatment(190). Once the immune system recognizes the vaccinated
antigen on the cancer cell, they will facilitate its elimination. In this work, monoclonal
antibodies and vaccines with respect to BC treatment will be discussed in further depth.
Targeted monoclonal antibodies are a mainstay in BC immunotherapy since the
late 1990s with the advent of trastuzumab for HER2+ BC; there are a total of 32 FDA
approved antibodies as of 2017(191). The goal of monoclonal antibodies is to target
tumors and (a) directly kill the tumor, (b) switch the immune system to attack the tumor,
(c), attract immune cells to the tumor microenvironment, (d) decrease tumor
vascularization, and (e) inhibit migration(191). Currently, antibodies used in treatment are
either used alone or in combination with cytotoxic chemotherapy, radiotherapy, inhibitor
molecules, other antibodies, or vaccines.
The most common use of mAbs is in the context of immune checkpoint inhibitor
blockade, targeting CTLA-4, PD-1, or PD-L1(192). When the antibody binds to each of
these molecules, it inhibits receptor binding; thus, blocking the immune checkpoint
pathways from getting activated. In the case of CTLA-4 blockade, it prevents activation
of T cells, whereas the PD-1 and PD-L1 blockade affects tumor and T-cell interactions.
The FDA-approved immune checkpoint inhibitors are: ipilimumab (Yervoy®, anti-CTLA4),

pembrolizumab

(Keytruda®,

anti-PD-1),

nivolumab

(Opdivo®,

anti-PD-1),

atezolizumab (Tecentriq®, anti-PD-1), avelumab (Bavencio®, anti-PD-L1), durvalumab
(Imfinzi®, anti-PD-L1). These immunotherapies are approved for many disease types,
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including melanoma, NSCLC, and metastatic RCC(192). In 2017, the FDA approved
pembrolizumab (Keytruda®) for adult and pediatric patients with unresectable or
metastatic, microsatellite instability high or mismatch repair deficient solid tumors that
have progressed following prior treatment, making it the first FDA-approved tissue
agnostic drug, meaning that the drug is prescribed based on the presence of target
biomarker, and not due to tumor type(193). Due to the success achieved in other tumors
targeting checkpoint inhibitors with monoclonal antibodies, it is being tested in breast
cancer as well through many clinical trials (Table 7).

Target
CTLA-4

PD-1

PD-L1

Tumor Type
HER2TNBC
Advanced TNBC
HER2HER2+
BC
TNBC
TNBC
BC
TNBC
TNBC
TNBC
Metastatic BC
TNBC
HER2+ Metastatic
Advanced TNBC

Clinical Trials Identifier
NCT02536794
NCT02381314
NCT02661100
NCT02661100
NCT02129556
NCT02309177
NCT02404441
NCT02555657
NCT02643303
NCT02628132
NCT02685059
NCT02725489
NCT02425891
NCT02478099
NCT02649686
NCT02708680

Table 7. List of checkpoint inhibitor antibodies currently in clinical trials and their
BC subtype.
Historically, vaccines have been developed for disease prevention, and have
focused on targeting B cell immunity and producing a lasting innate immune
response(175). Cancer vaccines, in contrast, have been developed to stimulate T cell
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responses for the treatment of a pre-existing cancer. These vaccines target antigens
specifically expressed or altered in the tumor, either due to mutations, splice variations,
or overexpression(175). Early cancer vaccines targeted CD8+ T cells with short peptides
that bound to MHC class I molecules (EMENS), but these responses were short-lived and
ineffective. This inspired a new wave of delivery methods which would target both CD8+
effector T cells and CD4+ helper T cells(194). These antigens are delivered as peptides,
proteins, named DNA, vectors, or dendritic cells(175). To enhance the response, antigen
delivery is typically combined with adjuvants such as granulocyte-macrophage colonystimulating factor (GM-CSF) or water in oil emulsions(175). A list of current cancer
vaccines can be found in table 8.
DNA/
Viral

Peptide/Protein

Cellular

Study
AVX901
Plasma mammaglobin-A
adHER2-/neu dendritic cell
HER2/neu peptide
Human MUC1 in adenovirus
CEA/TRICOM
Folate receptor binding peptide
Sialyl Lewis-KLH
Multiple Peptide
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
GP2
NY-ESO-1
MUC-1 peptide
Multi-peptide
E75 peptide
Globo H-KLH
NeuVax
HER2 intraceullular protein
HER-2 peptide/adoptive HER2-specific T cells
Allogeneic whole-cell vaccine
GSK2302024A
PANVAC
Allo-stim breast cancer vaccine

NCI Identifier
NCT01526473
NCT00807781
NCT01730118
NCT01376505
NCT02140996
NCT00048893
NCT02019524
NCT00470574
NCT01259505
NCT00304096
NCT00524277
NCT01522820
NCT00986609
NCT01660529
NCT01570036
NCT01516307
NCT01479244
NCT01922921
NCT00791037
NCT00722228
NCT01220128
NCT00179309
NCT01741038

Table 8. Current cancer vaccine clinical trials.
The most advanced vaccines have targeted BC patients overexpressing HER2.
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These patients have been shown to have low levels of antibodies and T cell immunity for
HER2, and these vaccines were therefore designed to amplify this low-level
response(191). The NeuVax (nelipepimut-S) with adjuvant GM-CSF has demonstrated
an improved 5-year disease-free survival of 89.7% compared to control (80.2%)(195).
There is currently a phase III study looking into the prevention of recurrence
(NCT01479244) and a phase II study evaluating efficacy in combination with trastuzumab
(NCT01570036). A list of ongoing vaccine clinical trials in BC can be found in table 9.

Clinical Trial Identifier
I - NCT02427581
(Suspended)
I - NCT01730118

BC Subtype

Vaccine Type

TNBC

Poly ICLC
HER2 dendritic cell vaccine

II - NCT01570036
I/II - NCT02061332
I - NCT01376505

HER2+
TNBC
ER+/HER2HER2+
BC, DCIS
BC

I - NCT02140996

BC

I/II - NCT02018458

Dendritic Cell Vaccine
E75
HER2 pulsed dendritic cell vaccine
HER2 vaccine
Ad-sig-hMUC-1/ecdCD40L vector
vaccine

Table 9. Current BC vaccine clinical trials.
Since vaccines created by short peptides can be costly, a variety of viral vectors
have been developed to deliver antigens. Common vectors include the poxvirus family,
measles, and adenovirus(175). Viral vectors generate more robust immunity than naked
DNA or peptide delivery, but after repeated load delivery they can induce antibodies
against the viral antigens that limit immunogenicity(175). To circumvent this, viral
vaccines use a series of vectors for immune priming. For example, the PROSTVAC
vaccine is a recombinant viral vaccine that contains genes encoding PSA and three costimulatory molecules for T cells(196). Its cousin, the PANVAC vaccine, is a recombinant
poxviral vaccine encoding the MUC1 and CEA genes, with one T cell co-stimulatory
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molecule.
Dendritic cells have also been used as vaccines, since they can be generated from
the peripheral blood of patients and are loaded with antigen peptides. These vaccines are
typically potent, but they are technically challenging and require expertise and specialized
laboratories for processing(175).
Cellular vaccines are derived from patient whole tumor cells or dendritic cells fused
with tumor cells and injected back into the patient. Monitoring these immunotherapies,
though, can be complex, especially since determining which of the tumor antigens are
immunogenic, and production of this treatment is labor-intensive. The first FDA approved
cellular vaccine was sipuleucel-T (ProvengeTM) and approved in 2010 for the treatment
of advanced prostate cancer(197). It works by re-infusing patients with their own APCs
that have been pulsed with prostatic acid phosphatase and GM-CSF. In the phase III
IMPACT trial, it demonstrated improved median overall survival by 4.1 months prostate
cancer(196). An investigational agent named lapuleucel-T (APC8024, Neuvenge) is the
HER2 cognate of sipuleucel-T and contains peripheral blood mononuclear cells cultured
with recombinant HER2 linked to GM-CSF, and has been studied in BC. In a phase I
clinical trial with 18 patients, it was well tolerated, with 5.5% patients achieving a partial
response, and 16.6% of patients achieving stable disease for up to 1 year(198).
1.4.3 Evading immunotherapy in BC
Regulating T cell response is necessary to minimize autoimmunity, and therefore
the immune system has developed a series of checkpoint blockades to aid in this process.
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) is a homologue of cluster of
differentiation 28 (CD28), a T cell co-stimulatory molecule, that binds to B7 on APCs. B7
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has a higher affinity for CTLA-4 than it does for CD28, allowing for CTLA-4 to outcompete
this activation and pause immune activation. CTLA-4 is constitutively expressed on
regulatory T cells (Treg), and will become upregulated in T cells after their activation. In
response, CTLA-4 expression will inhibit T cell activation and the efficacy of an anti-tumor
response.
Programmed death protein-1 (PD-1), on the other hand, is a CD28 and CTLA-4
homologue that is induced on normal, activated T cells. PD-1 promotes apoptosis in
activated T cells within the periphery, and it reduces apoptosis of Treg cells(194). When
these checkpoints fail, an armory of specialized cells will eliminate tumor-promoting
cells(199).
Along with dysfunctional antigen presenting cells, the tumor itself actively modifies
the tumor microenvironment to suppress effector T cells and induce inflammation. As a
result, the tumor microenvironment contains a robust population of regulatory T cells and
myeloid-derived suppressor cells (MDSC), which suppress innate and adaptive
responses(200).
With the overexpression of a number of checkpoint molecules, the tumor evades
T cell recognition. Chronic exposure of the cancer cells to antigen leads to PD-1
upregulation and lead to T cell exhaustion(194). Additionally, programmed death ligand1 (PD-L1) is the ligand of PD-1 and is found upregulated in tumors. When PD-L1 is
expressed, T cells are prevented from recognizing tumor-specific antigens. In cancer,
high levels of PD-L1 in the tumor have been correlated with poor prognosis and
progression(201). Dysregulation of immune checkpoint blockade pathways can lead to
tumorigenesis, and efforts to target these pathways have been made. Recently, many
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immunotherapies have been developed to target checkpoint signaling axes.
1.4.4 Current challenges in monitoring vaccine immunotherapy
Immunotherapy has dramatically increased cancer survival and response rates for
the past few decades. This is possibly due to its potential to achieve long-term disease
control in a significant population of patients as compared to targeted therapies.
Additionally, tumor progression while on immunotherapy peaks later combined with a
median duration of response spanning up to years. Unfortunately, the mechanism behind
this long-term response is unclear, and a strict definition of clinical endpoints is lacking.
The most commonly used clinical guidelines defining tumor response to
immunotherapy come from the immune-modified response evaluation criteria in solid
tumors (imRECIST). This criteria was adapted from response criteria in solid tumors
(RECIST), since immunotherapy can produce unconventional responses and overall
survival benefits that were not captured by RECIST(202). Criteria for imRECIST define
tumor burden as unidimensional with up to five target lesions and two per organ. New
lesions do not categorically represent progressive disease (PD), and measurable new
lesions are then incorporated into the total tumor burden. Non-target lesions do not define
PD, and contribute to definition complete response. PD can be negated by subsequent
non-PD after 4 weeks from the first documented tumor. Additionally, best response may
occur after any number of PD assessments(202).
For vaccines response monitoring, in particular, a few immunodynamic endpoints
have been defined, depending on the vaccine type(203). For dendritic cell vaccines, T
cell response post vaccination in the tumor via IHC is a standard measurement.
Additionally, multicolor immunofluorescence of Treg cells, CD1a, CD8, CD94, CD207,
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and HLA-DR calculated as a ratio of pre/post scores are also encouraged. For non-cell
based vaccines, peripheral blood mononuclear cells (PMBCs) are characterized. T cell
receptor repertoire analysis Flow cytometry is used to quantify and phenotype the T cell
response, and is a highly quantitative, reproducible, and standardized test(204). T cell
functions are calculated through flow cytometry of perforin, granzyme, and intracellular
cytokine expression. Additionally, ELISPOT can be used to assess functionality after
antigen-specific stimulation, but is limited by lack of reproducibility and requires a
knowledge of antigens to be tested(205). Whole T cell repertoire through CDR3
spectratyping and next generation sequencing is now being used to assess T cell
diversity(206). This method does not require an a priori knowledge of antigens and can
be performed with less than 1 mL of whole blood. While these methods all provide insight
into the immune system after vaccination, they require tissue or blood samples from the
patient, and do not recapitulate events within the entire tumor microenvironment in situ in
the analysis. Furthermore, site monitoring of the immune response still remains of critical
consideration in the field of immunotherapy, and molecular imaging techniques have been
employed.
ImmunoPET imaging has been targeting immune biomarkers CTLA-4, PD-1,
CD47, CD11b, T cell receptor, CXCR4, B7-H3, granzyme B, CD3+ T cells and IFN-γ in
various preclinical studies(207,208).

89Zr-

and

64Cu-

labelled PD-L1(209) and

89Zr-

MPDL3280A (NCT02453984) PET tracers are in clinical development for imaging PD-L1.
First-in-human PD-L1 imaging studies demonstrated heterogeneous tumor uptake
among tumors with minimal PD-L1 expression through IHC, coupled with high
background uptake in secondary lymphoid tissues(210). This study proved clinical
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feasibility, although improvements are necessary to improve background uptake and
expression correlating to imaging results.

18F-Clofarabine

(CFA) is in development for

monitoring immune cell proliferation through deoxycytidine kinase imaging(211). T cell
activation

through

the

deoxyguanosine

pathway

is

in

trials

using

18F-D-

arabinofuranosylguanine (AraG) PET imaging(212). CD8+ T cells are imaged through
89Zr/64Cu-anti-CD8(213,214)

and 89Zr-IAB22M2C PET imaging(58).

The potential for imaging provides a unique opportunity to directly monitor immune
responses within the tumor microenvironment before tumor shrinkage and response can
be verified through other means. Immunotherapy regimens are still being optimized, and
significant efforts have been made to identify and validate predictive biomarkers to aid in
treatment decisions. These biomarkers could be used alone or in combination imaging,
and additionally with ex vivo analysis and validation throughout treatment.
1.5 Specific aims and summary of research
The studies outlined in this dissertation have been partitioned into three specific
aims. In the first aim found in Chapter 2, titled “Monitoring Src Status after Dasatinib
Treatment in HER2+ Breast Cancer with

89Zr-trastuzumab

PET imaging”, I explored the

relationship between Src and HER2 is explored as is the ability of

89Zr-trastuzumab

to

monitor changes in HER2 after Src treatment. In this study, upon abrogation of Src
signaling with dasatinib, an increase in

89Zr-trastuzumab

binding and uptake was

observed in in vitro cell studies and in vivo animal studies of trastuzumab-sensitive (BT474) and trastuzumab-resistant (JIMT-1) lines. The uptake to standard 18F-FDG imaging
was compared to find that this metabolic tracer failed to distinguish differences in tumor
uptake after dasatinib treatment. Ex vivo tumor analysis showed a correlation between
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pSrc (Y416) abrogation and pHER2 (Y1221/1222) expression, and

89Zr-trastuzumab

uptake.
In the second aim, described in Chapter 3, entitled “Using

89Zr-cetuximab

PET

imaging to visualize membrane EGFR expression following dasatinib treatment in TNBC”,
the ability of 89Zr-cetuximab was explored to measure changes in EGFR localization after
dasatinib treatment, and if any correlation can be made with an improved response to
combination dasatinib and cetuximab treatment. Using TNBC cell lines MDA-MB-231
(KRAS mutant), MDA-MB-468 (KRAS wild-type-wt), an increase in

89Zr-cetuximab

binding and internalization was demonstrated after dasatinib treatment, coupled with a
decrease in both pSrc (Y416) expression, and in nuclear EGFR expression as shown by
western blots. In vivo studies of using the tumors established from these two cell lines
including a TNBC patient-derived xenograft (JAX TM00089, KRAS wt), an increase in
89Zr-cetuximab

uptake was demonstrated after dasatinib treatment, with a concomitant

improvement in treatment responses with combination dasatinib and cetuximab therapy
in kras wild-type cell lines. Ex vivo validation studies showed a correlation between EGFR
expression and 89Zr-cetuximab uptake.
In the final aim found in Chapter 4, titled “Using immunoPET to monitor tumor
response to immunotherapy”, the ability for

89Zr-labeled

anti-IFNγ (89Zr-anti-IFNγ) was

evaluated to visualize changes in tumor uptake after a HER2/neu DNA vaccine that
induces an active T-cell response against rat neu antigen. In transgenic mice and mice
bearing syngeneic tumors, a significant increase was observed in

89Zr-anti-IFNγ

uptake

within the tumor after vaccination, with a low uptake in secondary lymphoid organs
(spleen, lymph nodes). Further validation indicated that this was due to an increase in
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IFN-γ production and CD8 T-cell infiltrates within the tumor.
As is pertains to this thesis, ways to monitor response to targeted therapy and
immunotherapies are warranted. These results will provide fundamental insights into the
biology of the tumor microenvironment for further refinement of treatment strategies and
combinations.
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CHAPTER 2: MONITORING SRC STATUS AFTER DASATINIB TREATMENT IN
HER2+ BREAST CANCER WITH 89ZR-TRASTUZUMAB PET IMAGING
This chapter was adapted in full from “Monitoring Src status after dasatinib
treatment in HER2+ BC with

89Zr-trastuzumab

PET imaging” by Brooke McKnight and

Nerissa T. Viola-Villegas, originally published in Breast Cancer Research and used with
their permission.
2.1 INTRODUCTION
The human epidermal growth factor receptor 2 (HER2) has become a critical
therapeutic target with trastuzumab (Herceptin®) as the mainstream, first-in-line standard
of care in HER2-positive BC patients(215,216). Unfortunately, response rates to HER2targeted therapy remain dismal due to acquired and de novo resistance, which in part,
can be attributed to alterations in receptor tyrosine kinases (RTKs)(189), and downstream
signaling transduction pathways, such as Src(217,218).
Src is a non-receptor tyrosine kinase expressed ubiquitously that interacts with
several RTKs(158). Its activation enhances cellular migration and survival(149). It has
been shown that the hyperactivation of Src leads to HER2 stabilization and vice
versa(157), establishing a functional relationship between the two oncogenes(157). This
was reported in a study by Tan et al. wherein Src abrogation concomitantly led to
decreased HER2 levels within 7-14 days of treatment with a Src inhibitor, PP2 in
vitro(157). Thus, Src is implicated as a key molecule in resistance to trastuzumab therapy,
making this signaling axis an attractive target for inhibition.
Dasatinib (Sprycel®) is a Src and BCR/ABL tyrosine kinase inhibitor and was FDAapproved for leukemia in 2006(219). Preclinical data reported by Seoane et al.
demonstrated the synergistic effects of dasatinib with trastuzumab as evidenced by
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attenuated phosphorylated levels of Src, ERK and AKT in HER2+ BC(220). These
preclinical findings were validated in a prospective phase I-II trial exploring combinatorial
efficacy and safety of dasatinib, trastuzumab and paclitaxel in patients with BC(221).
Monitoring of tumor response to this drug cocktail was conducted through
immunohistochemistry (IHC) analysis of patients’ skin samples. However, better ways to
non-invasively monitor tumor response can be achieved by exploring the direct causal
relationship between HER2 and Src.
In this study, the potential of

89Zr

(t1/2 ~ 3.27 d) labeled trastuzumab was

investigated as a surrogate tool to monitor biologic effects of dasatinib (Sprycel) treatment
in HER2+ BC. First evaluation the specificity of

89Zr-

trastuzumab in BT-474

(HER2+/ER+/PR-), JIMT-1 (HER2+, trastuzumab resistant), and MDA-MB-468 (triple
negative) cell lines was evaluated with its ability to resolve changes in HER2 expression
during dasatinib treatment. Next, the utility of

18F-FDG

and

89Zr-trastuzumab

as a

predictive imaging tool was examined using the same group of mice-bearing BT-474 and
JIMT-1 tumors treated with dasatinib. After imaging, HER2 PET uptake was correlated to
changes in tumor volume, immunoblots, and immunohistochemistry.
2.2 RESULTS
2.2.1 Characterization of 89Zr-trastuzumab
Radiolabeling yields of >95% were obtained with >97 % purity after purification via
spin column. A specific activity of 2.98 ± 0.2 mCi/mg (20.9 ± 5.6 Bq/µmol) was
established. The labeled antibody retained immunoreactivity towards HER2 with 85%
retention (Figure 12, n = 3).
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Figure 12. 89Zr-trastuzumab retains immunoreactivity in BT-474. Immunoreactivity of
89Zr-trastuzumab showed retained reactivity with r2 = 0.96.
2.2.2 In vitro treatment studies with dasatinib
BT-474 (Fig. 13A) and JIMT-1 (Fig. 13B) cells were treated with increasing
concentrations of dasatinib to achieve an IC50 value for 72 h post-treatment. IC50 value of
1.3 ± 0.12 µM and 0.22 ± 0.09 µM were achieved for BT-474 and JIMT-1 respectively.
BT-474 and JIMT-1 cells were treated with dasatinib for 6-48 h and western blots were
performed on treated and untreated cell lysates to observe protein expression. In BT-474
cells (Fig. 13C), there was no change in total HER2 or total Src protein expression upon
treatment with dasatinib. After 6 h of exposure to dasatinib, total abrogation of pSrc (Y416,
directly associated with dasatinib Src tyrosine kinase activity(222)) and pHER2
(Y1221/1222, autophosphorylation site) were observed. In JIMT-1 cells (Fig. 13D),
attenuation of pHER2 (Y1221/1222) after 24 h and pSrc (Y416) activity after 6 h was
displayed post-dasatinib treatment. There was no change in total HER2 or Src protein
levels upon treatment as shown by densitometry.
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Figure 13. Dasatinib treatment decreases pSrc (Y416) and pHER2(Y-1221) protein
levels in vitro. BT-474 (A) or JIMT-1 (B) cells were treated with increasing concentrations
of dasatinib for 72 h to achieve IC50 values of 1.3 ± 0.12 µM and 0.8 ± 0.02 µM,
respectively. BT-474 cells (C) and JIMT-1 (D) were treated with IC50 dasatinib up to 48 h
and western blots were performed for HER2, Src, pSrc (Y416), and pHER2 (Y1221/1222).
Densitometry results are shown as the ratio of target protein/GAPDH.
Next, the ability of HER2 to internalize trastuzumab after dasatinib timecourse
treatment was investigated using

89Zr-trastuzumab

(Fig. 14). A steady decrease in

89Zr-

trastuzumab internalization was exhibited by both BT-474 and JIMT-1. Internalization of
89Zr-trastuzumab

in untreated BT-474 was measured at 10.37 ± 1.62% without dasatinib

treatment, however, internalized fractions decreased after 6 h and 24 h of dasatinib
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treatment with ~7.68 ± 0.53% (p = 0.02), and 7.42 ± 0.74% (p = 0.03) respectively. At 48
h, only ~4.78 ± 0.42% (p = 0.006) of the radiotracer was found intracellularly. JIMT-1 cells
also showed a decrease in internalization upon treatment. From 2.6 ± 0.25% internalized
in untreated cells, bound activity was reduced to 1.22 ± 0.10% (p = 0.009) after 24 h, and
0.17 ± 0.5% (p < 0.0001) after 48 h of treatment. No significant reduction in internalized
radiotracer was observed after 6 h of dasatinib exposure (1.96 ± 0.46%, p = 0.10).
These results are similar to the amount of total membrane-bound HER2 present
extracellularly (and thus, available for tracer targeting) during dasatinib treatment as
represented by the total amount of

89Zr-trastuzumab

bound (Fig. 14). Compared to

untreated BT-474 cells with 14.10 ± 1.22% bound radiotracer, a decrease was observed
in treated groups after dasatinib exposure for 6 h (11.79 ± 1.00%, p = 0.0854) and 24 h
(11.42 ± 2.04%, p = 0.038). Further reduction was observed after 48 h with 8.88 ± 1.44%
(p = 0.0002). In JIMT-1 cells, a similar trend was observed with lower

89Zr-trastuzumab

binding in groups treated for 6 h (2.46 ± 1.02%, p = 0.9578), 24 h (1.26 ± 1.00%, p
=0.2075) and 48 h (0.34 ± 0.21%, 0.0277) relative to untreated cells at 3.16 ± 0.50%.
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Figure 14. 89Zr-trastuzumab binding and uptake decreases upon dasatinib
treatment. Internalization and binding assays of 89Zr-trastuzumab on BT-474 and JIMT1 cells treated with dasatinib IC50 from 0-48 h showed a decrease in probe internalization
and binding over time
These results are in good agreement with the western blot findings. In BT-474, an
abrogation of pHER2(Y1221/1222) was observed after 6 h dasatinib treatment. Coupled
with the internalization assays, the same decrease in tracer internalization was observed
after 6 h. Similarly, in JIMT-1, a decrease in pHER2 after 24 h dasatinib treatment was
observed, which is where drop off in internalization of the tracer occurs. These results
suggest that there is an association between dasatinib treatment and a decrease in
internalization, which results in a reduction in total cellular accumulation (89Zrtrastuzumab %bound + internalized).
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Figure 15. 89Zr-trastuzumab binding and uptake decreases upon dasatinib
treatment. Treatment and imaging scheme illustrate treatment of tumors for 7 d and/or
14 d with dasatinib followed by PET imaging with 18F-FDG. 89Zr-trastuzumab was
administered a day after with imaging acquired 48 h p.i. Tx = Treatment.
2.2.3 Validation of 89Zr-trastuzumab specificity to HER2
From in vitro studies using BT-474 (HER2+/ER+), JIMT-1 (HER2+/ER-), and MDAMB-468 (HER2-/ER+) cells, co-administration of 25-fold unlabeled trastuzumab exhibited
lower binding of 89Zr-trastuzumab in HER2+ cell lines and did not change binding in MDAMB-468 HER2- cell line (Fig. 16A). In BT-474, there was a 6-fold decrease of

89Zr-

trastuzumab binding in trastuzumab blocked cells compared to control (1.07 ± 0.24% vs.
6.64 ± 1.14%, p < 0.0001). JIMT-1 cells exhibited a 2-fold decrease in

89Zr-trastuzumab

binding in 25-fold trastuzumab blocked cells compared to control (0.65 ± 0.18 vs. 1.46 ±
0.24, p = 0.0007). MDA-MB-468 cells did not exhibit a difference in

89Zr-trastuzumab

binding between 25-fold blocked cells and control (0.71 ± 0.40 vs. 1.11 ± 0.56, p = 0.34).
Mice bearing BT-474, JIMT-1, or MDA-MB-468 xenografts were imaged with 89Zrtrastuzumab at 48 h p.i. (Fig. 16B-C). MDA-MB-468 tumors exhibited the lowest uptake
of 3.9 ± 0.6 %ID/g, compared to BT-474 (17.9 ± 2.2 %ID/g, p < 0.001) and JIMT-1 (7.7 ±
0.6 %ID/g, p < 0.001) tumors. Interestingly, there was significantly less 89Zr-trastuzumab
uptake in JIMT-1 tumors compared to BT-474 (p < 0.0001).
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Figure 16. 89Zr-trastuzumab is specific for HER2. BT-474, JIMT-1, and MDA-MB-468
cells were incubated with 100 ng 89Zr-trastuzumab alone or co-incubated with 25-fold
unlabeled Trastuzumab before being lysed and radioactivity measured using a gamma
counter (A); nude mice bearing MDA-MB-468, BT-474, or JIMT-1 tumors were imaged
with 89Zr-trastuzumab 48 h p.i. (B); tumor ROIs showing significant uptake in HER2+
tumors, but no uptake in MDA-MB-468 HER2- tumors (C).
Tissue distribution addressed concerns against enhanced permeation retention
(EPR) effect. In BT-474 tumor,

89Zr-trastuzumab

uptake in the tumor was 16.01 ± 3.78

%ID/g, which is significantly higher than an isotype-matched IgG control (1.02 ± 0.87
%ID/g, p = 0.0002) (Fig. 17, Table 10). 89Zr-trastuzumab had an average tumor uptake of
4.13 ± 2.36 %ID/g (Fig. 17, Table 11) in JIMT-1 tumors, whereas the non-specific IgG
control probe exhibited a significantly lower tumor accumulation of 0.79 ± 0.24 %ID/g (p
= 0.0338).

66

Figure 17. 89Zr-trastuzumab tumor uptake compared to isotype matched control.
Mice bearing BT-474 and JIMT-1 tumors were injected with 89Zr-IgG or 89Zr-trastuzumab
and tumors were removed 48 h p.i. and measured using a gamma counter. In both cell
lines, specific 89Zr-trastuzumab uptake is significantly higher than isotype control IgG.

67

89Zr-trastuzumab

Mean

89Zr-IgG

S.D.

Mean

S.D.

Blood

2.39

±

1.14

1.71

±

1.01

Tumor

16.10

±

3.79

1.02

±

0.87

Heart

3.17

±

1.43

0.50

±

0.21

Lungs

13.37

±

9.79

0.50

±

0.28

Liver

9.27

±

5.56

9.12

±

2.66

Kidneys

4.53

±

3.85

5.27

±

2.47

Stomach

1.86

±

1.23

0.59

±

0.30

Intestines

3.74

±

0.80

3.44

±

1.41

Spleen

8.15

±

3.75

0.54

±

0.35

Pancreas

1.76

±

1.20

0.21

±

0.20

Brain

0.25

±

0.29

0.15

±

0.04

Bone

10.34

±

3.26

0.03

±

0.01

Muscle

0.33

±

0.18

0.06

±

0.02

Table 10. 89Zr-trastuzumab and 89Zr-IgG biodistribution in BT-474 tumors.
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89Zr-trastuzumab

Mean

89Zr-IgG

S.D.

Mean

S.D.

Blood

6.69

±

2.53

1.23

±

0.65

Tumor

4.13

±

2.36

0.08

±

0.02

Heart

2.20

±

0.92

0.39

±

0.18

Lungs

3.01

±

2.25

0.65

±

0.44

Liver

4.70

±

1.46

9.43

±

6.96

Kidneys

4.49

±

1.28

5.10

±

1.59

Stomach

1.13

±

0.46

0.34

±

0.17

Intestines

3.79

±

1.07

3.08

±

0.35

Spleen

2.79

±

1.38

0.36

±

0.16

Pancreas

0.93

±

0.38

0.12

±

0.06

Brain

0.33

±

0.19

0.12

±

0.04

Bone

0.65

±

0.40

0.02

±

0.01

Muscle

0.33

±

0.17

0.04

±

0.04

Table 11. 89Zr-trastuzumab 89Zr-IgG biodistribution in JIMT-1 tumors.
2.2.4 In vivo monitoring of tumor response to dasatinib
Mice bearing palpable BT-474 tumors were dosed with dasatinib for 7 and 14 days
and imaged with 18F-FDG and 89Zr-trastuzumab (Fig. 18). Tumor uptake of 18F-FDG was
not statistically different between untreated mice (3.60 ± 1.51% ID/g) and those treated
with dasatinib for 7 d (3.86 ± 0.59 %ID/g, p = 0.99) and 14 d (4.63 ± 0.21 %ID/g, p = 0.80)
(Fig. 19A). In comparison,

89Zr-trastuzumab

exhibited a significant decrease in tumor

accumulation in both treated groups (7 d: 11.05 ± 2.10 %ID/g, p < 0.0001, and, 14 d: 9.2
± 1.85 %ID/g, p < 0.0001) compared to untreated tumors (17.88 ± 2.18 %ID/g) (Fig. 19B).
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No significant difference in probe uptake was observed between 7 and 14 d treated
cohorts (p = 0.3925) (Fig. 19C). A correlation between changes in tumor volumes
measured prior and after treatment vs.

89Zr-trastuzumab

VOI PET uptake displayed a

significant positive correlation (r = 0.85, p = 0.001) (Fig. 19D) wherein a decrease in tumor
volume matched a lower PET readout.

Figure 18. 89Zr-trastuzumab binding and uptake decreases upon dasatinib
treatment. Treatment and imaging scheme illustrates treatment of tumors for 7 d and/or
14 d with dasatinib followed by PET imaging with 18F-FDG. 89Zr-trastuzumab was
administered a day after with imaging acquired 48 h p.i. (B). Tx = Treatment.
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Figure 19. 89Zr-trastuzumab PET imaging predicts tumor response to treatment in
BT-474 xenografts. Untreated (left) and treated BT-474 tumors for 7 d (middle) or 14 d
(right) with 75 mg/kg dasatinib were imaged with FDG-PET (A). In the same group of
mice, PET imaging with 89Zr-trastuzumab demonstrated attenuated tracer accumulation
in treated groups compared to control (B). Tumor VOIs demonstrated lower tumor uptake
of 89Zr-trastuzumab in treated groups compared to control; no observed changes were
detected by FDG in both control and treated groups (C). % change in tumor volume during
treatment correlated with 89Zr-trastuzumab uptake (D). T = tumor, L = liver. *** denotes p
< 0.001.
In JIMT-1 tumor bearing mice, FDG-PET did not distinguish untreated tumors (3.81
± 0.78 %ID/g) vs. dasatinib-treated groups (7d: 3.36 ± 0.89 %ID/g, p = 0.7338; 14 d: 3.20
± 1.37 %ID/g, p = 0.6126) (Fig. 20A). Using the same mice, tumor uptake of

89Zr-

trastuzumab displayed VOIs of 8.04 ± 0.71 %ID/g for control; a two-fold decrease in
uptake after 7 d (3.88 ± 1.47 %ID/g, p < 0.0001) and 14 d (4.45 ± 1.23 %ID/g, p < 0.0001)
was observed during dasatinib treatment (Fig. 20B). Similar to BT-474 xenografts, there
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was no observed difference in tracer accumulation observed between treated cohorts (p
= 0.7120) (Fig. 20C). Changes in tumor volumes displayed a direct, positive correlation
with 89Zr-trastuzumab PET uptake (r = 0.82, p = 0.0002) (Fig. 20D).

Figure 20. 89Zr-trastuzumab PET imaging predicts tumor response to treatment in
JIMT-1 xenografts. Untreated (left) and 7 d (middle) or 14 d (right) treated JIMT-1 tumors
imaged with FDG (A). The same group of mice imaged with 89Zr-trastuzumab after 48 h
p.i. (B). VOIs drawn on the tumors displayed lower accumulation of 89Zr-trastuzumab in
treated groups compared to control but no change in FDG-PET tumor uptake was
observed across all cohorts (C). % Change in tumor volume correlated with 89Zrtrastuzumab uptake (D) T = tumor, L = liver. *** denotes p < 0.001.
2.2.5 Ex Vivo analysis of BT-474 and JIMT-1 Tumors
After imaging, tumors were removed for ex vivo validation of the PET readout.
From the immunoblot analysis, BT474 tumors showed a moderate decrease in total Src
levels upon treatment with dasatinib, whereas its activity was mitigated by 2.6-fold as
displayed by pSrc (Y416) levels in both 7 and 14 d treated cohorts (Fig. 21A). Additionally,
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there is a decrease in total HER2 via densitometry after 7 d and 14 d treatments (Fig.
21A). A positive correlation between pSrc (Y416) (r = 0.70, p = 0.025) (Fig. 21B) and
pHER2 (r = 0.64, p = 0.046) (Fig. 21C) (measured by densitometry) against tumor VOI

values for BT-474 was observed.
Figure 21. Ex vivo validation on excised BT-474 tumors confirm PET uptake.
Western blots were performed for HER2, Src, and pSrc (Y416) expression using BT-474
tumor lysates (A); a plot of the pSrc (Y416) densitometry shows a linear relationship with
89Zr-trastuzumab PET uptake (B); a plot of the pHER2 (Y1221) densitometry vs. tumor
VOI shows a positive linear relationship with 89Zr-trastuzumab PET uptake (C).
Treated and control JIMT-1 tumors did not show a difference in total HER2 or Src
expression, however, a noticeable decrease in both pSrc and pHER2 after 7 and 14 d
treatments was displayed (Fig. 22A). Moreover, a significant, positive association
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between pSrc (Y416) (r = 0.68, p = 0.022) and 89Zr-trastuzumab tumor VOI was achieved
(Fig. 22B). A direct relationship between dephosphorylated HER2 and tracer uptake in
the tumor was also demonstrated (r = 0.63, p = 0.037) (Fig. 22C).

Figure 22. Ex vivo validation on excised JIMT-1 tumors confirm PET uptake.
Western blots were performed for HER2, Src, and pSrc (Y416) expression using JIMT-1
tumor lysates (A); a plot of the pSrc (Y416) densitometry shows a linear relationship with
89Zr-trastuzumab PET uptake (B); a plot of the pHER2 (Y1221) densitometry vs. tumor
VOI shows a positive linear relationship with 89Zr-trastuzumab PET uptake (C).
IHC was performed to visualize subcellular localization of HER2 and pSrc (Y416)
in excised tumors. Unmodulated BT-474 tumors showed strong positive membranous
HER2 staining (Fig. 23A, top left panel), whereas, predominant cytoplasmic HER2
localization was exhibited in tumors treated for 14 days with dasatinib. (Fig. 23A, top
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right). Lower pSrc (Y416) staining was observed in treated tumors (Fig. 23A, bottom right)
compared to control (Fig. 23A, bottom left). Control JIMT-1 tumors exhibited lower
expression of membrane-localized HER2 (Fig. 23B, top left) compared to BT-474 but
translocation to cytoplasmic regions was observed in treated sections (Fig. 23B, top right).
Higher pSrc (Y416) staining is displayed in control (Fig. 23B, bottom right) versus
dasatinib treated tumor sections (Fig. 23B, bottom left).

Figure 23. Immunohistochemistry on excised BT-474 and JIMT-1 tumors show
HER2 and pSrc (Y416) changes. IHC (40× magnification) was performed on excised
BT-474 tumors (A) and JIMT-1 (B) showing HER2 (top) and pSrc (Y416, bottom)
expression with (right) and without (left) dasatinib treatment (A).
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2.3 DISCUSSION
Trastuzumab has been the standard of care for two decades for HER2+ BC(134).
Unfortunately, about half of patients with HER2-overxpressing BC do not respond to
trastuzumab due to de novo and acquired resistance mechanisms(223). The nonreceptor tyrosine kinase Src was shown to be a key modulator of trastuzumab response,
and

is

an

important

downstream

node

of

multiple

trastuzumab

resistance

pathways(149,158,218,223,224). Targeting Src with dasatinib in vitro re-sensitized
trastuzumab-resistant cell lines, suggesting this pathway as a strategy to overcome
resistance(158). Additionally, patients with high levels of phosphorylation of Src at the
Y416 residue have presented a lower clinical response rate and higher progressive
disease after trastuzumab treatment, compared to those with lower pSrc (Y416) levels,
suggesting that pSrc activation is correlated with trastuzumab resistance(225).
Clinical trials (NCT01306942, NCT00566618, and NCT00820170) are currently
examining dasatinib as part of a multicombinatorial treatment in BC. Previous studies
have focused on monitoring dasatinib response by radiolabeling dasatinib itself(226). This
method has its limitations, since this can potentially miss functional effects upstream or
downstream of the Src signaling pathway. Previous studies have demonstrated the
relationship of Src and HER2 where it is shown that hyperactivated Src is stabilized by
aberrant HER2 signaling, and one study in particular demonstrated that modulating c-Src
with PP2 in vitro decreased HER2 levels after 7 days of treatment and abrogated it
completely after 14 days of treatment(157,227). Thus, HER2 PET as a surrogate
predictive marker of dasatinib treatment is worth investigating with 89Zr-trastuzumab PET
imaging currently in patient trials not only for HER2+ tumor detection(228) but as a marker
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of response to other targeted treatment (NCT01081600 for AUY922 HSP90 inhibitor,
NCT01565200 for T-DM1 ).
Previous studies have stated that using 89Zr-trastuzumab PET imaging to monitor
response to therapy would only be feasible if the drug is directly acting on HER2(59).
Using 89Zr-trastuzumab as a surrogate marker of targeted inhibition of effector molecules
downstream of the HER2 signaling pathway has been conceptually proven, for example
with Hsp90 inhibition(37). To the best of our knowledge, this is the first study that
demonstrated the potential of 89Zr-trastuzumab PET to monitor Src response to dasatinib
treatment. Specifically, we have shown that

89Zr-trastuzumab

detects lower membrane

HER2 expression with concomitant internalization of HER2 after 6 h (BT-474) or 48 h
(JIMT-1) dasatinib treatment, as shown by our internalization assays. The lower
internalization was coupled with a lower total HER2 present on the cell surface, confirmed
by

89Zr-trastuzumab

binding experiments and western blots of pHER2(Y1221/1222),

which activates HER2 receptor activation. From our in vivo studies,

89Zr-trastuzumab

detected changes in HER2 expression upon inhibition of functional Src, where standardof-care FDG-PET imaging has failed to detect differences in tumor uptake after dasatinib
treatment. Importantly, the PET uptake directly correlated with tumor regression. The
PET results were histologically validated with a concomitant decrease in membranous
HER2 staining in treated groups coupled with the abrogation of pSrc (Y416) staining.
Furthermore, western blot analysis probing for functional Src activity exhibited a direct
relationship with the HER2 PET readout. It is worth noting that our studies are limited to
single agent Src inhibition; the utility of HER2 PET in combinatorial therapies including
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Src in HER2+ BC still warrants further investigation.
In conclusion, 89Zr-trastuzumab can potentially delineate changes in Src activity in
HER2+ BC in both trastuzumab-sensitive and resistant phenotypes.
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CHAPTER 3: USING 89ZR-CETUXIMAB PET IMAGING TO VISUALIZE MEMBRANE
EGFR EXPRESSION FOLLOWING DASATINIB TREATMENT IN TNBC
3.1 INTRODUCTION
TNBC accounts for 20% of all diagnosed BC and lack of therapeutic targets
(ER/PR/HER2) makes it more difficult to treat, resulting in chemotherapies such as taxane
or anthracycline as the mainstay standard of care(229). While many TNBC patients
initially respond to chemotherapy, the high rate of recurrence and progression makes it a
far more aggressive disease with worse prognosis compared to other subtypes.
Gene expression profiling studies identified EGFR as a potential biomarker
indicating possible treatments due to its overexpression in TNBC(230,231). A number of
EGFR-targeted therapies that were previously approved for other cancer types are
currently explored for TNBC, including monoclonal antibodies (panitumumab and
cetuximab) and small molecule inhibitors (gefitinib, erlotinib, and afatinib)(232).
Unfortunately, achieving significant response rates in the clinic were dismal(233,234)
possibly due to the lack of biomarkers to select appropriate patients who would be
predited to respond. One explanation may be attributed to the receptor’s nuclear
translocation, diminishing drug targeted delivery to cell-surface receptors. nEGFR acts as
a transcription factor regulator involved in tumorigenesis(235,236). Interestingly, the
expression of nEGFR has been correlated with poorer outcomes in many
cancers(82,237,238),

and

resistance

to

anti-EGFR

therapies,

including

cetuximab(168,239). Previous studies have shown that Src Family Kinase (SFK)
inhibition with dasatinib blocks nEGFR translocation, transporting EGFR to the plasma
membrane; thus, enhancing cetuximab sensitivity in TNBC and non-small cell lung cancer

79
(168,239,240).
Studies developing

89Zr(t

1/2

~ 3.27 d) labeled cetuximab (Erbitux®) as a positron

emission tomography (PET) tracer have been reported. This EGFR-specific imaging
probe is currently in clinical trials to select cancer patients who may benefit from
cetuximab treatment in many cancer types(241–243). To date, 89Zr-cetuximab has shown
promise in visualizing tumors expressing EGFR, and could be used to monitor EGFR
receptor expression and steer individualized treatments(244).
In this aim, it was hypothesized that

89Zr-cetuximab

could be used as a tool to

monitor membrane EGFR expression after dasatinib treatment in TNBC.

89Zr-cetuximab

specificity was evaluated in EGFR-positive TNBC cell lines MDA-MB-231 (KRAS mutant)
and MDA-MB-468 (KRAS wild type (wt)) and was compared against low EGFRexpressing TNBC MDA-MB-453 (KRAS mutant) cells. After establishing the tracer’s
specificity, its potential to assess changes in membranous EGFR density was
investigated in both EGFR-positive TNBC xenografts post-treatment with dasatinib
through in vitro internalization assays and western blots. An EGFR-positive, Kras wt
TNBC patient derived xenograft (PDX, JAX TM-00089) was also investigated for ex vivo
treatment studies. Validation of

89Zr-cetuximab

PET was conducted using western blots,

immunohistochemistry (IHC) and autoradiography.
3.2 RESULTS
3.2.1 Radiolabeling and characterization of 89Zr-cetuximab
89Zr-cetuximab

radiolabeling yields of >90% were obtained with >95% purity after

purification via spin column. A specific activity of 4.7 ± 0.3 mCi/mg was established. The
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labeled antibody retained immunoreactivity towards EGFR with 74.8 ± 3.4% (Fig. 24)
n=3).

Figure 24. 89Zr-cetuximab retains immunoreactivity in MDA-MB-468. A Lindmo assay
was performed to measure immunoreactivity of 89Zr-cetuximab after modifications and
shows retained reactivity towards EGFR.
The potential of

89Zr-cetuximab

was investigated to assess changes in

membranous EGFR levels was examined. Using the same treatment scheme, treated
and untreated cells were incubated with 89Zr-cetuximab at 4 °C to prevent internalization.
Surface-bound activity increased for both MDA-MB-231 (17.9 ± 3.6% vs. 26.0 ± 3.0%, p
= 0.042) and MDA-MB-468 (18.9 ± 0.6% vs. 47.3 ± 3.8 %, p = 0.0002) after dasatinib
treatment (Fig. 25A).
Internalization rates of

89Zr-cetuximab

after dasatinib treatment were investigated

over time and compared against membrane bound fractions (Fig. 25B). An increase in
internalization of the tracer after 48 h of drug treatment compared to control was observed
in MDA-MB-231 cells (16.6 ± 3.3% vs. 26.2 ± 3.7%, p = 0.0002). Similar but more
pronounced effects were observed in treated MDA-MB-468 cells where internalized
fractions were higher by 1.5-fold (27.7 ± 3.33%, p = 0.0098) and three-fold (42.6 ± 4.39%,
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p < 0.0001) at 24 h and 48 h respectively, compared to control groups (17.9 ± 0.8%).
Membrane-bound activity for both cell lines did not show a significant difference between
control and treated groups likely due to internalization. The low-EGFR expressing MDAMB-453 demonstrated minimal binding and internalization of the tracer. Collectively, this
in vitro binding assay suggests that the radiotracer was able to measure higher
membrane-localized

EGFR

levels

after

blockade

of

Src

activity.
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A.

B.

Figure 25. Internalization and uptake of 89Zr-cetuximab. MDA-MB-231 and MDA-MB468 cells exposed to dasatinib for 48 h showed higher surface-bound 89Zr-cetuximab
compared to untreated controls (A); incubation from 8-48 h with dasatinib showed higher
internalized fractions of the tracer at later time points (B). * denotes p < 0.05, *** denotes
p < 0.001.
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The low-EGFR expressing MDA-MB-453 demonstrated minimal binding and
internalization of the tracer (Fig. 26). This suggests that exposure to dasatinib resulted in
higher membrane-bound EGFR levels available, which can be visualized and quantified
by 89Zr-cetuximab. Importantly, an increase in cell surface EGFR concomitantly leads to
higher receptors available for drug delivery.

Figure 26. Non-specific tracer uptake in MDA-MB-453. In vitro 89Zr-cetuximab
internalization in MDA-MB-453 cells (A). Comparison of 89Zr-cetuximab tracer % bound,
internalized, and total tracer bound and internalized between MDA-MB-231, MDA-MB468, and MDA-MB453 cell lines (B).
3.2.2 89Zr-cetuximab is specific for tumors expressing EGFR in vivo
The specificity of 89Zr-cetuximab for EGFR was investigated through in vivo
imaging using mice bearing different EGFR-expressing TNBC tumors (MDA-MB-468 =
MDA-MB-231 > MDA-MB-453). In MDA-MB-231, tumor uptake was 6.8 ± 1.0 %ID/g at 24
h p.i. and 7.0 ± 0.4 %ID/g at 48 h p.i. Tumor accumulation plateaued at 96 h with 8.7 ±
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2.9 %ID/g (Fig. 27A,C). In MDA-MB-468 xenografts, tumor uptake was 7.8 ± 1.3 %ID/g
at 24 h p.i., 7.6 ± 1.7 %ID/g at 48 h p.i. and 6.8 ± 1.2 %ID/g at 96 h p.i. (Fig. 27B-C). At
48 h p.i., the optimal time where tumor-to-background was identified, the accumulation of
89Zr-cetuximab

was significantly lower in this control tumor compared to MDA-MB-231

(6.7 ± 0.4 %ID/g, p < 0.0001) and MDA-MB-468 (7.6 ± 1.7 %ID/g, p = 0.0012) (Fig. 27D).
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D.

Figure 27. In vitro timecourse imaging of 89Zr-cetuximab in MDA-MB-231 and MDAMB-468 xenografts. Female nude mice bearing MDA-MB-231 tumors were injected with
89Zr-cetuximab and imaged from 24-96 h p.i. and tumor VOIs were measured (A). Female
nude mice bearing MDA-MB-468 tumors were injected with 89Zr-cetuximab and imaged
from 24-96 h p.i. and tumor VOIs were measured (B). Tumor time activity curve
demonstrating tumor VOIs throughout imaging time in both cell lines (C). 89Zr-cetuximab
imaging tumor VOIs in MDA-MB-231 and MDA-MB-468 tumor bearing mice (D). ***
denotes p < 0.001.

86
3.2.3 EGFR expression after dasatinib treatment in vitro
The half maximal inhibitory concentration (IC50) values of 0.88 ± 0.10 µM (Fig. 28A)
and 19.3 ± 0.06 µM (Fig. 28B) were achieved for MDA-MB-231 and MDA-MB-468 cells,
respectively.
A.

B.

Figure 28. Achieved IC50 values for MDA-MB-231 and MDA-MB-468 cells.
MDA-MB-231 (A) or MDA-MB-468 (B) cells were treated with increasing concentrations
of dasatinib for 72 hours to achieve IC50.
In MDA-MB-231 cell lysates (Fig. 29A) incubated with dasatinib for 48 h, a
decrease in phospho-EGFR (Y845) from 1.17 to 0.8 and phospho-Src (Y416) levels from
1.19 to 0.74 as measured by densitometry were observed. Total levels of EGFR remained
the same. In MDA-MB-468 cells (Fig. 29A), a two-fold decrease in pEGFR (Y845, 1.17 to

87
0.69) and pSrc (Y416, 1.87 to 0.83) levels after 48 h exposure to dasatinib was also
observed. Total EGFR levels changed between untreated and (0.88 to 0.95) treated cells.
Total Src levels for both cell lines were slightly lower in the treated lysates.
Next, using the same cell lines, the nuclear (N) and membranous plus cytoplasmic
(C) localization of EGFR after treatment was investigated(Fig. 29B). In MDA-MB-231,
there is approximately 21.3% nEGFR present in the untreated samples, which dropped
to as much as 10-fold upon treatment. Interestingly, total Src protein in the nuclear region
increased in cells exposed to the drug (43% to 59%). In MDA-MB-468 cells (Fig. 29C),
64% of EGFR was found in the nucleus of the untreated samples, whereas treatment
decreased localization to 45%. More nuclear Src i was observed (50%) in the treated cells
compared to control (41%). Collectively, these results demonstrates concordance with
previous reports wherein mitigated Src activity and expression decreased nuclear EGFR.
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Figure 29. In vitro dasatinib treatment alters EGFR compartmentalization. MDA-MB231 (left) and MDA-MB-468 (right) cells were treated with dasatinib IC50 (+) values for 48
h or left untreated (-). Lysates were evaluated for pEGFR (Y845), EGFR, pSrc (Tyr416),
and Src (A); nuclear (N) and membrane plus cytoplasmic (C) extracts were collected from
MDA-MB-231 (B) and MDA-MB-468 (C) cells after 48 h dasatinib treatment or from control
cells and evaluated for EGFR and Src localization.
3.2.4 In vivo monitoring of membrane EGFR with 89Zr-cetuximab
Tumor-bearing athymic nude mice treated with either dasatinib or vehicle (Fig. 29)
were imaged with 89Zr-cetuximab at 48 h p.i. In MDA-MB-231 xenografts, (Fig. 30A) 89Zr-
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cetuximab had higher tumor accumulation in treated vs. control groups (8.7 ± 1.6 %ID/g
vs. 11.9 ± 3.7 %ID/g, p = 0.025)(Fig. 30B).
A.

B.

Figure 30. In vivo 89Zr-cetuximab PET imaging in MDA-MB-231 xenografts. Mice
bearing MDA-MB-231 tumors were left untreated (left) or treated with dasatinib (right) for
5 days before undergoing 89Zr-cetuximab PET imaging at 48 h p.i. (A). 89Zr-cetuximab
tumor VOIs demonstrate higher uptake of the tracer in treated mice compared to control
(B). * denotes p < 0.05.
Autoradiography of excised tumors demonstrated spatial distribution of the tracer
with higher focal uptake observed in treated (Fig. 31A, right) vs. control (Fig. 31A, left)
tumor sections. Immunohistochemistry on serial sections displayed compartmentalization
of EGFR (Fig. 31B, top) and pSrc (Y416) (Fig. 31B, bottom) levels with (left) and without
(right) treatment. In control tumors, elevated EGFR protein appeared localized to the
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nucleus, whereas after dasatinib treatment an increase in membranous staining of EGFR
was observed. Cytoplasmic phospho-Src (Y416) staining was observed control tumors
but staining was abrogated upon treatment.
Western blot densitometry analysis demonstrated a significant increase in total
EGFR in treated mice when compared to untreated mice (0.35 ± 0.05 vs. 0.23 ± 0.07, p
= 0.043) (Fig. 31C, Table 12). Functional EGFR (pEGFR-Y845) was mitigated after
dasatinib treatment. Based on densitometric ratios of EGFR/GAPDH, a ratio of 0.64 ±
0.31 was observed in control tumors vs. 0.08 ± 0.16 in treated groups (p = 0.0173)(Table
12). An almost three-fold decrease in pSrc (Y416) expression was displayed between
tumors that were given vehicle and dasatinib (1.57 ± 0.554 vs. 0.638 ± 0.06, p = 0.0151).
Total Src expression was not significantly different between control and dasatinib treated
tumors (0.498 ± 0.13 vs. 0.583 ± 0.10, p = 0.3406). A positive correlation was achieved
between total EGFR and tumor VOI (r = 0.83, p = 0.011) (Fig. 31D).
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A.

C.

B.

D.

Figure 31. Ex vivo analysis on MDA-MB-231 tumors. Ex vivo autoradiography (A),
H&E (B, bottom), and IHC of EGFR (B, top) and pSrc (Y416, B, middle) shows differences
in tracer localization and expression after dasatinib treatment (right) compared to control
(left). Western blots of control (left) and dasatinib treated (right) tumors were evaluated
for pEGFR (Y845), EGFR, pSrc (Y416), and Src (C). Densitometry for EGFR was
correlated to tumor VOI (D).
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Control
Mean ± S.D.

Dasatinib
Mean ± S.D.

P-value

pEGFR (Y845)

0.64

±

0.31

0.08

±

0.16

0.02

EGFR

0.23

±

0.07

0.35

±

0.05

0.04

1.6
0.5

±
±

0.55
0.13

0.64
0.58

±
±

0.06
0.1

0.02
0.34

pSrc (Y416)
Src

Table 12. Densitometry of MDA-MB-231 tumors.
Treated MDA-MB-468 tumors (Fig. 32A) exhibited an almost two-fold increase in
89Zr-cetuximab

uptake compared to control, untreated tumors (14.25 ± 3.92 %ID/g vs.

8.45 ± 1.72 %ID/g, p = 0.0013) (Fig. 32B).
A.

B.

Figure 32. In vivo 89Zr-cetuximab PET imaging in MDA-MB-468 xenografts. Mice
bearing MDA-MB-468 tumors were left untreated (left) or treated with dasatinib (right) for
5 days before undergoing 89Zr-cetuximab PET imaging at 48 h p.i. (A). 89Zr-cetuximab
tumor VOIs demonstrate higher uptake of the tracer in treated mice compared to control
(B). ** denotes p < 0.01.
Autoradiographic images of excised tumors displayed an increase in tracer uptake
in dasatinib treated (right) tumors compared to control untreated tumors (left) (Fig. 33A).
IHC on serial sections for EGFR (top) showed dark positive EGFR staining in the nucleus
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and cytoplasm in untreated tumors, which changed to strong membranous EGFR staining
after treatment. A close examination of pSrc (Y416) expression (bottom) also showed a
positive cytoplasmic stain in untreated tumors, which was attenuated in the treated tissue
sections (Fig. 33B).
Immunoblots further reinforced the tracer readout. A significant increase in total
EGFR (0.12 ± 0.03) compared to control tumors (0.05 ± 0.03, p = 0.024) was achieved
(Fig. 33C, Table 13). Phosphorylation of EGFR at Y845 displayed a decreasing trend
after dasatinib treatment compared to control (0.07 ± 0.03 vs. 0.11 ± 0.4). We observed
a two-fold decrease in pSrc (Y416) protein after dasatinib treatment (0.30 ± 0.6 vs. 0.47
± 0.02, p = 0.006). Similarly, to MDA-MB-231, there was no significant change in total Src
protein level after dasatinib treatment (0.56 ± 0.08 vs. 0.58 ± 0.12, p = 0.842).
Densitometry of total EGFR significantly correlated with tumor VOI (r = 0.89, p =
0.007)(Fig. 33D).
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A.

C.

B.

D.

Figure 33. Ex vivo analysis on MDA-MB-468 tumors. Ex vivo autoradiography (A),
H&E (B, bottom), and IHC of EGFR (B, top) and pSrc (Y416, B, middle) shows differences
in tracer localization and expression after dasatinib treatment (right) compared to control
(left). Western blots of control (left) and dasatinib treated (right) tumors were evaluated
for pEGFR (Y845), EGFR, pSrc (Y416), and Src (C). Densitometry for EGFR was
correlated to tumor VOI (D).
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Control
Mean ± S.D.

Dasatinib
Mean ± S.D.

P-value

pEGFR (Y845)

0.11

±

0.04

0.07

±

0.03

0.12

EGFR

0.05

±

0.03

0.12

±

0.03

0.02

pSrc (Y416)
Src

0.47
0.56

±
±

0.01
0.08

0.3
0.58

±
±

0.06
0.12

0.01
0.84

Table 13. Densitometry of MDA-MB-468 tumors.
3.2.5 Effects of combinatorial dasatinib and Cetuximab therapy
The addition of cetuximab in combination with dasatinib after neoadjuvant Src
inhibition was next explored. In this longitudinal study, mice treated with dasatinib prior to
PET imaging were further stratified into two arms after PET imaging. One group received
continuous dasatinib treatment while a second group received dasatinib plus cetuximab
(Fig. 34). The same control group of mice used in the imaging scan was monitored for
tumor progression throughout the study.

Figure 34. Treatment Scheme. Mice were implanted with MDA-MB-231 or MDA-MB468 tumors and allowed to acclimate for 10 days before either receiving dasatinib (50
mg/kg for 5 d) or left untreated. Mice then underwent 89Zr-cetuximab PET imaging 48 h
p.i. of the tracer. After imaging, dasatinib treated mice were stratified into treatment
groups of dasatinib only (50 mg/kg for 5 d) or dasatinib (50 mg/kg for 5 d) plus cetuximab
(0.2 mg i.p. 2x/week).
In MDA-MB-231 tumor bearing mice, no tumor response benefit was achieved in
both treatment arms (Fig. 35A). No correlation was derived between 89Zr-cetuximab VOI
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and % change in tumor volume after treatment (Fig. 35B) (r = 0.095, p = 0.735).
On the other hand, a synergistic effect was observed in MDA-MB-468 tumors (p
= 0.021) receiving the combinatorial therapy compared to dasatinib treatment alone (Fig.
35C). An examination of the correlation between tumor VOI and % change in tumor
volumes revealed a negative correlation wherein higher accumulation of

89Zr-cetuximab

in the tumor resulted in slower growth. (r = -0.62, p = 0.013)(Fig. 35D).
A.

C.

B.

D.

Figure 35. Tumor response to combination treatment or cetuximab alone. Tumor
volume (mm3) of MDA-MB-231 tumors undergoing treatment for 30 days (A). Correlation
between 89Zr-cetuximab tumor VOI (%ID/g) and percent change in tumor volume after
treatment regimen in MDA-MB-231 (B). Tumor volume (mm3) of MDA-MB-468 tumors
undergoing treatment for 30 days (C). Correlation between 89Zr-cetuximab tumor VOI
(%ID/g) and percent change in tumor volume after treatment regimen in MDA-MB-468
(D).
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3.2.6 Evaluating changes in EGFR localization after Dasatinib Treatment in TNBC
PDX
The effects of dasatinib treatment and the potential of 89Zr-cetuximab to monitor
changes in membranous EGFR density in an EGFR-expressing TNBC PDX tumor model
was investigated. Palpable tumors dosed with dasatinib for 5 days had a significantly
higher tracer uptake compared to the control untreated arm (7.27 ± 2.3 %ID/g vs. 4.48 ±
1.14 %ID/g, p = 0.0273) (Fig. 36A-B).

A.

B.

Figure 36. 89Zr-cetuximab PET imaging in TM00089 PDX tumors. Mice bearing
TM00089 PDX xenograft tumors were treated with dasatinib (50 mg/kg for 5 d) or left
untreated before imaging with 89Zr-cetuximab at 48 h p.i. (A). 89Zr-cetuximab tumor VOIs
demonstrate higher uptake of the tracer in treated mice compared to control (B).
Tumors were removed post-imaging for autoradiography and IHC. 89Zr-cetuximab
tracer distribution increased in the dasatinib treated tumor (Fig. 37A, right), compared to
control tumor (Fig. 37A, left). Immunohistochemistry on serial sections for EGFR was
evaluated (Fig. 37B). Positive nuclear and membranous EGFR staining in control tumors
(left) were observed, whereas in dasatinib-treated tumors (right), an increase in diffused
membranous EGFR staining was observed (Fig. 37B, top). Examination of pSrc (Y416)
expression (Fig. 37B, bottom) showed a decrease in total staining between control,
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untreated tumors (left) and dasatinib treated tumor sections (right).
To assess the treatment response to combination dasatinib and cetuximab
therapy, the mice were treated with the combination for three additional weeks and tumor
volumes were measured (Fig. 37C). There was a significant (p = 0.0006) improvement in
response to treatment in the combination mice compared to untreated control. Untreated
mice had an average tumor volume of 85.18 ± 26.71 mm3, compared to combination
treated mice with an average tumor volume of 3.53 ± 7.07 mm3, with 3 out of the 4 tumors
completely regressing in volume. Change in tumor volume expressed as a percentage of
starting tumor volume was correlated to 89Zr-cetuximab tumor uptake (%ID/g) (Fig. 37D).
There was a significant, negative correlation between tumor regression and VOI (r = 0.682, p = 0.043).
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B.

A.

C.

D.

Figure 37. Ex vivo tumor TM00089 tumor analysis and extended combination
treatment. Ex vivo autoradiography (A), H&E (B, bottom), and IHC of EGFR (B, top) and
pSrc (Y416, B, middle) shows differences in tracer localization and expression after
dasatinib treatment (right) compared to control (left). Correlation between 89Zr-cetuximab
tumor VOI (%ID/g) and percent change in tumor volume after treatment regimen in
TM00089 (C). Tumor volume (mm3) of TM00089 tumors undergoing treatment for 30 days
(D).
3.3 DISCUSSION
Recently,

89Zr-labelled

antibodies nimotuzumab(245), imgatuzumab(246), and

panitumumab(36,247), and affibody ZEGFR:2377(22) have been under investigation for
use in imaging EGFR expression in vivo in addition to

89Zr-cetuximab(248).

Throughout

these studies, EGFR has been established as a promising and robust target for
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immunoPET imaging and targeted radiotherapeutics(249). Unfortunately, disparities
between in vivo EGFR expression and

89Zr-cetuximab

PET uptake have been

observed(248). This may be in part, due to the compartmentalization of EGFR between
the nucleus and plasma membrane(168). The non-receptor tyrosine kinase Src has
shown to be a key modulator of nEGFR translocation(239), and is an important
downstream node of cetuximab response pathways(166,168,240,250). The literature and
these studies have shown that targeting Src with dasatinib in TNBC cell lines expressing
high levels of nEGFR in vitro resulted in a translocation of EGFR to the plasma
membrane, suggesting this pathway a strategy to enhance EGFR available for further
anti-EGFR treatments(251). Additionally, patients with high nEGFR expression have poor
survival and prognosis in non-small cell lung cancer(237).
The Window of Opportunity Trial of dasatinib in operable triple negative BCs with
nEGFR (NCT02720185) is currently underway to determine if dasatinib can prevent
nuclear translocation of EGFR in stage I-III TNBC. Patients will be subjected to oral
dasatinib (100 mg) treatment 7-10 days prior to planned surgery or research biopsy and
plasma membrane EGFR expression will be measured. An increase of at least 25%
membrane EGFR expression from baseline to post-dasatinib treatment will be considered
significant. With this perspective, the initiative to validate 89Zr-cetuximab as a tool to noninvasively monitor the translocation of nEGFR to the membrane is potentially useful for
selection patients who’ve responded to dasatinib and could further benefit from EGFR
targeted therapies.
Specifically, these results have shown that

89Zr-cetuximab

detects higher plasma

membrane EGFR expression with concomitant nEGFR translocation after 48 h of
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dasatinib treatment, as shown by binding and internalization assays. The lower
internalization was coupled with an increase in total EGFR levels and a decrease in
pSrc(Y416) levels, which confers Src response to dasatinib, as measured by western
blots. In vivo studies demonstrated

89Zr-cetuximab

uptake increased after dasatinib

treatment in TNBC xenografts MDA-MB-231 and MDA-MB-468. This was validated
through ex vivo autoradiography, histology, and western blots. Immunohistochemistry
looking at EGFR localization demonstrated an increase in membranous EGFR after
dasatinib treatment in all xenografts, coupled with a decrease in pSrc(Y416) expression.
Western blots of tumor lysates have shown an increase in total EGFR levels, with a
concomitant decrease in pEGFR(Y845) and pSrc (Y416) levels, conferring response to
dasatinib. Further analysis into utilizing this read out as a predictive biomarker of
cetuximab response was evaluated in KRAS mutant cells MDA-MB-231, and KRAS wt
cells MDA-MB-468. Tumor VOI significantly correlated with tumor response to treatment
in MDA-MB-468 cells, and was coupled with a significant treatment benefit, whereas in
MDA-MB-231 cells, there was no benefit to cetuximab observed. Taken collectively, 89Zrcetuximab PET imaging can potentially be utilized in clinical trials to measure EGFR
translocation from the nucleus to the membrane in patients treated with dasatinib, and
potentially other Src inhibitors.
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CHAPTER 4. UTILIZING IMMUNOPET IMAGING TO MONITOR TUMOR RESPONSE
TO IMMUNOTHERAPY
This chapter was adapted in full from “Interferon-gamma PET imaging as a
predictive tool for monitoring response to tumor immunotherapy” by Heather Gibson,
Brooke McKnight, Agnes Malysa, Greg Dyson, Wendy Wiesend, Claire McCarthy, Joyce
Reyes, Wei-Zen Wei, and Nerissa T. Viola-Villegas originally published in Cancer
Research and used with their full permission.
4.1 INTRODUCTION
During adaptive immunotherapy, activated T cells infiltrating a tumor are often the
principal components of treatment providing a “search-and-destroy” mechanism through
specific recognition of tumor-associated antigens (TAA)(252,253). Recent emerging
tumor-targeted ITx strategies are met with positive and durable outcomes in a subset of
patients, however many remain non-responsive, exposing a strong urgency for consistent
methods to monitor therapeutic response in a timely manner(203). Peripheral immune
monitoring assays are often restricted to one antigen, are non-standardized, and may not
reflect the dynamic activity occurring within the tumor(254,255). Post-treatment biopsy
can be used to evaluate tumor infiltrates(256) however tumor heterogeneity and general
accessibility may impact the adequacy and/or feasibility of this approach(257). Imageguided focal analysis of intratumoral immune activity may eliminate these issues by
providing non-invasive, real-time efficacy predictions in situ. To date, ITx positron
emission tomography (PET) tracer development has focused on immune cell surface
molecule detection, particularly against CD3(47), and CD8(258). Others have developed
tracers targeting immune checkpoint molecules PD1/PD-L1(42,43,259–262) to help
identify candidate patients for checkpoint blockade therapy. These probes are limited,
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however, as they do not mark functional downstream effector tumoricidal activity.
The cytokine interferon-γ (IFN-γ) is predominantly produced by activated Type 1 T
helper (Th1)-skewed CD4 T cells, cytotoxic CD8 T cells (CTL), and both NK and NKT
cells(263). Both Th1 and CTL contribute to antigen-specific tumor cell recognition and
destruction, which is particularly advantageous in the context of immunotherapeutic
approaches including checkpoint blockade, adoptive cell therapies, and vaccination(264–
266). IFN-γ signaling contributes to tumor cell killing by a variety of mechanisms including
upregulation of Fas/FasL and MHC molecules (267,268), however tumor expression of
PD-L1 is also positively regulated by IFN-γ signaling, which ultimately serves as a
feedback mechanism to quell immune activation.
The focus of this study described in this chapter underscores the development of
a monoclonal antibody PET tracer targeting IFN-γ. The results show that IFN-γ PET
associates with response to immunotherapy. Tumors treated with TAA DNA vaccination
show increased IFN-γ detection with an influx of T cells. The level of IFN-γ uptake
inversely correlates to tumor growth rate. Alternatively, in a model of induced T cell
exhaustion, T cells were found to infiltrate the tumor but failed to produce detectable IFNγ as measured by PET imaging. Results further demonstrated that IFN-γ PET provides
consistent sensitivity for the detection of immunotherapy response when compared to
antigen-specific peripheral immune monitoring. Collectively, IFN-γ PET may serve as a
non-invasive, comprehensive approach to the evaluation of tumor immunotherapy.
4.2 RESULTS
4.2.1 PET imaging to visualize Neu+ tumors and CD3+ T cell infiltration
First, tumors bearing Neu, which is the target of our vaccine in subsequent studies,
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were visualized by imaging tumor bearing mice with an anti-neu probe,

64Cu-Ab4. 64Cu

was selected as the tracer due to its short half-life (t1/2 ~ 12.07 h) and its applicability
towards serial imaging studies. NeuT mice (n = 4) with palpable tumors exhibited a tumor
uptake of 5.43 ± 0.72 %ID/g at 4 h p.i., and increased to 7.15 ± 0.45 %ID/g at 24 h p.i. (p
= 0.5163)(Fig. 38A). Time-course imaging displayed a significant decrease in liver (17.0
± 2.2 %ID/g to 9.5 ± 2.38 %ID/g, p < 0.0001) and heart (15.5 ± 2.3 %ID/g to 6.7 ± 1.8
%ID/g, p < 0.0001) uptake from 4 h to 24 h, respectively (Fig. 38B). Tumor volumes as
measured in mm3 were significantly correlated to tumor uptake at 24 h p.i. (r =0.832, p =
0.002)(Fig. 38C).

Figure 38. Visualizing presence of Neu+ tumors with 64Cu-Ab4. NeuT mice bearing
palpable tumors (left) or no tumor (right) were imaged with 64Cu-Ab4 4 h or 24 h p.i. (A);
time course imaging uptake of tumor, liver, heart, and muscle (B); NeuT tumor volumes
were correlated to tumor uptake as measured in %ID/g at 24 h p.i. (C).
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CD3+ T-cell infiltrates were next visualized within the tumor microenvironment with
an anti-CD3 tracer, 89Zr-anti-CD3. Tumor bearing NeuT mice were injected with 89Zr-antiCD3 and serially imaged from 4 h to 72 h p.i. (Fig. 39). Tumor uptake did not significantly
change over time, with 3.4 ± 0.5 %ID/g at 4 h p.i., and decreasing to 3.1 ± 0.6 %ID/g at
72 h p.i. (p = 0.960). Heart uptake increased from 5.35 ± 2.8 %ID/g to 6.23 ± 3.83 %ID/g
after 72 h p.i. (p = 0.607). Liver uptake significantly increased after 72 h, from 8.28 ± 2.02
%ID/g to 10.78 ± 1.36 %ID/g (p = 0.005). Spleen uptake significantly increased after just
48 h, from 10.08 ± 0.9 %ID/g to 16.58 ± 1.65 %ID/g (p < 0.0001), and continued to rise
after 72 h to 18.53 ± 3.0 %ID/g (p < 0.0001).

89

Figure 39. Time course imaging of 89Zr-anti-CD3. Mice were injected with Zr-antiCD3 and images of MIP are shown for each time point (top). L = liver, S = spleen. A plot
of the volumes-of-interest obtained from select tissues is shown over time from 4-72 h p.i.
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4.2.2 89Zr-anti-IFN-γγ PET tracer identifies localized IFN-γγ production
The rat mAb AN-18 to murine IFN-γ was labeled with

89Zr

using desferrioxamine

as the chelate (89Zr-anti-IFN-γ) in good yields and purities according to previously
reported methods(269). Timecourse imaging was performed on mice bearing tumors at
24, 72, and 120 h p.i. (Fig. 41). At 24 h, there was 12.0 ± 3.2% ID/g within the tumor. At
72 h p.i., there was 11.7 ± 3.1 %ID/g within the tumor, and plateaued at 12.7 ± 3.0 %ID/g
after 120 h p.i. Time activity curves demonstrate a consistently low muscle uptake. At 72
h p.i., heart uptake decreases to below tumor uptake levels, and is the time where we
determined subsequent imaging experiments would take place. Spleen uptake, a
secondary lymphoid organ, was consistent throughout all timepoints.

Figure 40. Time course imaging of 89Zr-anti-IFNγγ. Mice were injected with 89Zr-antiIFNγ and images of MIP are shown for each time point (top). H = heart, T = tumor. A plot
of the volumes-of-interest obtained from select tissues is shown over time from 24-120 h
p.i.

In mice treated with CpG-ODN to stimulate IFN-γ, whole-body PET images were
acquired 72 h p.i., a time point identified to exhibit reliable tracer uptake in the tumor, with
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low liver and blood pool background (Fig. 41A). VOIs drawn on splenic tissues
demonstrated higher tracer accumulation (3.50 ± 0.61 %ID/g, n=3) in CpG-ODN-treated
groups compared to untreated controls (Ctrl: 0.83 ± 0.12 %ID/g, n=3) (Fig. 38B).
Tissue distribution of 89Zr-anti-IFN-γ at 72 h p.i. demonstrated 20.04 ± 12.2 %ID/g
uptake in the spleen (Fig. 41B, Table 14). Uptake within the blood circulation (0.67 ± 0.69
%ID/g), as well as tissues responsible for excretion, liver (9.77 ± 9.12 %ID/g), and kidneys
(3.93 ± 0.6 %ID/g) were low. There was also low uptake in the bone and muscle.
Specificity was further confirmed through competitive binding experiment where a
decrease in spleen uptake (20.04 ± 12.20 vs. 1.88 ± 2.74 %ID/g, n=4, p=0.0061) with 10X
cold mAb blockade was observed, consequently increasing non-specific tissue
accumulation in the blood (19.46 ± 12.69 %ID/g, p=0.0043), heart (10.57 ± 8.91, p=0.30),
and liver (11.69 ± 9.82 %ID/g, p=0.99). Notable differences in splenic uptake in the
imaging and tissue distribution (10-fold lower mass) are due to “mass effects”, wherein a
greater mass of protein administered potentially saturated receptor binding sites and
rendered slower pharmacokinetics(57).
Since IFN-γ is a soluble protein, the mechanism of localized IFN-γ imaging was
investigated. Plated TUBO tumor cells were exposed to IFN-γ and/or 89Zr-anti-IFN-γ tracer
in quintuplicate followed by analysis of membrane binding and internalization (Fig. 41C).
TUBO cells incubated with 89Zr-anti-IFN-γ alone show limited tracer surface binding (1.13
± 0.28%) and internalization (0.29 ± 0.13%). When TUBO is pre-incubated with IFN-γ,
enhanced

89Zr-anti-IFN-γ

surface binding (13.62 ± 2.60%) and internalization (3.93 ±

1.07%) is observed (membrane: p=0.00039, internalized: p=0.0015). Detection of tracer
binding to TUBO cells after IFN-γ exposure suggests localized imaging may be due to
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sequestration of IFN-γ on its receptor in vivo.

Figure 41. Validation of specificity of 89Zr-anti-IFN-γγ A) BALB/c mice treated with CpGODN and imaged with the tracer 72 h p.i. displayed higher uptake in the spleen compared
89
to control (Ctrl) untreated cohorts (n=3 each). B) Tissue distribution of Zr-anti-IFN-γ at
72 h p.i. demonstrated lower probe accumulation in the spleen upon competitive
89
saturation with 10× cold AN-18 mAb (n=4 each). C) Binding of Zr-anti-IFN-γ receptor89
localized IFN-γ was tested in vitro. TUBO cells were incubated with Zr-anti-IFN-γ alone
89
(n=5), or with recombinant IFN-γ (rIFN-γ) and washed before addition of Zr-anti-IFN-γ
(n=5). Activity was measured by a gamma counter and adjusted for cell count. * denotes
p < 0.05, *** denotes p < 0.001.
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Control

10×
× mAb block

Mean ± S.D.

Mean ± S.D.

p-value

Spleen

20.04

± 12.20

1.88

± 2.74

0.0061

Blood

0.67

± 0.69

19.46

± 12.69

0.0043

Heart

0.30

± 0.04

10.57

± 8.91

0.2956

Liver

9.77

± 9.12

11.69

± 9.82

0.9999

Kidneys

3.93

± 0.60

10.64

± 7.18

0.7755

Bone

4.19

± 1.18

1.01

± 0.94

0.9951

Muscle

0.73

± 0.65

1.08

± 1.23

>0.9999

Tissue

Table 14. Biodistribution with 89Zr-anti-IFNγγ
4.2.3 IFN-γγ PET detects active anti-tumor immunity in situ in a syngeneic tumor
model
To test the capacity of

89Zr-anti-IFN-γ

as a non-invasive measure of anti-tumor

immune response, neu+ TUBO tumor bearing BALB/c mice were imaged after receiving
two rounds of HER2/neu DNA vaccination as detailed in Figure 42A. This vaccine induces
HER2-specific humoral and T cell responses and ~10% equivalent of cross-reactive antineu T cells without cross-reactive neu-specific antibody(270). Tumor volumes began to
stabilize or regress within 1 week after the second vaccination compared to untreated
TUBO-bearing mice (Fig. 42A). Mice were injected with

89Zr-anti-IFN-γ

tracer for PET

imaging (Fig. 42B and Fig. 43) at 72 h p.i. A nearly two-fold increase in tumor uptake was
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observed in vaccinated (Vx: 10.07 ± 1.50 %ID/g, n=6) versus control mice (Ctrl: 5.97 ±
0.61 %ID/g, n=6, p=0.0001). An 89Zr-labeled rat IgG isotype control tracer demonstrated
similar tumor accumulation (72 h p.i.) in both untreated (5.27 ± 0.79 %ID/g) and
vaccinated (5.93 ± 0.85 %ID/g) mice. This suggests baseline intratumoral IFN-γ levels are
low without treatment. The notable low accumulation of the isotype control tracer after
vaccination supports the specificity of the IFN-γ tracer and suggests increased

89Zr-anti-

IFN-γ uptake is not simply due vascular permeability and retention effects post-ITx.
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Figure 42. PET evaluation of immunotherapy response in orthotopic TUBO
mammary tumors. Tumor volume was monitored in both untreated control (Ctrl, n=11,
left) and vaccinated (Vx, n=12, right) tumors. TUBO cells were inoculated 10 days prior
to the start of vaccinations, given on days 0 and 14. PET imaging was conducted on day
15 (Ctrl) and 21 (Vx) (A); Representative whole body maximum intensity projections (MIP,
top row) and planar (bottom row) images of control (left panels, n=6) and vaccinated (right
89
panels, n=6) mice with Zr-anti-IFN-γ tracer (left). White circle = tumor, L = liver, H =
89
heart, S = spleen, Th = Thymus. Tumor VOIs were measured for each mouse with an Zr
labeled rat IgG isotype control included for each treatment group (n=3, untreated control;
n=6, vaccinated control) (B); MIP image (top panels) and planar sections (bottom panels)
89
of Zr-anti-CD3 images in control (left, n=5) and vaccinated mice (middle, n=6) (C). A
89
non-specific Zr labeled Armenian hamster IgG isotype control was used to measure
tumor VOI in a separate group of untreated mice (right, n = 3).
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Figure 43. MIP images of
(right) TUBO bearing mice.

89Zr-anti-IFNγ
γ.

γ Detection in all control (left) and vaccinated

4.2.4 Detection of tumor infiltrating lymphocytes via CD3 immunoPET
Total T cell presence in the tumor microenvironment was assessed in separate
groups of mice via immunoPET imaging of CD3+ tumor infiltrating lymphocytes using
89Zr-anti-CD3

(Fig. 42C and Fig. 44). Vaccinated tumors exhibited a modest, insignificant

increase of CD3 tracer binding compared to control (6.25 ± 0.37 %ID/g, n=6 vs. 4.58 ±
0.83 %ID/g, n=5, p=0.16). Both cohorts failed to demonstrate a significant change in
uptake compared to Armenian hamster isotype control IgG (5.90 ± 1.26 %ID/g, n=3,
p=0.87 (Ctrl), p=0.49 (Vx)). Untreated TUBO tumors have endogenous T cell infiltrates
as detected by flow cytometry upon dissociation (Fig. 45A). However, CD3 immunoPET
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suboptimally detected these TILs in both untreated and vaccinated mice with measured
VOIs similar to the non-specific IgG tumor accumulation. This may be due to excessive
uptake by the spleen, a T cell-homing secondary lymphoid tissue (Ctrl: 17.06 ± 3.56
%ID/g, Vx: 18.36 ± 1.49 %ID/g, Fig. 45B), which can act as a tracer “sink.” In contrast,
limited splenic accumulation was observed with the IFN-γ PET probe (Ctrl: 3.58 ± 0.81
%ID/g, p<0.0001, Vx: 4.97 ± 0.97 %ID/g, p<0.0001).

Figure 44. MIP images of
(right) TUBO bearing mice.

89Zr-anti-CD3.

Detection in all control (left) and vaccinated
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Figure 45. T cell detection in TUBO-bearing BALB/c. Tumors from untreated TUBObearing mice were dissociated and stained with CD45, to detect total leukocyte infiltrates,
and the T cell receptor beta chain (TCRβ), to identify the T cell fraction, by flow cytometry
89
(A); spleen VOIs were calculated for each TUBO-bearing mouse imaged with either Zr89
anti-IFNγ or Zr-anti-CD3 (B).
4.2.5 Ex vivo validation via IHC, qPCR, and ELISA
Upon completion of imaging, tissues were collected for ex vivo validation. Tumor
tissue was assessed to verify CD3+ and CD8+ T cell presence, as well as expression of
IFN-γ. Transcripts levels of CD3, CD8 and IFN-γ were increased in tumor tissue after
vaccination (Fig. 46A, Ctrl: n=11, Vx: n=13), in concordance with the PET imaging data.
Cultured TUBO cell cDNA is included as a negative control. CD3 and CD8 proteins were
increased after treatment (46B) and intratumoral IFN-γ protein was also confirmed and
quantitated by ELISA (Fig. 46C). ELISA results showed higher total IFN-γ in Vx (n=11)
versus Ctrl (n=10) TUBO tumors (85.37 ± 65.89 vs. 41.69 ± 20.12 pg/mg tissue, p=0.043).
Peripheral vaccine-induced immunity was measured by HER2/neu-specific serum
IgG (Fig. 46D) and splenic T cell responses (Fig. 46E). HER2-specific IgG was only
detected in vaccinated mice (18.68 ± 7.40 µg/mL, n=14, p<0.0001). TUBO tumors
constitutively express the cell surface oncogene neu, which is foreign in wild-type BALB/c
mice. Neu-specific IgG is detected in unvaccinated control TUBO-bearing mice (1.58 ±
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1.60 µg/mL, n=13), which is further increased in vaccinated animals (6.18 ± 7.34 µg/mL,
n=14, p=0.0019). While the HER2 DNA vaccine itself does not induce anti-neu IgG(270),
tumor cell killing likely enhances immune activity to this foreign antigen. Detection of
HER2-specific IFN-γ-producing T cells was restricted to vaccinated mice, similar to antiHER2 IgG (119.40 ± 95.18/106 splenocytes (SC), n=7, vs. 0.83 ± 2.04/106 SC in untreated
controls, n=6, p=0.0012). Peripheral anti-neu T cells were detected in all vaccinated
animals (8.33 ± 7.75/106 SC) while only 1 of 4 untreated controls showed T cell
responsiveness to neu (0.83 ± 2.04/106 SC, p=0.033). The absolute quantities of HER2
and neu-specific IgG and T cells were ~10-fold lower than similarly vaccinated non-tumorbearing mice(270). This may be due to tumor-associated immune suppression by
myeloid-derived suppressor cells or regulatory T cells (Tregs), which are reportedly
increased in TUBO-bearing mice(270–272).

116

Figure 46. Ex Vivo validation of immunotherapy response in TUBO-bearing mice.
Tumors were removed after imaging and validated. A) Total RNA obtained from Ctrl (n=11)
and Vx (n=13) tumor tissue was analyzed by qPCR with primers specific to CD3 (left),
CD8 (middle), and IFN-γ (right). Cultured TUBO cells serve as control (n=2). B) Western
blots from lysed decayed tumor tissues post-CD3 or IFN-γ PET were conducted to
analyze presence of CD3 and CD8 protein in the Vx vs Ctrl mice. C) IFN-γ ELISA was
conducted with protein lysates of TUBO tumor segments of control Ctrl (n=10) and Vx
(n=11) mice. D) HER2 and neu-specific IgG were measured in serum by flow cytometry
(Ctrl: n=13, Vx: n=14). E) HER2 and neu-responsive T cells were measured by IFN-γ
ELISPOT (Ctrl: n=6, Vx: n=7). * denotes p < 0.05, ** denotes p < 0.01, *** denotes p<
0.001.
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4.2.6 Detection of ITx response in a spontaneous tumor model
The capacity of IFN-γ PET imaging to detect anti-tumor immune activity was tested
in a spontaneous tumor setting. Neu transgenic (NeuT) mice are engineered to express
a transforming rat neu under the mouse mammary tumor virus promoter(273), allowing
immune system recognition of neu as a self-antigen(270). Studies were conducted in
male NeuT mice, which develop 1-2 spontaneous neu+ salivary tumors between 30-40
weeks of age(273). Once tumors were palpable, Tregs were depleted using anti-CD25
mAb clone PC61 to enhance ITx response given NeuT mice are immune tolerant to rat
neu(270,274), followed by two HER2/neu DNA vaccinations. Vaccination of NeuT mice
(n=7) controlled tumor growth rate compared to untreated (n=6) tumor-bearing NeuT mice
(Fig. 47A, p=0.032). IFN-γ PET of vaccinated tumors displayed a nearly two-fold higher
uptake of

89Zr-anti-IFN-γ

(8.37 ± 0.35 %ID/g, n=4) vs. control (4.63 ± 0.47 %ID/g, n=3,

p=0.001), indicating infiltration of functional anti-tumor T cells (Fig. 47B and Fig. 48B). An
examination of tumor infiltrates via CD3 PET (Fig. 47C and Fig. 48B) revealed a similar
trend (8.05 ± 1.47 %ID/g vs. 4.43 ± 0.72 %ID/g, n=3 per group, p=0.012).
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Figure 47. PET detection of anti-tumor immunity in spontaneous tumor-bearing
NeuT mice. Control, untreated mice (Ctrl, n=6) were imaged by PET after palpable
tumors were permitted to grow 31 days. For vaccinated mice (Vx, n=7), upon detection of
palpable spontaneous salivary tumors, regulatory T cells (Treg) were depleted 10 d prior
to the first vaccination. Mice received two HER2/neu DNA vaccinations 14 d apart. PET
imaging was conducted 7 days after the final vaccination (A); representative whole body
maximum intensity projections (MIP, top row) and planar (bottom row) images of control
89
(left panels, n=3) and HER2/neu DNA-vaccinated (right panels, n=4) mice with Zr-antiIFN-γ tracer (left) (B). White circle = tumor, L = liver, S = spleen. Tumor VOIs were
calculated for each mouse. C) Representative CD3 PET images of MIP (top) and planar
sections (bottom) are shown for Ctrl (left) vs. Vx groups (right). * denotes p< 0.05.
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A.

B.

Figure 48. 89Zr-anti-IFNγγ and 89Zr-anti-CD3 PET in all tumor-bearing NeuT mice. MIP
89
89
images of (A) Zr-anti-IFNγ and (B) Zr-anti-CD3 detection in all control (left) and
vaccinated (right) NeuT mice bearing spontaneous salivary tumors. Tumors are indicated
by arrow; L = liver.
Validation of T cell infiltration and IFN-γ production was conducted by qPCR in
tumor tissue samples (Fig. 49A). CD3 and CD8 detection showed a variable modest,
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insignificant increase after vaccination, while IFN-γ mRNA increased (Ctrl: n=3, Vx: n=5,
p=0.036). Peripheral immune response to the vaccine was evaluated by measuring
serum anti-HER2 and anti-neu IgG as well as spleen-resident HER2- and neu-responsive
IFN-γ-producing T cells. Tolerance to HER2/neu in NeuT mice was apparent with a
comparatively lower ITx response vs. wild-type BALB/c mice bearing TUBO tumors in
Figure 2. HER2-specific IgG was detected in vaccinated animals (Fig. 49B, 8.7 ± 4.9
µg/mL, n=8, p=0.0016 vs. Ctrl, n=5), while anti-neu IgG was negligible or absent in all
samples tested. Despite increased intratumoral detection of IFN-γ in vaccinated NeuT
mice by PET, peripheral T cell response to neu was low (Fig. 49C, 15.80 ± 8.84/106 SC,
n=5) with HER2 vaccination, and was not significantly increased relative to untreated
control (n=5, p=0.27). that detected in non-immune tolerant BALB/c mice bearing TUBO
(10.0%, Fig. 49C). These results support the hypothesis that peripheral immune
monitoring may be an inadequate measure of anti-tumor immunity with tumor-responsive
T cells preferentially localizing within the tumor, supporting the use of in situ analysis
methods such as PET imaging.
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Figure 49. Ex vivo validation of anti-tumor immunity in spontaneous tumor-bearing
NeuT mice. A) Total RNA was isolated from tumor tissue and qPCR analysis for CD3,
CD8, and IFN-γ was conducted (n=3 each) B) Serum HER2 (Ctrl, n=5; Vx, n=8) and neuspecific IgG (Ctrl, n=5; Vx n=8) was measured by flow cytometry. C) HER2 and neuresponsive T cells were measured by IFN-γ ELISPOT (n=5 each). * denotes p < 0.05, **
denotes p < 0.01.
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4.2.7 IFN-γγ PET imaging is an indicator of immune activation status in situ
To test the capacity of 89Zr-anti-IFN-γ to predict treatment outcomes, BALB/c mice
(n=11) bearing variably-sized TUBO tumors were treated with our HER2 vaccine as
described previously, resulting in a range of growth slopes (Fig. 50A, Fig. 51).

89Zr-anti-

IFN-γ PET imaging was conducted two weeks after the final vaccination and tumor volume
was monitored for an additional ten days. Tumor-localized

89Zr-anti-IFN-γ

tracer uptake

inversely correlated with tumor growth rate (Fig. 50B and Fig. 4.13, r=-0.64, 95% CI: (0.90,-0.06); p=0.034), suggesting IFN-γ PET is an indicator of the effects of ITx on these
tumors.
The outcome of IFN-γ PET in a setting where tumor-infiltrating T cells are present
but have become exhausted was evaluated. TUBO-bearing mice were treated with
passive ITx, mAb 7.16.4 to rat neu. This mAb has been shown to inhibit neu signaling in
addition to initiating host anti-tumor immunity(275,276). Once tumors were established at
~50 mm3, 1 mg doses of 7.16.4 were given i.p. at 3-4 day intervals for a total of 5
treatments, which reduced and stabilized tumor growth (Fig. 50C).

89Zr-anti-IFN-γ

(n=5)

or control IgG (n=6) PET imaging was conducted on day 30 after treatment onset, at
which time tumor growth had resumed. Tumor uptake of IFN-γ tracer was
indistinguishable from IgG control, suggesting a lack of immune activity (Fig. 50D). CD8
T cell infiltration was evaluated by IHC (Fig. 50E). Blinded pathologist enumeration of the
three regions with highest infiltration was calculated, showing a 12-fold increase in CD8
T cells after 7.16.4 treatment versus control (Ctrl: 3 ± 1, 7.16.4: 36 ± 19). Vaccinated
TUBO tumor had the largest detected CD8 infiltration (74 ± 25). Overall, CD8+ tumor
infiltration was intermittent, with high-density regions scattered among areas with no
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detectable CD8+ TILs (Fig. 50E). We further validated CD8 T cell infiltration after 7.16.4
therapy by flow cytometry in a parallel cohort of treated and control mice (Fig. 50F, n=4
each). An overall increase in CD45+ infiltrates (Ctrl: 6.84 ± 1.85%, 7.16.4: 16.95 ± 5.88%,
p=0.036) and CD8+ T cells (Ctrl: 0.41 ± 0.19%, 7.16.4: 4.96 ± 1.96%, p=0.018) was
detected after mAb treatment. Interestingly, the majority of CD8+ TILs expressed the T
cell exhaustion marker PD-1 (Fig. 50G, 79.7 ± 10.3%) compared to control tumors (20.5
± 9.3%, p=0.0001). Collectively these results suggest this treatment model promotes an
inactive and exhausted CD8 T cell status despite tumor infiltration, leading to reduced
IFN-γ production which can be detected by 89Zr-anti-IFN-γ PET imaging.
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E.

3±1

36 ± 19

74 ± 25
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Figure 50. IFN-γγ PET depicts response to ITx. Tumor volume was monitored in TUBObearing vaccinated BALB/c mice (n=11). TUBO cells were inoculated 13 days prior to the
start of vaccinations, to allow for variability in tumor volumes at treatment onset. Vaccines
were given on days 0 and 14. PET imaging was conducted on day 28 (A); weekly tumor
89
growth rate, calculated by regression analysis of log tumor growth, versus Zr-anti-IFNγ tracer uptake is plotted for each mouse and evaluated by Pearson’s correlation (B);
tumor growth was monitored during passive immunotherapy with anti-neu mAb 7.16.4,
given as 5 doses at 1.5 mg i.p. every 3-4 days as indicated beginning 15 days after tumor
89
89
inoculation. Zr-anti-IFN-γ (n=5) or Zr-rat-IgG control (n=6) PET imaging was
89
conducted 30 days after treatment onset (C); tumor VOIs were calculated for Zr-anti89
IFN-γ or Zr-rat-IgG tracers in 7.16.4 treated TUBO-bearing mice (D); intratumoral
localization of CD8 was analyzed by IHC on FFPE tissue (400×). H&E sections are
included. CD8 enumeration is found in the lower right corner of each panel (E); control
and 7.16.4-treated tumors (n=4 each) were dissociated and analyzed for T cell infiltration
by flow cytometry by staining for CD45 and CD8 (F); PD-1 expression was analyzed by
flow cytometry (G) on CD8+ tumor infiltrates from (F). * denotes p < 0.05, ***denotes p <
0.001.

Figure 51. 89Zr-IFN-γγ PET of vaccinated mice for correlation to tumor growth. MIP images of
detection in all vaccinated TUBO mice bearing tumors.

Zr-anti-IFNγ

89
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4.3 DISCUSSION
Several major drawbacks to the use of general T cell surface markers and immune
checkpoint ligands for PET imaging can complicate the assessment of immunotherapy
response. T cells are densely present in normal secondary lymphoid tissues, such as the
spleen, thymus and lymph nodes, which may hinder tumor-specific T cell imaging.
Intratumoral detection of total CD3+ T cells and CD8+ cytotoxic lymphocytes has been
shown to positively correlate with patient outcomes(277,278). However, the chronic
inflammatory tumor microenvironment promotes checkpoint molecule expression, driving
cytotoxic T cells into an exhausted state with diminished effector activity. Visualizing
components of checkpoint signaling axes (e.g. PD1/PD-L1) can provide go-or-no-go
treatment decisions by selecting patients with higher likelihood of responding to
checkpoint blockade(279). In general, these methods do not measure downstream
effector function of cytotoxic T cells. Larimer et al. reported on the utility of a peptidebased imaging tracer specific granzyme B, a cytotoxin released by activated CTL using
a syngeneic colon cancer model(45). The tracer identified responders from nonresponders after mono- or combinatorial anti-CTLA-4 and anti-PD1 targeted inhibition;
however, it is unclear whether the peptide tracer (7.46 ± 2.24 µg per mouse) solicited
inhibitory effects on the enzymatic activity of granzyme B. Nevertheless, the study
substantiates the rationale that imaging effector molecules along the T cell signaling axis
may provide a better readout of immune response to treatment.
In this study, the capabilities of IFN-γ PET were demonstrated to measure active
anti-tumor immunity, providing a predictive tool for non-invasive in situ tumor evaluation.
This approach is highly specific to the tumor compared to total T cell imaging due to the
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fact that IFN-γ is secreted by CTLs within the tumor. Imaging CD3, on the other hand,
targets the general T cell population that are not only localized in the tumor but also in
other lymphoid tissues. Find antibody-based tracers to immune cell surface molecules
were found to may create artifacts in the experimental system. Efforts to label CD8specific full-length mAbs (clones 2.43 and non-depleting YTS-105.18) resulted in
depletion of the target cell population and tracer accumulation in the kidneys with lack of
secondary lymphoid tissue detection (data not shown) despite detection of CD8+ tumor
infiltrates by flow cytometry and IHC (Fig. 6E-F). Anti-CD3 mAb clone 2C11 is routinely
utilized for its pan-T cell receptor agonist activity, which may also potentially alter T cell
function in vivo. Alternatively, it is conceivable that tracers to surface receptors may
antagonize signaling, which could create off-target effects. Careful selection of antibody
clones or construction of antibody fragment-based tracers like the CD8 diabody
generated by Tavare et al.(213) or the VHH probe by Rashidian et al.(258) may alleviate
some of these factors, but thorough quality control is necessary. Tracers targeting soluble
cell products may also circumvent many of these problems.
A caveat to detection of cytokines by PET imaging is the soluble nature of these
proteins. Localization of

89Zr-anti-IFN-γ

was observed in the spleen after CpG-ODN

treatment and in the tumor after HER2/neu vaccination, suggesting the tracer is
sequestered within the tissue.89Zr-anti-IFN-γ complexes in vitro and find maximal binding
when TUBO cells are pre-incubated with IFN-γ, supporting the working hypothesis that
localized imaging is due to detection of IFN-γ associated with its receptor.
Ex vivo validation experiments showed a general trend in agreement with the PET
imaging results, a direct correlation to tracer uptake is difficult to establish. These assays,
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similar to a biopsy, are sampling a fragment of a heterogeneous tumor, yielding
opportunity for equivocal results. Further, our IHC analyses on TUBO tumors (Fig. 6E)
show the tissue is non-uniform, with regions of variable CD8 T cell infiltration after ITx
ranging from moderate density to a virtual absence. For these reasons, imaging tools like
immunoPET are advantageous, bridging a clinical need by providing a more
comprehensive view of the entire tumor microenvironment.
These results showed

89Zr-anti-IFN-γ

tracer uptake can be indicative of response

to therapy in both cancer vaccination and TAA-specific mAb models. IFN-γ PET further
demonstrated it may be more sensitive for determining response to immunotherapy when
compared to peripheral immune evaluation, a point which should be evaluated further.
IFN-γ PET has the potential to serve as a universal non-invasive measurement of immune
activity in situ for a variety of cancers with virtually any immunotherapy modality with no
need for knowledge of specific antigens or cumbersome ex vivo antigen recall assays.
Additionally, the utility of IFN-γ PET can potentially expand beyond cancer immune
monitoring to include examination of localized inflammatory conditions such as injury,
infection, or autoimmune disease. Taken together, these results support the development
of IFN-γ PET tracers for clinical evaluation of tumor immunotherapy.
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CHAPTER 5. MATERIALS AND METHODS
5.1 In vitro cell culture and in vitro tumor induction
5.1.1 Cell culture and propagation
All cells were adhered and grown at 37 °C with 5% CO2 according to the following
conditions listed in Table 15. All cells were split once they reached 80% confluence and
were tested for mycoplasma with MycoAlert Mycoplasma Detection Kit (Lonza) and
certified by the Biobanking and Correlative Services Core at Wayne State University.
Cell Line

Characteristic

BT-474

ER+, HER2+

JIMT-1

HER2+,
trastuzumab
resistant

MDA-MB468

TNBC, EGFRhigh

MDA-MB231

TNBC, EGFRhigh

2×/week

MDA-MB453

TNBC-EGFR
low

2×/week

ATCC

3×/week

Dr. Guido
Forni (U.
Torino,
Torino, Italy)

TUBO

Neu+

Media
1:1 DMEM:F12
(VWR) + 5% FBS +
1% Pen-Strep + 1%
NEAA

Passage
1×/ week

2×/week

DMEM + 1% Penstrep + 5% FBS

DMEM (High
Glucose),10% NCTC,
10% FBS, 1% Lglutamine, 1% NEAA,
1% Pen-Strep, 0.1%
2-mercaptoethanol,
1% Sodium
Bicarbonate,
oxalacetic acid,
sodium pyruvate,
insulin

Table 15. Cell lines and growth conditions.

3×/week

Obtained
Dr. Jason S.
Lewis
(MSKCC, NY,
USA)
Dr. Jason S.
Lewis
(MSKCC, NY,
USA)
Dr. Julie
Boerner
(Wayne State,
Detroit, USA)
Dr. Steven
Patrick
(Wayne State,
Detroit, USA)
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5.1.2 Tumor induction
All animal handling and manipulations were conducted in accordance with the
guidelines set by Wayne State University Institutional Animal Use and Care Committee.
Female athymic nu/nu mice (6-8 week old) were purchased from Charles Rivers
Laboratories (Wilmington, MA). All cells in 150 µL 1:1 media:Matrigel (BD Biosciences,
Bedford, MA) were injected on the right shoulder at concentrations listed in Table 16.
Monitoring of tumor growth was performed weekly with calipers. The tumor volume was
calculated using the formula: length × width × height × pi/6. Mice with tumor volumes
ranging from 150 – 250 mm3 were utilized.
Cell Line

Characteristic

Xenograft Protocol (cells)

BT-474

ER+, HER2+

Estrogen pellet 3 days prior
(0.72 mg slow-release)
10×106

JIMT-1

HER2+, trastuzumab
resistant

5×106

MDA-MB-468

TNBC, EGFR-high

3×106

MDA-MB-231

TNBC, EGFR-high

5×106

MDA-MB-453

TNBC-EGFR low

5×106

TM00089

TNBC, PDX

-

Table 16. Tumor inoculation protocol.
5.1.3 NeuT mice and TUBO tumor induction
Heterozygous BALB/NeuT (NeuT) mice were in-house bred and provided to us by
the lab of Professor Wei-Zen Wei. NeuT male mice, which express a transforming rat neu,
develop atypical ductal hyperplasia in 1-2 parotid glands by 6 weeks of age which
progresses to multifocal acinic cell adenocarcinoma in situ at ~19 weeks of age(273).
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BALB/c mice (6-8 week old) were purchased from Charles River Laboratories
(Wilmington, MA) and were inoculated with TUBO cells in the #4 mammary fat pad.
Monitoring of tumor growth was performed weekly with calipers.
5.2 Antibody conjugation to chelates
p-Benzyl-isothiocyanate-desferrioxamine (DFO-Bz-SCN, Macrocylics, Inc.) or pSCN-Bn-1,4,7-triazacyclononane-1,4-7-triacetic acid (NOTA, Macrocyclics, Inc.) was
conjugated to the antibodies listed on Table 17 according to previously published
protocols(269). The synthesis was performed using the mole equivalence of DFO or
NOTA to the antibody listed in Table 17 in 0.9% saline, pH ~9 at 37 °C for 1 h. The
monoclonal antibody (mAb) DFO- or NOTA-conjugates were obtained by passing through
a spin column filter with a molecular weight cut-off of 30 kDa (GE Vivaspin 500) using
sterile saline as eluting buffer.
Antibody

Company

DFO:mAb
Mole Ratio

Specific
Activity
(mCi/mg)

Genentech

1:4

4

Sigma-Aldrich

1:4

5

Genentech

1:5

5

1:5
1:5

5
5

145-2C11
AN-18

1:5

5

012-000-003

Anti-armenian
hamster IgG

eBioscience
eBioscience
Jackson
ImmunoResearch
Jackson
ImmunoResearch

1:5

5

eBio299Arm

Anti-neu

In House

1:4*
(NOTA:mAb)

5

7.16.4

Trastuzumab
(Herceptin ®)
Non-specific
human IgG
Cetuximab
(Erbitux®)
Anti-CD3
Anti-IFNγ
Anti-rat IgG

Table 17. Antibodies and labeling conditions.
Note: *the chelate used for conjugation was NOTA.

Clone or Catalog
No.
(if applicable)

14506
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5.3 Radiochemistry
5.3.1 89Zr-radiochemistry
Approximately 1 mCi (37 MBq) of 89Zr-oxalate (3D Imaging, LLC) was neutralized
to pH 7.0 – 7.2 using 1 M Na2CO3. mAb-DFO (200 µg) was added to the 89Zr solution and
pH was adjusted back to 7.0 if needed. The reaction was quenched after 1-1.5 h
incubation

at

room

temperature

upon

addition

of

5

µL

of

50

mM

ethylenediaminetetraacetic acid (EDTA) (pH ~7.0) to eliminate any non-specifically bound
radiometal.
5.3.2 64Cu-radiochemistry
mAb-NOTA (200 µg) was added to 1 mCi (37 MBq) 64Cu solution and the pH was
adjusted to ~5 with 0.1 M ammonium acetate. The reaction was quenched after 1-1.5 h
incubation at room temperature upon addition of 5 µL of 50 mM EDTA (pH ~7.0) to
eliminate any non-specifically bound radiometal.
5.3.3 Radiolabeling efficiency
Radiolabeling

efficiency

was

determined

via

radio-instant

thin

layer

chromatography (iTLC) using silica gel-impregnated iTLC strip (Agilent Technologies,
Santa Clara, CA) and 50 mM EDTA as the solid and mobile phase respectively. Pure
89Zr-mAb

or

64Cu-mAb

was obtained through spin column centrifugation (GE Vivaspin

500, MWCO: 30 kDa) with saline used for eluting unbound radiometal. mAbs were
assessed for immunoreactivity as previously described(280).
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5.4 Drugs and Treatments
Drug

Company

Treatment Dose

Dasatinib
(Sprycel™)
Cetuximab

Sellechem

75 mg/kg (Aim 1)
50 mg/kg (Aim 2)
0.3 mg

Genentech

Treatment
Length
7 or 14 d
5d
2×/week
3 weeks
1 h prior to
imaging

CpG-ODN

Integrated DNA
Technologies

100 µg

HER2/neu
DNA
Vaccine
7.16.4

In house

20 µg pGM-CSF +
50 µg pE2TM

See scheme
in Chapter 4

In house

1 mg in filtered
ascites

5×
every 3-4 d

Delivery
Vehicle
1:1
water:glycerol
Saline
i.p. injection
PBS
Intramuscular
injection
PBS
Intramuscular
injection
PBS
i.p. injection

Table 18. Drugs used in the studies.
5.4.1 Molecular therapy
Dasatinib was administered to tumor-bearing mice via oral gavage (p.o.) for
treatment length described in Table 18. Untreated control mice were given a 1:1 mix of
water and glycerol (150 µL total volume via oral gavage) as placebo. Cetuximab (i.p.) was
administered intraperitoneally (i.p.) to tumor bearing mice (Table 18). Food and water was
given ad libitum. Tumor volumes were recorded 2-3 times per week. Percent change in
tumor volume was analyzed using measurements obtained before the start of treatment
to the time of imaging following formula: ((start tumor volume – end tumor volume)/start
tumor volume)×100.
5.4.2 Immunotherapy
For NeuT vaccination, mice were depleted of Tregs by intraperitoneal (i.p.)
injection of 500 µg anti-CD25 mAb PC61 10 days prior to the first vaccination. The
HER2/neu DNA vaccine consists of an admixture of 20 µg of pGM-CSF (encoding murine
GM-CSF) and 50 µg pE2TM (encoding the extracellular and transmembrane regions of
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human HER2) in 50 µL PBS, which is injected intramuscularly (i.m.) into each
gastrocnemius followed immediately by application of electrode gel and square wave
electroporation using a BTX830 (BTX Harvard Apparatus, Holliston, MA).
Mice bearing TUBO tumors were injected i.p. 5 times every 3-4 days with sterilefiltered ascites containing 1 mg anti-neu mAb 7.16.4 diluted in PBS to a final volume of
300 µL.
5.5 IC50 Calculations
Wells (96-well clear bottom plate, Corning) were seeded with ~1×104 cells and
incubated for 18 h. Dasatinib was dissolved in DMSO (Sigma-Aldrich) at a 50 mM
concentration. Serial dilutions of dasatinib (1nM to 1 mM) were made and cells were
treated in 100 μL complete media and incubated for 72 h. Media was removed and cells
were washed 1× with phosphate buffered saline (PBS) before addition of alamar blue
(Life Technologies) in fresh media (1:10 Alamar blue:media) to measure cell viability.
After 4 h incubation, absorbance was read at 570 nm on an Infinite M200 plate reader
(Tecan). IC50 was calculated as the log(concentration) vs. absorbance – control well
absorbance in GraphPad Prism (v. 7.02).5.5
5.6 Internalization Assay
Internalization of radiolabeled antibodies was evaluated on appropriate cell lines.
Wells were seeded with ~5×105 cells and incubated for 18 h. Cells were treated with the
established IC50 for dasatinib (Sellechem, reconstituted in DMSO) in complete media.
After incubation, media was removed, and cells were washed 1 × PBS. Radiolabeled
protein [1 µCi/mL (37 kBq/mL), 150 ng] in 1 mL of media was then added to each well.
The plates were incubated at 37 °C for 2 h. Following the incubation period, the media
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was collected, and the cells were rinsed with 1 mL 1× PBS, twice. Surface-bound activity
was removed by washing the cells in 1 mL 100 mM acetic acid + 100 mM glycine (1:1,
pH 3.5) at 4 °C. The cells were then lysed with 1 mL 1 M NaOH. All washes (media plus
PBS, acid and alkaline) were collected in separate tubes and measured for bound activity
using a gamma counter (Perkin Elmer). The %-internalized activity was calculated as the
ratio of the activity of the lysate and the total activity collected from the media, PBS, acid
and base washes, normalized to 50,000 cells counted using a Countess II Automated
Cell Counter (Thermo Fisher).
5.7 In vitro competitive binding assay
Binding of radiolabeled mAbs was evaluated in appropriate cell lines. Wells were
seeded with ~10×104 cells and incubated for 18 h. After incubation, radiolabeled protein
[1 µCi/mL (37 kBq/mL, 100 ng)] in 1 mL of media was added to each well with or without
10-fold excess unlabeled mAb (1 μg). The plates were incubated at 4 °C for 1 h. Following
the incubation period, the media was collected and the cells were rinsed with 1 mL 1×
phosphate buffered saline (PBS) twice. The cells were then lysed with 1 mL 1 M NaOH.
All washes (media plus PBS and alkaline) were collected in separate tubes and measured
for counts using a gamma counter (Perkin Elmer). The %-bound activity was calculated
as the ratio of the activity of the lysate and the total activity collected from the media, PBS,
acid and base washes, and was normalized to cell count using a Countess II Automated
Cell Counter (Thermo Fisher).
5.8 Western Blotting
Cells were lysed on ice using 1× RIPA buffer (Pierce) supplemented with HALT
protease and phosphatase inhibitor cocktail (Pierce.). Tumors were mechanically lysed
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using a handheld homogenizer Polytron PE 1200E (VWR) in the same buffer. Total
protein was calculated by the Pierce BCA Protein Assay Kit (Thermo Fisher) using the
microplate procedure and read at A562 nm.
Lysates were prepared in NuPAGE lithium dodecyl sulfate (LDS) sample buffer
(Life Technologies) supplemented with 2-mercaptoethanol (Sigma-Aldrich), and brought
up to 15 µL with lysis buffer, and incubated at 95 °C for 5 min. Proteins (15 µg for cell
lysates, and 10 µg for tumor lysates) and ladder (Precision Plus, BioRad) were separated
on a 4-12% before transfer to Immobilon-P polyvinylidene difluoride (PVDF) membrane
(Millipore Sigma. Membranes were blocked in 5% non-fat dry milk in tris-buffered saline
(TBS) (KD Medical)-0.1% Tween20 (Amresco) for 1 h at room temperature. Primary
antibodies were diluted 1:1000 in TBST with 0.02% sodium azide and incubated at 4 °C
for 16 h with gentle rocking before blotting with horseradish peroxidase (HRP)-linked
secondary antibodies in 5% milk-TBST for 2 h at room temperature (Table 19). Proteins
were visualized using Amersham ECL (GE) and images collected using a ChemiDoc
(BioRad) system. Images were analyzed using Image Lab (BioRad) software and
densitometry was calculated using ImageJ software
(NIH) following previously described protocol (SYBIL).
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Antibody
HER2
pHER2 (Y1221/1222

Clone
D8F12
6B12

Company (Catalog Number)
Cell Signaling (4290)
Cell Signaling (2243)

Src
pSrc (Y416)

36D10
D49G4

Cell Signaling (2109)
Cell Signaling (6943)

EGFR-XP
pEGFR (Y845)
CD8α
CD3ε
GAPDH
Β-tubulin
Histone H3

D38B1
N/A
D4W2Z
D4V8L
G-9
9F3
1B1B2

Cell Signaling (8839)
Cell Signaling (2231)
Cell Signaling (98941)
Cell Signaling (99940)
Santa Cruz (365062)
Cell Signaling (2128)
Cell Signaling (14269)

Table 19. Antibody clones and catalog numbers used for western blotting.
Anti-rabbit and anti-mouse HRP-linked secondary antibodies were purchased from
GE (NA934, NA931).
5.9 PET Imaging
Injections were administered intravenously (i.v.) in the lateral tail vein in 100-150
µL sterile saline (Table 20). Small-animal PET scans were acquired from 1-120 hours p.i.
using a microPET R4 or Focus220 scanner (Siemens Concorde Microsystems). The mice
were fully anesthetized with 1-2% isoflurane (Baxter, Deerfield, IL) during the scan.
Images were reconstructed via filter back projection. ASIPro VMTM software (Concorde
Microsystems) was used to analyze volumes-of-interest (VOI) on various planar sections
from the acquired image by manually drawing on the tumor site and on select organs.
The average VOI was calculated and expressed as % injected dose per gram of tissue
(%ID/g).

140

Tracer
18F-FDG
89Zr-trastuzumab
89Zr-IgG

(human)

89Zr-cetuximab

Imaging
Dose (µ
µCi)
150-200
200-240
200-240
180-200

Antibody
Dose (µ
µg)
66.7-80
66.7-80
36-40

180-240

42.8 – 57.1

89Zr-anti-IFNγ
89Zr-anti-CD3
89Zr-anti-rat

IgG

89Zr-anti-hamster

IgG
64Cu-Ab4

Imaging Time (h p.i.)
1h
48 h
48 h
48 h
72 h
72 h
72 h
72 h

200-240

66.8 - 80

24 h

Table 20. Tracers and used imaging or antibody doses.
5.10 Biodistribution
89Zr-trastuzumab

biodistribution was performed 48 h p.i. in BT-474 or JIMT-1 tumor

bearing Nude mice. To prove specificity,

89Zr-IgG

[20-30 µCi, 0.74-1.11 MBq, 336.02-

504.0 nmol, 5-7.5 µg] was injected in mice with BT-474 or JIMT-1 tumors to assess nonspecific accumulation of the tracer.

89Zr-anti-IFNγ

biodistribution was performed at 72 h

p.i. in BALB/c mice, and for blocking studies, 80 μg of cold AN-18 was co-injected with
the probe in a separate cohort of mice. Select organs were harvested post-sacrifice,
weighed and measured for bound radioactivity with a gamma counter (Perkin Elmer 2480
Wizard 2).
20-30 µCi of the tracer [20-30 µCi, 0.74-1.11 MBq, 336.02-504.0 nmol, 5-7.5 µg]
was injected into the lateral tail vein. Tissues of interest were removed at indicated
timepoints and counts were performed using a gamma counter (Perkin Elmer Wizard2).
The %ID/g was calculated as the % of activity bound to the tissue normalized against total
administered activity per gram of tissue weight.
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5.11 Autoradiography and immunohistochemistry (IHC)
5.11.1 Autoradiography
Autoradiography was performed following previously reported protocols(281).
Briefly, after PET imaging tumors were excised and snap frozen in liquid nitrogen before
being embedding in OCT medium and cut into 5 µm sections (Leica CM 1850) and
mounted on positively charged slides (Fisher). Digital autoradiography was performed by
placing slides in a film cassette against a phosphor imaging plate (Fujifilm BAS-MS2325,
Fuji Photo Film) at -20 °C for 18 h. Phorphor imaging plates were read at a pixel resolution
of 25 µm with a Typhoon 7000 IP plate reader (GE Healthcare).
5.11.2 Frozen immunohistochemistry and hematoxylin and eosin (H&E)
Sections were fixed in ice-cold acetone for 10 minutes and dried at room
temperature for 20 minutes. Endogenous peroxidase activity was blocked with 3% H2O2
for 10 minutes before blocking with protein block solution from the mouse and rabbit
specific HRP/3,3’-diaminobenzidine(DAB) detecting IHC kit (abcam, ab64264) for 1 h at
room temperature. Slides were incubated with primary antibodies for 18 h at 4 °C (Table
21). Slides were developed using the same HRP/DAB detecting IHC kit and dehydrated
with alcohols and xylenes before being covered with permount and coverslipped. Imaging
was performed using a slide scanner (Leica SCN400) and visualized using Leica SCN400
image viewer software.
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Antibody

Clone

HER2
Src
EGFR-XP

D8F12
36D10
D38B1

Catalog
Number
4290
2109
8839

Dilution
1:200
1:50
1:50

Table 21. Antibody catalog numbers and dilutions for IHC.
5.11.3 FFPE Immunohistochemistry and H&E
After euthanasia, tumors were harvested and fixed in formalin before being
embedded in paraffin. Blocks were sectioned into 4 µm sections using a Sakura AccuCut SRM microtome (Catalog#: SRM-200 CV) and adhered onto positively charged slides
(Histomax Plus, VWR). Slides were then incubated for 12 minutes at 65 °C and
deparrafinized in washes of xylene and graded alcohols. Antigen retrieval was performed
in PT module buffer (TA-250-PM4X, Fisher) for CD8 (1:200). Primary antibody
incubations were performed for 1 h at room temperature in a humidified chamber.
Secondary antibody incubations and DAB were performed following manufacturers
protocols. CD8 T cell enumeration was conducted by a blinded board-certified
pathologist. Each tumor sample was screened for hotspots of CD8 lymphocytes using a
Nikon Eclipse Ci microscope at 100× magnification. The number of CD8+ T lymphocytes
was counted in the three regions of highest infiltration at 400x magnification with a 0.55
mm field diameter, and an average was calculated. For H&E staining, tissue sections
were dipped in xylenes, graduated alcohol and distilled water washes. They were then
stained with hematoxylin (TA-125-MH, Fisher) for 5 minutes, rinsed with an acid wash for
1 minute and a bluing agent for 15 seconds. Eosin staining was applied to slides for 1
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minute and slides were rinsed in 95% ethanol three times. Lastly, sections went through
a series of graded alcohol and xylenes steps to dehydrate sections in preparation for
mounting with Permount (UN1294, Fisher). Pictures were taken with a Spot Idea camera
using Spot 5.2 software (Spot, Sterling Heights, MI).
5.12 Quantitative real-time PCR
Tumor tissue was snap frozen in liquid nitrogen. Total tumor RNA was collected
by Trizol preparation (Thermo Fisher, Waltham, MA) after homogenization. cDNA was
synthesized with ProtoScript II reverse transcriptase (New England Biolabs, MA). Realtime qPCR was conducted with iTaq Universal SYBR Green Supermix (Bio-Rad
Laboratories, Hercules, CA) using 10 ng cDNA/well and 500 nM primers specific to the
indicated gene (Life Tech, Carlsbad, CA) (Table 22). Relative mRNA quantities are
calculated by 2-∆CT compared to GAPDH.
Target

Forward primer

Reverse primer

CD3

CACTCTGGGCTTGCTGATGG

TCATAGTCTGGGTTGGAACAGG

CD8

GCTGGTAGTCTGCATCCTGCTT
C

TTGCTAGCAGGCTATCAGTGTT
GTG

IFNγ

GAGCTCATTGAATGCTTGGC

GCGTCATTGAATCACACCTG

PD-1

CGTCCCTCAGTCAAGAGGAG

GTCCCTAGAAGTGCCCAACA

GAPDH

AAGCTCACTGGCATGGCCTTC

TGCTTCACCACCTTCTTGATGTC

Table 22. qPCR primers.
5.13 ELISA
Tumor tissue was homogenized in standard RIPA buffer with protease inhibitor
cocktail (Sigma-Aldrich). Protein concentration was measured by BCA assay
(ThermoFisher). High protein binding plates (ThermoFisher) were coated with 3 µg/mL
anti-mouse-IFN-γ mAb clone AN-18 (eBioscience) in coating buffer (0.1 M Na2HPO4, pH
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to 9.0) and washed prior to addition of samples or standard curve using recombinant
mouse IFN-γ (Peprotech, Rocky Hill, NJ) in duplicate. IFN-γ was detected with biotinconjugated anti-mouse IFN-γ clone R4-6A2 (eBioscience), avidin-HRP (ThermoFisher),
and TMB substrate (ThermoFisher).
5.14 Serum IgG measurement
Serum HER2- and neu-specific IgG were quantified by flow cytometry with a BD
FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ), using HER2 overexpressing SKOV3 cells or neu transfected 3T3/NKB cells as previously described(282).
Regression analysis was conducted using standard curves of anti-HER2 mAb TA-1
(Calbiochem, Burlington, MA) or anti-neu mAb 7.16.4 (Calbiochem, Burlington, MA).
5.15 IFN-γγ ELISPOT
HER2- and neu-specific IFN-γ production was measured by ELISPOT assay as
previously described(283). Recombinant HER2 or neu (10 µg/mL, Sino Biologicals,
Beijing, China) were incubated with splenocytes for 48 h in round-bottom wells, followed
by transfer to anti-IFN-γ coated (clone AN-18, eBioscience) ELISPOT plates (Millipore
Sigma, Burlington, MA) for an additional 48 h. Spots were detected by biotinylated antiIFN-γ (clone R4-6A2, eBioscience) and avidin-HRP (Becton Dickinson, Franklin Lakes,
NJ), followed by enumeration with an ImmunoSpot analyzer (Cellular Technology Limited,
Cleveland, OH). Results are expressed as spot forming units (SFU) per 106 cells.
5.16 Tumor dissociation and flow cytometry
TUBO tumors from untreated BALB/c mice were dissociated using the
GentleMACs Dissociator and mouse tumor dissociation kit (Miltenyi, Germany) following
the manufacturer protocol. Cells were stained with a combination of antibodies listed in
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Table 23. All antibodies/dyes were purchased from eBIoscience (San Diego, CA).
Samples were analyzed on a BD FACSCantoII flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) and samples were gated on the viable fraction.
Antibody

Fluorophore

Clone

CD45

FITC

30-F11

TCRβ

APC

H57-597

CD8

PE-Cy7

53-6.7

PD-1

APC

J43

Viability dye

eFluor780

Table 23. Flow cytometry antibodies and reagents.
5.17 Statistical Analysis
Statistical analysis was performed using two-way ANOVA test in in vitro assays
and tumor uptake comparison. An unpaired t-test was used for tumor VOI comparisons.
A value of P<0.05 was considered statistically significant. Data were expressed as the
mean ± S.D.
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS
The studies described herein encompass three parts including i) examination of
89Zr-trastuzumab

BC; ii) “Using

to “monitor the status of Src status after dasatinib treatment in HER2+

89Zr-cetuximab

pet imaging to visualize membrane EGFR expression

following dasatinib treatment in triple negative breast cancer”, and iii) “Using immunoPET
imaging to monitor tumor response to immunotherapy.” The results are summarized
below.
6.1 Conclusions
In chapter 2, the relationship between Src activation and HER2 was investigated.
89Zr-trastuzumab

was hypothesized to provide a surrogate read out of Src inhibition in

HER2+ breast cancer.

89Zr-trastuzumab

is specific for HER2+ breast cancers. After

dasatinib treatment in mice bearing BT-474 or JIMT-1 tumors,

89Zr-trastuzumab

uptake

decreased compared to control, untreated tumors, and where standard-of-care FDG-PET
imaging did not visualize differences in uptake between treated and untreated groups.
89Zr-trastuzumab

tumor uptake correlated with tumor regression and abrogation of pSrc

(Y416) levels as measured by tumor western blot.

89Zr-trastuzumab

can potentially

assess tumor response to dasatinib in HER2+ breast cancer and could be used as a
surrogate tool to monitor early changes in Src signaling downstream of HER2.
In chapter 3,

89Zr-cetuximab

was utilized as a surrogate marker of EGFR

membrane expression and availability. Upon dasatinib treatment in vitro EGFR localized
to the plasma membrane, and pSrc (Y416) levels decreased, suggesting dasatinib
efficacy.

89Zr-cetuximab

was specific for high-EGFR expressing TNBC cell lines through

in vitro uptake and internalization assays, and through in vitro PET imaging studies with
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a lowly EGFR expressing MDA-MB-453 cell line used as an uptake control. After dasatinib
treatment, EGFR localized to the plasma membrane, where

89Zr-cetuximab

binding and

internalization increased. In tumor models, 89Zr-cetuximab tumor uptake was significantly
higher in dasatinib treated mice compared to control mice. Interestingly, in KRAS+ MDAMB-468 tumors, this translocation was associated with a cetuximab treatment benefit
when combining dasatinib and cetuximab after imaging, whereas in KRAS-mutant MDAMB-231 tumors, there was no cetuximab treatment benefit, which has been observed
clinically. In conclusion,

89Zr-cetuximab

could be used as a marker of EGFR localization

to predict response to cetuximab treatment, while still keeping KRAS status in mind.
In chapter 4, a new immunoPET probe targeting IFN-γ was developmed. Using
89Zr-IFN-γ

PET imaging, active immunotherapy response was visualized, and it was

concluded that targeting soluble cytokine IFNγ with

89Zr-anti-IFNγ

activated cytotoxic T cells is superior to monitoring TILs with
immunotherapy. In a syngeneic and spontaneous tumor model,

as a read out of

89Zr-anti-CD3
89Zr-anti-IFNγ

after
tumor

uptake increased after dendritic cell vaccine compared to untreated control, and
response, as measured by tumor VOI, was correlated with tumor regression. There was
an increase in CD3, CD8, and IFNγ mRNA after vaccination, an increase in CD8 T cell
infiltration via IHC after vaccination, and an increase in IFNγ protein as measured by
western blot. 89Zr-anti-IFNγ PET uptake did not increase above baseline levels in a model
where T cells have become exhausted and display PD-1. Collectively, IFN-γ PET may
serve as a non-invasive, comprehensive approach to evaluate tumor immunotherapy.
6.2 Future directions
A main challenge surrounding cancer therapeutics is designing a treatment
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strategy that targets many heterogeneous cancer populations. Currently, breast tumors
are characterized individually and thoroughly prior to treatment to identify a personalized
approach to therapy, yet challenges remain in accurate breast tumor subtyping.
Inaccuracies arise from mistakes in the collection and laboratory processing step, and
when metastasis has occurred, from the inability to collect samples from every lesion.
Utilizing immunoPET would meet this need by enabling non-invasive, full body profiling
of all lesions in the body before, during, and after treatments to tailor each regimen to the
patient’s tumor load. The studies described in this dissertation have supported this
hypothesis through imaging response to tyrosine kinase inhibitors and immunotherapies
alike, and these results provided fundamental insights into the biology of the tumor
microenvironment, allowing for further refinement of treatment strategies.
A promising area of research for BC is through combination therapy. The most
widely

used

combination

treatments

include

targeting

the

PI3K/AKT/mTOR

pathways(284). For example, the BOLERO study had demonstrated efficacy of combining
a m-TOR inhibitor and endocrine therapy to restore hormonal sensitivity(284). Palbocib
(Ibrance®) has been combined with letrozole (Femara®) to treat ER+/HER2- patients in
the metastatic realm. Trastuzumab has been combined with lapatinib (Tykeb®) or
pertuzumab (Perjeta®) to treat HER2+ metastatic BCs(284). Many clinical trials have also
been evaluating the use of combination checkpoint inhibitors, for example combining the
blockade of CTLA-4 and the PD-1/PD-L1 pathways. Early results have shown an increase
in efficacy of immunotherapy and slowing of primary tumor growth and metastasis(285).
To enhance response rates, a number of studies have suggested combining
checkpoint inhibitors with targeted therapies, since there is evidence linking oncogene
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de-addiction and immunomodulation. In EGFR overexpressing TNBC, responses to PD1 and PD-L1 antibodies have been dismal, potentially due to the PD1/PD-L1 pathway as
a mechanism of resistance for EGFR-TKIs. In preclinical studies, mutant EGFR lung
cancer models treated with anti-PD-1 have demonstrated delayed tumor growth,
suggesting a synergistic effect between anti-EGFR therapies and anti-PD-L1 in the
clinic(286). Additionally, PD-1/PD-L1 antibodies have been combined with VEGF blocking
agents in vivo and resulted in a synergistic anti-tumor effect(287). Currently, a phase II
clinical trial is recruiting for TNBC (NCT02849496) patients to undergo combination
atezolizumab (Opdivo®, anti-PD-L1) and veliparib (ABT-888, PARP inhibition) therapy. A
similar study in small cell lung cancer showed that combining atezolizumab with
chemotherapy as first line treatment resulted in significantly longer overall survival and
progression free survival compared to chemotherapy alone.
These strategies would allow for disruption of tumor-induced immunosuppression,
and therefore allow for the immune system to recognize the tumor presence and improve
the anti-tumor response of checkpoint inhibitors and targeted therapies. In order to
improve anti-cancer responses, inhibitory molecules would be blocked first to allow the
immune system to directly attack the cancer. One consideration is the issue of toxicity in
combining therapies. It would be important to appropriately dose and time treatment
regimens to achieve high response and low off-target effects, especially since
immunomodulation typically targets the entire immune system. Additionally, it is important
that synergy is achieved with combination therapy, and not just two independent
responses, or one therapy decreasing the targetable population of its partner treatment.
A main challenge for combination therapy is designing a strategy that targets many
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heterogeneous subtypes of cancer. To achieve this, though, the phenotype of each
individual BC case should be thoroughly investigated and subtyped before treatment
allowing researchers and clinicians to gather a general overview of what can be targeted.
A more precise and personalized characterization of each cancer case and potential
pathways of resistant on a patient-to-patient basis would be useful in determining
appropriate treatments. This could include pre-treatment characterization of targetable
tumor associated antigens (TAAs) (such as PD-1, HER2, or EGFR, for example) through
IHC, FISH, or immunoPET imaging. Additionally, blood samples for immune cell
population expression could be used to determine which T-cells to target. Whole genome
profiling is also of use for prognosis. It is also important during treatment to constantly
monitor the tumor microenvironment and immune profile to make necessary adjustments
to combinations, and immunoPET could meet this need. For example, tumors can be
monitored for expression of targetable biomarkers before treatment in a non-invasive
way. After treatment has begun, tumors could be re-tested for continuous expression of
the targeted biomarker, as well as surveillance of expression of known resistance
pathways. Finally, after a treatment regimen has concluded, tumors can be re-imaged for
expression of targeted biomarker to see if treatment was successful. Furthermore, we
have demonstrated that targeted biomarkers can be visualized with various PET tracers,
allowing for personalized imaging strategies.
In the final imaging study, panitumumab (Vectibix®) was labeled with

89Zr

at a

target specific activity of 5 mCi/mg. Mice bearing MDA-MB-468 tumors were imaged
following the scheme outlined in Figure 52A. At 42 h p.i., untreated mice demonstrated a
14.8 ± 1.2 %ID/g tumor uptake, compared to dasatinib treated mice with 16.9 ± 0.5%ID/g
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(p < 0.001)(Fig. 52B).

89Zr-panitumumab

imaged tumors had significantly higher uptake

as compared to tumors imaged with a human IgG isotype control (p < 0.001)(Fig. 52C).
A.

B.

C.

Figure 52. 89Zr-panitumumab PET imaging in MDA-MB-468 tumors. Mice bearing
MDA-MB-468 tumors were treated ith 50 mg/kg dasatinib for 5 d or left untreated before
undergoing imaging with 89Zr-panitumumab at 48 h p.i. (A); untreated mice (left)
demonstrate lower tumor uptake compared to dasatinib treated mice (right) (B); 89Zrpanitumumab imaged mice demonstrated significantly higher tumor uptake as compared
to a non-specific isotype IgG (C).
When compared to

89Zr-cetuximab

PET imaging,

89Zr-panitumumab

imaged

tumors demonstrated higher uptake (14.8 ± 1.2 %ID/g vs. 8.5 ± 1.7 %ID/g, p < 0.001)(Fig.
53). This body of work has demonstrated that cell-surface and soluble protein biomarkers
can potentially be used to aid in diagnosis, treatment decisions, and treatment monitoring.
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Figure 53. 89Zr-panitumumab PET imaging compared to 89Zr-cetuximab. Mice
bearing MDA-MB-468 tumors were imaged with 89Zr-cetuximab (left) or 89Zrpanitumumab (right) at 48 h p.i.
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APPENDIX – INTELLECTURAL PROPERTY
The information on the

89Zr-α-IFNγPET

tracer described in Chapter 4 comprises

intellectual property of Wayne State University and is covered by a provisional patent filed
by the university.

154
REFERENCES
1.

Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: Current
applications and future directions. Cancer. 2014. page 3433–45.

2.

Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat.
Rev. Cancer. 2002. page 683–93.

3.

Peng H, S. Levin C. Recent Developments in PET Instrumentation. Curr Pharm
Biotechnol. 2010;11:555–71.

4.

Eubank WB, Mankoff DA, Schmiedl UP, Winter TC, Fisher ER, Olshen AB, et al.
Imaging of oncologic patients: Benefit of combined CT and FDG PET in the
diagnosis of malignancy. Am J Roentgenol. 1998;171:1103–10.

5.

Van Wauwe JP, De Mey JR, Goossens JG. OKT3: a monoclonal anti-human T
lymphocyte antibody with potent mitogenic properties. J Immunol. 1980;124:2708–
13.

6.

Grillo-López A, White C., Dallaire B, Varns C, Shen C, Wei A, et al. Rituximab: the
first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm
Biotechnol

[Internet].

2000;1:278–87.

Available

from:

http://dx.doi.org/10.1038/nrc3236%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/1457
6843%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/11467356%5Cnhttp://www.pubm
edcentral.nih.gov/articlerender.fcgi?artid=2844047&tool=pmcentrez&rendertype=
abstract
7.

England TN. Use of Chemotherapy Plus a Monoclonal Antibody Against Her2.
English

J

[Internet].

2001;344:783–92.

Available

from:

155
http://www.nejm.org/doi/full/10.1056/NEJM200103153441101
8.

Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al.
Antibody-drug conjugates: Current status and future directions. Drug Discov.
Today. 2014. page 869–81.

9.

Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody
drug conjugates using a multiscale mechanistic PK/PD model: A case study with
brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39:643–59.

10.

Vasalou C, Helmlinger G, Gomes B. A Mechanistic Tumor Penetration Model to
Guide Antibody Drug Conjugate Design. PLoS One. 2015;10.

11.

Kovtun Y V, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett
[Internet].

2007;255:232–40.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/17553616
12.

Loganzo F, Sung M, Gerber H-P. Mechanisms of Resistance to Antibody–Drug
Conjugates. Mol Cancer Ther [Internet]. 2016;15:2825–34. Available from:
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT-16-0408

13.

Winter G, Harris WJ. Humanized antibodies. Immunol Today. 1993;14:243–6.

14.

Tjandra JJ, Ramadi L, McKenzie IFC. Development of human anti‐murine antibody
(HAMA) response in patients. Immunol Cell Biol. 1990;68:367–76.

15.

Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting
radionuclides: Potentials and challenges. Bioconjug. Chem. 2009. page 825–41.

16.

Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in
antibody-based oncologic imaging. Cancer Lett. 2012. page 97–111.

17.

Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high

156
specific-activity zirconium-89. Nucl Med Biol. 2009;36:729–39.
18.

Lindenberg M, Turkbey I, Adler S, Do K, Kummar S, Kurdziel K, et al. Dosimetry
and first human experience with 89Zr Panitumumab. J Nucl Med [Internet].
2015;56:1029-.

Available

from:

http://jnm.snmjournals.org.libezproxy.open.ac.uk/content/56/supplement_3/1029.s
hort
19.

Tolmachev V, Velikyan I, Sandström M, Orlova A. A HER2-binding Affibody
molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the
111In-labelled analogue. Eur J Nucl Med Mol Imaging [Internet]. 2010;37:1356–67.
Available

from:

http://www.scopus.com/inward/record.url?eid=2-s2.0-

77954955636&partnerID=tZOtx3y1%5Cnhttp://dx.doi.org/10.1007/s00259-0091367-7
20.

Xavier C, Blykers A, Vaneycken I, D’Huyvetter M, Heemskerk J, Lahoutte T, et al.
18F-nanobody for PET imaging of HER2 overexpressing tumors. Nucl Med Biol.
2016;43:247–52.

21.

Su X, Cheng K, Liu Y, Hu X, Meng S, Cheng Z. PET imaging of insulin-like growth
factor type 1 receptor expression with a 64Cu-labeled Affibody molecule. Amino
Acids

[Internet].

2015;47:1409–19.

Available

from:

http://link.springer.com/10.1007/s00726-015-1975-4
22.

Garousi J, Andersson KG, Mitran B, Pichl ML, Stahl S, Orlova A, et al. PET imaging
of epidermal growth factor receptor expression in tumours using 89Zr-labelled
ZEGFR:2377 affibody molecules. Int J Oncol. 2016;48:1325–32.

23.

Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, et al. 68Ga-labelled

157
recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J
Nucl Med Mol Imaging. 2010;37:1397–407.
24.

Lütje S, Franssen GM, Sharkey RM, Laverman P, Rossi EA, Goldenberg DM, et al.
Anti-CEA antibody fragments labeled with [18F]AlF for PET imaging of CEAexpressing tumors. Bioconjug Chem. 2014;

25.

Wong P, Li L, Chea J, Delgado MK, Poku E, Szpikowska B, et al. Synthesis,
Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug
Lipid Nanoparticles in a Prostate Cancer Murine Model. Cancer Biother
Radiopharm [Internet]. 2017 [cited 2018 Jun 18];32:247–57. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28910151

26.

Zettlitz KA, Tavaré R, Knowles SM, Steward KK, Timmerman JM, Wu AM.
ImmunoPET of malignant and normal B cells with89Zr- and124I-labeled
obinutuzumab antibody fragments reveals differential CD20 internalization in vivo.
Clin Cancer Res. 2017;23:7242–52.

27.

Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, et al.
Noninvasive imaging of PSMA in prostate tumors with 89Zr-Labeled huJ591
engineered antibody fragments: The faster alternatives. Mol Pharm. 2014;11:3965–
73.

28.

Knowles SM, Tavaré R, Zettlitz KA, Rochefort MM, Salazar FB, Jiang ZK, et al.
Applications of immunopet: Using124I-anti-PSCA A11 minibody for imaging
disease progression and response to therapy in mouse xenograft models of
prostate cancer. Clin Cancer Res. 2014;20:6367–78.

29.

Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM. MicroPET/CT

158
imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously
or

orthotopically

in

NOD-scid

mice

using64Cu-NOTA-panitumumab

F(ab’)2fragments. Nucl Med Biol. 2015;
30.

Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 89Zr: From
radiochemistry to the clinic. Nucl Med Biol. 2013;40:3–14.

31.

Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, et al. Alternative
chelator for 89Zr radiopharmaceuticals: Radiolabeling and evaluation of 3,4,3-(LI1,2-HOPO). J Med Chem. 2014;57:4849–60.

32.

Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen
G a MS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zrlabeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.

33.

Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. PIsothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile
radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Eur J Nucl Med Mol Imaging. 2010;37:250–9.

34.

Holland JP, Williamson MJ LJ. Unconventional nuclides for radiopharmaceuticals.
Mol Imaging Biol. 2010;36:729–39.

35.

Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew BJ, et al. Enzymemediated methodology for the site-specific radiolabeling of antibodies based on
catalyst-free click chemistry. Bioconjug Chem. 2013;24:1057–67.

36.

Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, et al. Zirconium-89
labeled panitumumab: A potential immuno-PET probe for HER1-expressing

159
carcinomas. Nucl Med Biol. 2013;40:451–7.
37.

Holland JP, Caldas-Lopes E, Divilov V, Longo V a, Taldone T, Zatorska D, et al.
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu
expression in mice using Zr-DFO-trastuzumab. PLoS One [Internet]. 2010;5:e8859.
Available

from:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2810330&tool=pmcentr
ez&rendertype=abstract
38.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN,
Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas
M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M,
Brouwers AH de V. 89Zr-Lumretuzumab PET Imaging before and during HER3
Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res.
2017;23:6128–37.

39.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS.

89Zr-

DFO-J591 for immunoPET of prostate-specific membrane antigen expression in
vivo. J Nucl Med. 2010;51:1293–300.
40.

Perk LR, Visser OJ, Stigter-Van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra
JM, et al. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin
biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging.
2006;33:1337–45.

41.

Vugts DJ, Heuveling DA, Stigter-van Walsum M, Weigand S, Bergstrom M, van
Dongen GAMS, et al. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal
antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical

160
studies.

MAbs

[Internet].

2014;6:567–75.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/24492295%5Cnhttp://www.pubmedcentral.ni
h.gov/articlerender.fcgi?artid=PMC3984344
42.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, et al.
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled
Pembrolizumab.

J

Nucl

Med

[Internet].

2017;58:162–8.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/27493273%5Cnhttp://www.pubmedcentral.ni
h.gov/articlerender.fcgi?artid=PMC5209640
43.

Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, et al. Radiosynthesis
and preclinical PET evaluation of89Zr-nivolumab (BMS-936558) in healthy nonhuman primates. Bioorganic Med Chem. 2017;25:5407–14.

44.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et
al. In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian
Tumor Xenograft. J Nucl Med [Internet]. 2007;48:1313–9. Available from:
http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.107.041301

45.

Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, et
al. Granzyme B PET imaging as a predictive biomarker of immunotherapy
response. Cancer Res. 2017;77:2318–27.

46.

Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend WN, McCarthy CE, et al.
IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor
Immunotherapy. Cancer Res. 2018;

47.

Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Quantitative CD3 PET
Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. J Nucl Med

161
[Internet].

2016;57:1607–11.

Available

from:

http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.116.173930
48.

Tavare R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, et al.
Immuno-PET

of

Murine

T

Cell

Reconstitution

Postadoptive

Stem

Cell

Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. J Nucl Med
[Internet].

2015;56:1258–64.

Available

from:

http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.114.153338
49.

Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, et al. An
engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of
pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg
Res. 2013;185:45–55.

50.

Lohrmann C, O’Reilly E, ODonoghue J, Yu K, Pandit-Taskar N, Lyashchenko S,
Ruan S, Wu J, DeNoble P, Carrasquillo J, Schmidtlein C, Teng R, Lowery M,
Varghese A, Estrella H, Scholz W, Maffuid P, Lewis J and WW. First-in-Human
Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without
HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9
positive malignancies. J Nucl Med. 2017;58:385.

51.

Börjesson PKE, Jauw YWS, Boellaard R, de Bree R, Comans EFI, Roos JC, et al.
Performance of immuno-positron emission tomography with zirconium-89-labeled
chimeric monoclonal antibody U36 in the detection of lymph node metastases in
head and neck cancer patients. Clin Cancer Res [Internet]. 2006;12:2133–40.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16609026

52.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the

162
management of cancer. Nat. Rev. Clin. Oncol. 2017. page 531–48.
53.

Lorenz JM. Updates in Percutaneous Lung Biopsy: New Indications, Techniques
and Controversies. Semin Intervent Radiol. 2012;319–24.

54.

Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al.
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary
Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med [Internet].
2016;57:1523–8.

Available

from:

http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.115.172031
55.

El-Osta H, Hong DS, Wheler JJ, Fu S, Naing A, Falchook GS, et al. Outcomes of
research biopsies in phase I clinical trials: the MD anderson cancer center
experience.

Oncologist

[Internet].

2011;16:1292–8.

Available

from:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3228176&tool=pmcentr
ez&rendertype=abstract
56.

Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the Evaluation of Cancer
Treatment Response. J Nucl Med. 2009;

57.

Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM,
Beylergil V, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591
ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin
Cancer

Res

[Internet].

2015;21:5277–85.

Available

from:

http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-0552
58.

Pandit-Taskar N, ODonoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA,
Heller G, et al. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in
Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution,

163
Dosimetry, and Lesion Uptake. J Nucl Med [Internet]. 2016;57:1858–64. Available
from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.116.176206
59.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers a H, Jager PL, de Jong
JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive
lesions in patients with metastatic breast cancer. Clin Pharmacol Ther [Internet].
2010;87:586–92. Available from: http://dx.doi.org/10.1038/clpt.2010.12

60.

Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH,
Haasjes JG, et al. Trastuzumab pharmacokinetics influenced by extent human
epidermal growth factor receptor 2-positive tumor load. J. Clin. Oncol. 2010.

61.

Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population
pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
Cancer Chemother Pharmacol. 2005;56:361–9.

62.

Li C, Agarwal P, Gibiansky E, Jin JY, Dent S, Gonçalves A, et al. A Phase I
Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with
Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
and Normal or Reduced Hepatic Function. Clin Pharmacokinet [Internet]. 2017
[cited

2018

Jun

4];56:1069–80.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/27995530
63.

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase
I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with
advanced cancer. J Clin Oncol [Internet]. 2005;23:2534–43. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15699478

64.

Tran L, Baars JW, Aarden L, Beijnen JH, Huitema ADR. Pharmacokinetics of

164
rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies.
2010;19:7–13.
65.

Jauw YWS, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al.
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess
CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large
B Cell Lymphoma. Glod JW, editor. PLoS One [Internet]. 2017 [cited 2018 Jun
4];12:e0169828. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28060891

66.

Lamberts LE, Menke-Van Der Houven Van Oordt CW, Ter Weele EJ, Bensch F,
Smeenk MM, Voortman J, et al. ImmunoPET with anti-mesothelin antibody in
patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug
conjugate treatment. Clin Cancer Res. 2016;22:1642–52.

67.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular
imaging as a tool to investigate heterogeneity of advanced HER2-positive breast
cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The
ZEPHIR trial. Ann Oncol. 2016;27:619–24.

68.

Dijkers ECF, Kosterink JGW, Rademaker AP, Perk LR, van Dongen GAMS, Bart J,
et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for
HER2/neu ImmunoPET Imaging. J Nucl Med [Internet]. 2009;50:974–81. Available
from: http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.108.060392

69.

Carrasquillo J a, White JD, Paik CH, Raubitschek a, Le N, Rotman M, et al.
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac
monoclonal antibody distribution. J Nucl Med. 1999;40:268–76.

70.

Rizvi SNF, Visser OJ, Vosjan MJWD, van Lingen A, Hoekstra OS, Zijlstra JM, et al.

165
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan
therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zribritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging [Internet].
2012;39:512–20.

Available

from:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3276758&tool=pmcentr
ez&rendertype=abstract
71.

Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra B V., et al.
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal
Imaging Parameters in Women with HER2-Positive Breast Cancer. Mol Imaging
Biol. 2016;18:952–9.

72.

Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of
18F-FDG PET/CT: Incorporating exam-specific parameters in dose estimates.
BMC Med Imaging. 2016;

73.

Breast Cancer Facts - National Breast Cancer Foundation [Internet]. [cited 2018 Jul
9]. Available from: http://www.nationalbreastcancer.org/breast-cancer-facts

74.

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems
biology. Nat Rev Cancer [Internet]. 2012 [cited 2018 Aug 3];12:553–63. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/22785351

75.

Moasser MM. The oncogene HER2: Its signaling and transforming functions and
its role in human cancer pathogenesis. Oncogene. 2007. page 6469–87.

76.

Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A
hierarchical network of interreceptor interactions determines signal transduction by
Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol.

166
1996;
77.

Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR
monoclonal antibody cetuximab. Cancer Biol. Ther. 2011. page 777–92.

78.

Cao H, Lei ZM, Bian L, Rao C V. Functional nuclear epidermal growth factor
receptors in human choriocarcinoma JEG-3 cells and normal human placenta.
Endocrinology. 1995;136:3163–-3172.

79.

Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al. Localization of
epidermal growth factor receptor in hepatocyte nuclei. Hepatology. 1991;13:15–20.

80.

Lin SY, Makino K, Xia W, Matin a, Wen Y, Kwong KY, et al. Nuclear localization of
EGF receptor and its potential new role as a transcription factor. Nat Cell Biol.
2001;3:802–8.

81.

Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: Linking EGFR
pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J.
Cancer. 2006. page 184–8.

82.

Lo H-W, Xia W, Wei Y, Ali-Seyed M, Huang S-F, Hung M-C. Novel prognostic value
of nuclear epidermal growth factor receptor in breast cancer. Cancer Res.
2005;65:338–48.

83.

Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative
determination of nuclear and cytoplasmic epidermal growth factor receptor
expression in oropharyngeal squamous cell cancer by using automated quantitative
analysis.

Clin

Cancer

Res

[Internet].

2005;11:5856–62.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/16115926
84.

Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and

167
the basal phenotype: From expression profiling to clinical practice. Adv. Anat.
Pathol. 2007. page 419–30.
85.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al.
Pathological complete response and long-term clinical benefit in breast cancer: The
CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

86.

Conlin AK, Seidman AD. Taxanes in breast cancer: An update. Curr. Oncol. Rep.
2007. page 22–30.

87.

Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF,
et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;

88.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast
cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin.
Oncol. 2016. page 674–90.

89.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Shyr Y, Pietenpol JA. Transcriptome
Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological
Subgroups and Reveals Therapeutic Strategies. Present 33rd Annu San Antonio
Breast Cancer Symp [Internet]. 2010;Abstract PD01-07. Available from:
http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_842%5Cnhttp:
//ascopost.com/articles/february-15-2011/triple-negative-breast-cancer-proving-tobe-genetically-diverse

90.

Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic
modalities and novel combination therapies. Cancer Treat. Rev. 2018. page 110–
22.

91.

Changavi A, Shashikala A, Ramji A. Epidermal growth factor receptor expression

168
in triple negative and nontriple negative breast carcinomas. J Lab Physicians. 2015;
92.

Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy
number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;

93.

Jeong W, Doroshow JH, Kummar S. United States Food and Drug Administration
approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer
[Internet]. NIH Public Access; 2013 [cited 2018 Jul 9];37:110–44. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23972982

94.

Moradi-Kalbolandi S, Hosseinzade A, Salehi M, Merikhian P, Farahmand L.
Monoclonal antibody-based therapeutics, targeting theepidermal growth factor
receptor family: from herceptin toPan HER. J Pharm Pharmacol. 2018;

95.

Sacco AG, Worden FP. Molecularly targeted therapy for the treatment of head and
neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther [Internet].
2016;9:1927–43.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/27110122%5Cnhttps://www.ncbi.nlm.nih.gov
/pmc/articles/PMC4831599/pdf/ott-9-1927.pdf
96.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, et al. The
relevance of ADCC for EGFR targeting: A review of the literature and a clinicallyapplicable method of assessment in patients. Crit. Rev. Oncol. Hematol. 2015.
page 179–90.

97.

Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against
epidermal growth factor receptor is internalized without stimulating receptor
phosphorylation. Proc Natl Acad Sci U S A [Internet]. 1986;83:3825–9. Available
from:

169
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=323616&tool=pmcentre
z&rendertype=abstract
98.

Gridelli C, Maione P, Ferrara ML, Rossi A. Cetuximab and other anti-epidermal
growth factor receptor monoclonal antibodies in the treatment of non-small cell lung
cancer. Oncologist. 2009;14:601–11.

99.

Alanazi IO, Khan Z. Understanding EGFR Signaling in Breast Cancer and Breast
Cancer Stem Cells: Overexpression and Therapeutic Implications. Asian Pacific J
Cancer

Prev

[Internet].

2016;17:445–53.

Available

from:

http://koreascience.or.kr/journal/view.jsp?kj=POCPA9&py=2016&vnc=v17n2&sp=
445
100. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth
factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol. 2009.
page 1–9.
101. Bonomo P, Loi M, Desideri I, Olmetto E, Delli Paoli C, Terziani F, et al. Incidence
of skin toxicity in squamous cell carcinoma of the head and neck treated with
radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol
[Internet].

2017;120:98–110.

Available

from:

http://dx.doi.org/10.1016/j.critrevonc.2017.10.011
102. Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized
phase II study of the anti-epidermal growth factor receptor monoclonal antibody
cetuximab with cisplatin versus cisplatin alone in patients with metastatic triplenegative breast cancer. J Clin Oncol. 2013;31:2586–92.
103. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001:

170
Randomized phase II study of cetuximab in combination with carboplatin in stage
IV triple-negative breast cancer. J Clin Oncol. 2012;
104. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab
shows activity in colorectal cancer patients with tumors that do not express the
epidermal growth factor receptor by immunohistochemistry. J Clin Oncol.
2005;23:1803–10.
105. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni
N, et al. KRAS wild-type state predicts survival and is associated to early
radiological response in metastatic colorectal cancer treated with cetuximab. Ann
Oncol. 2008;19:508–15.
106. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in
metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–12.
107. Huang F, Xu LA, Khambata-Ford S. Correlation between gene expression of IGF1r pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin
Cancer Res. 2012;18:1156–66.
108. Nevo J, Mattila E, Pellinen T, Yamamoto DL, Sara H, Iljin K, et al. Mammary-derived
growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab
resistance. Clin Cancer Res. 2009;15:6570–81.
109. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN.
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2
Therapy and Personalized Medicine. Oncologist [Internet]. 2009;14:320–68.
Available

from:

171
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2008-0230
110. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al.
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in
Breast Cancer: American Society of Clinical Oncology/College of American
Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med [Internet].
2014;138:241–56.

Available

from:

http://www.archivesofpathology.org/doi/abs/10.5858/arpa.2013-0953-SA
111. Myers MB. Targeted therapies with companion diagnostics in the management of
breast cancer: Current perspectives. Pharmgenomics. Pers. Med. 2016. page 7–
16.
112. Carlson RW, Moench SJ, Hammond MEH, Perez E a, Burstein HJ, Allred DC, et
al. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
J Natl Compr Canc Netw. 2006;4 Suppl 3:S1-22; quiz S23-4.
113. Krishnamurti U, Silverman JF. HER2 in Breast Cancer: A Review and Update. Adv
Anat Pathol. 2014;21:100–7.
114. Vincent-Salomon A, Jouve M, Genin P, Fréneaux P, Sigal-Zafrani B, Caly M, et al.
HER2 status in patients with breast carcinoma is not modified selectively by
preoperative chemotherapy and is stable during the metastatic process. Cancer.
2002;94:2169–73.
115. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, et al. HER2 gene
status in primary breast cancers and matched distant metastases. Breast Cancer
Res

[Internet].

2007;9:R31.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/17511881%5Cnhttp://www.pubmedcentral.ni

172
h.gov/articlerender.fcgi?artid=PMC1929093
116. Dehdashti farrokh, wu ningying, Naughton michael j., Ma CX, Marquez-Nostra B
V., Diebolder P, et al. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating
HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat.
2018;1–8.
117. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al.
Structure of the extracellular region of HER2 alone and in complex with the
Herceptin Fab. Nature. 2003;421:756–60.
118. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX. Insights
into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer
Cell. 2004;5:317–28.
119. Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo
B, et al. Treatment of HER2 positive advanced breast cancer with T-DM1: A review
of the literature. Crit. Rev. Oncol. Hematol. 2016. page 96–106.
120. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A
unique structure for epidermal growth factor receptor bound to GW572016
(Lapatinib): Relationships among protein conformation, inhibitor off-rate, and
receptor activity in tumor cells. Cancer Res. 2004;64:6652–9.
121. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al.
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2
tyrosine kinase. Cancer Res. 2004;64:3958–65.
122. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after
trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-

173
year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017;
123. Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, et al.
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor
Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival
From NSABP B-31 and NCCTG N9831. J Clin Oncol [Internet]. 2014 [cited 2019
Mar

14];32:3744–52.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/25332249
124. Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics [Internet].
2009;3:289–301.

Available

from:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2726059&tool=pmcentr
ez&rendertype=abstract
125. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al.
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J
Med. 2006;
126. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al.
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast
Cancer. N Engl J Med. 2015;
127. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab
emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;
128. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after
trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer
(ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3

174
trial. Lancet Oncol [Internet]. 2016 [cited 2018 Oct 23];17:367–77. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26874901
129. Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, et al. Development and clinical application
of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp.
Hematol. Oncol. 2017.
130. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in
multiple solid cancers. ESMO Open [Internet]. 2017;2:e000279. Available from:
http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2017-000279
131. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, et al. Effects of
radiotherapy and of differences in the extent of surgery for early breast cancer on
local recurrence and 15-year survival: An overview of the randomised trials. Lancet.
2005.
132. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer - An overview
and update. Mol Cell Endocrinol. 2015;
133. Perez EA. Impact, mechanisms, and novel chemotherapy strategies for
overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
Breast Cancer Res. Treat. 2009.
134. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl
J

Med

[Internet].

2007;357:39–51.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/17611206
135. Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, et al.
Loss of Phosphatase and tensin homologue deleted on chromosome 10 engages
ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen

175
resistance in breast cancer. Cancer Res. 2009;
136. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain, breast, and prostate
cancer. Science (80- ). 1997;
137. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations
correlate with hormone receptors, node metastasis, and ERBB2, and are mutually
exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;
138. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;
139. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: Turning
promise into triumph. Trends Pharmacol. Sci. 2012. page 122–8.
140. Playford MP, Schaller MD. The interplay between Src and integrins in normal and
tumor biology. Oncogene. 2004. page 7928–46.
141. Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic
myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent
manner. J Biol Chem [Internet]. American Society for Biochemistry and Molecular
Biology;

2010

[cited

2018

Jul

9];285:21446–57.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/20452982
142. Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, et
al. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer
Exhibiting Low Estrogen Receptor-Mediated Transactivation. PLoS One [Internet].
Public Library of Science; 2016 [cited 2018 Jul 9];11:e0157397. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27308830
143. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, et al.

176
Combined Src and ER blockade impairs human breast cancer proliferation in vitro
and in vivo. Breast Cancer Res Treat [Internet]. 2011 [cited 2018 Jul 9];128:69–78.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20669046
144. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in
breast cancer: epidermal growth factor receptor and c-Src interactions in breast
cancer. Breast Cancer Res. 2000;
145. Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, et al. Physical and
functional interactions between Cas and c-Src induce tamoxifen resistance of
breast cancer cells through pathways involving epidermal growth factor receptor
and signal transducer and activator of transcription 5b. Cancer Res. 2006;66:7007–
15.
146. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer.
Oncogene. 2000;19:5636–42.
147. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, et al.
Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the
University of Chicago Phase II Consortium. Invest New Drugs. 2012;30:1211–5.
148. Creedon H, Brunton VG. Src kinase inhibitors: promising cancer therapeutics? Crit
Rev Oncog [Internet]. 2012 [cited 2018 Jul 9];17:145–59. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22471705
149. Mayer EL, Krop IE. Advances in targeting Src in the treatment of breast cancer and
other solid malignancies. Clin. Cancer Res. 2010. page 3526–32.
150. Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, et al. A phase
II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer

177
(Cancer and Leukemia Group B 30602). J Thorac Oncol Off Publ Int Assoc Study
Lung

Cancer

[Internet].

2010;5:380–4.

Available

from:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=
med6&AN=20087228%5Cnhttp://nt2yt7px7u.search.serialssolutions.com/?sid=O
VID:Ovid+MEDLINE%28R%29+%3C2008+to+2010%3E&genre=article&id=pmid:
20087228&id=doi:10.1097%2FJTO.0b013e3181cee36e&is
151. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A phase
II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castrationresistant prostate cancer: A California Cancer Consortium study. Anticancer Drugs.
2009;20:179–84.
152. MacKay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, et al. A phase
II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic
or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma:
A trial of the PMH phase II consortium. Invest New Drugs. 2012;30:1158–63.
153. Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, et al. Phase
II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients
with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer.
2011;11:306–11.
154. Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, et al.
Gene array and fluorescence in situ hybridization biomarkers of activity of
saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Clin Cancer Res. 2010;16:4165–77.
155. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted

178
Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis. Mol
Cancer

Ther

[Internet].

2010;9:2322–32.

Available

from:

http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-09-1212
156. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of
p95HER2, a truncated form of the HER2 receptor, and response to Anti-HER2
therapies in breast cancer. J Natl Cancer Inst. 2007;99:628–38.
157. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, et al. ErbB2 promotes Src synthesis
and stability: Novel mechanisms of Src activation that confer breast cancer
metastasis. Cancer Res. 2005;65:1858–67.
158. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating
trastuzumab resistance by targeting SRC, a common node downstream of multiple
resistance pathways. Nat Med [Internet]. 2011 [cited 2018 Feb 12];17:461–9.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21399647
159. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An
oncogenic isoform of HER2 associated with locally disseminated breast cancer and
trastuzumab resistance. Mol Cancer Ther [Internet]. 2009;8:2152–62. Available
from: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-09-0295
160. Wang L, Yu X, Dong J, Meng Y, Yang Y, Wang H, et al. Combined SRC inhibitor
saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect
on trastuzumab-resistant breast cancer. Biochem Biophys Res Commun.
2016;479:563–70.
161. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. C-Src-mediated
phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is

179
associated with modulation of receptor function. J Biol Chem. 1999;
162. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of
epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for
the etiology of multiple human cancers. Proc Natl Acad Sci U S A. 1995;
163. Osherov N, Levitzki A. Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐
Family Kinases. Eur J Biochem. 1994;
164. Sato K-I. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J
Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2013 [cited
2018

Jul

17];14:10761–90.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/23702846
165. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and
epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated
resistance of inhibition of pancreatic tumor growth. Clin Cancer Res. 2011;17:483–
93.
166. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong E a, et al.
Epidermal growth factor receptor cooperates with Src family kinases in acquired
resistance to cetuximab. Cancer Biol Ther. 2009;8:696–703.
167. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar APN. Src inhibitor dasatinib
inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett.
2009;
168. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired
resistance to cetuximab. Oncogene. 2009;
169. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib

180
sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011;30:561–
74.
170. Xie YM, Hung MC. Nuclear localization of P185neuTyrosine kinase and its
association with transcriptional transactivation. Biochem Biophys Res Commun.
1994;
171. Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in
the tumor microenvironment. Carcinogenesis [Internet]. Oxford University Press;
2015

[cited

2018

Jul

9];36:1085–93.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/26354776
172. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature
of immune function genes associated with recurrence-free survival in breast cancer
patients. Breast Cancer Res Treat [Internet]. 2012 [cited 2018 Jun 4];131:871–80.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21479927
173. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, et al. High
Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast
Cancers Correlates with Lower Recurrence Rates. Cancer Res [Internet]. 2007
[cited

2018

Jun

4];67:10669–76.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/18006808
174. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. TumorAssociated Lymphocytes As an Independent Predictor of Response to Neoadjuvant
Chemotherapy in Breast Cancer. J Clin Oncol [Internet]. 2010 [cited 2018 Jun
4];28:105–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19917869
175. Ernst B, Anderson KS. Immunotherapy for the Treatment of Breast Cancer. Curr

181
Oncol Rep [Internet]. Springer US; 2015 [cited 2018 Jun 4];17:5. Available from:
http://link.springer.com/10.1007/s11912-014-0426-9
176. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity’s
Roles in Cancer Suppression and Promotion. Science (80- ) [Internet]. 2011 [cited
2018

Jul

2];331:1565–70.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/21436444
177. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive
Immunity to Cancer. Annu Rev Immunol [Internet]. 2011 [cited 2018 Jul 2];29:235–
71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21219185
178. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al.
Tumor-Infiltrating CD8

+

Lymphocytes Predict Clinical Outcome in Breast Cancer.

J Clin Oncol [Internet]. 2011 [cited 2018 Jul 2];29:1949–55. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21483002
179. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho H-I, Antonia S, et al.
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during
cancer immunotherapy in mice. J Clin Invest [Internet]. 2010 [cited 2018 Jul
2];120:1111–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20234093
180. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, et al. CD25 Blockade
Depletes and Selectively Reprograms Regulatory T Cells in Concert with
Immunotherapy in Cancer Patients. Sci Transl Med [Internet]. 2012 [cited 2018 Jul
2];4:134ra62-134ra62.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/22593175
181. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol

182
Cell Endocrinol. 2014;
182. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune
response: crosstalk between adaptive and innate immune cells during breast
cancer progression. Breast Cancer Res [Internet]. 2007 [cited 2018 Jul 2];9:212.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17705880
183. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with
aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol
2008 2112 [Internet]. Nature Publishing Group; 2008 [cited 2018 Jul 3];21:1527.
Available from: https://www.nature.com/articles/modpathol2008160
184. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, et al. In situ
immune response after neoadjuvant chemotherapy for breast cancer predicts
survival. J Pathol. 2011;
185. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al.
Durable complete responses in heavily pretreated patients with metastatic
melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;
186. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N
Engl J Med. 2015;
187. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD1 blockade induces responses by inhibiting adaptive immune resistance. Nature.
2014;
188. Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma - National
Cancer

Institute

[Internet].

[cited

2018

Nov

5].

Available

from:

183
https://www.cancer.gov/news-events/cancer-currents-blog/2015/oncolyticvirusmelanoma
189. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy.
BBA Clin. 2015. page 280–8.
190. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and
immune checkpoint blockade. Expert Rev Anticancer Ther [Internet]. 2012 [cited
2018

Jun

4];12:1597–611.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/23253225
191. Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L.
New Strategies Using Antibody Combinations to Increase Cancer Treatment
Effectiveness. Front Immunol [Internet]. Frontiers; 2017 [cited 2018 Jul 5];8:1804.
Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2017.01804/full
192. Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune Checkpoitn
Inhibitors: An Innovation in Immunotherpay for the Treatment and Managment of
Paatients With Cancer. Asia Pac J Oncol Nurs. 2017;
193. Commissioner O of the. Press Announcements - FDA approves first cancer
treatment for any solid tumor with a specific genetic feature. Office of the
Commissioner;

[cited

2018

Nov

8];

Available

from:

https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.ht
m
194. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al.
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol
[Internet].

2014

[cited

2018

Jun

4];11:509–24.

Available

from:

184
http://www.ncbi.nlm.nih.gov/pubmed/25001465
195. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al.
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with
booster inoculations to prevent disease recurrence in high-risk breast cancer
patients. Ann Oncol Off J Eur Soc Med Oncol [Internet]. Oxford University Press;
2014

[cited

2018

Jul

6];25:1735–42.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/24907636
196. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J
Med

[Internet].

2010

[cited

2018

Jun

4];363:411–22.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/20818862
197. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer Immunotherapy:
Sipuleucel-T and Beyond. Pharmacotherapy [Internet]. 2011 [cited 2018 Jul
6];31:813–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21923608
198. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with
autologous antigen-presenting cells activated with the HER-2 -based antigen
lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER2-overexpressing breast cancer. J Clin Oncol. 2007;
199. Lacroix M, Toillon R-A, Leclercq G. p53 and breast cancer, an update. Endocr Relat
Cancer [Internet]. 2006 [cited 2018 Jul 2];13:293–325. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16728565
200. Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast
Cancer Res Treat [Internet]. 2012 [cited 2018 Jun 4];133:11–21. Available from:

185
http://www.ncbi.nlm.nih.gov/pubmed/22057973
201. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for
immune modulation. Nat Rev Drug Discov [Internet]. 2013 [cited 2018 Jun
4];12:130–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23370250
202. Hodi FS, Ballinger M, Lyons B, Soria J-C, Nishino M, Tabernero J, et al. ImmuneModified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining
Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol
[Internet].

2018

[cited

2018

Nov

6];36:850–8.

Available

from:

http://ascopubs.org/doi/10.1200/JCO.2017.75.1644
203. Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, et al.
Immunodynamics: A cancer immunotherapy trials network review of immune
monitoring in immuno-oncology clinical trials. J. Immunother. Cancer. 2016.
204. Riley JL. Combination Checkpoint Blockade — Taking Melanoma Immunotherapy
to the Next Level. N Engl J Med. 2013;
205. Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for
ELISPOT: Toward a standard that can be applied across laboratories. Methods Mol
Biol. 2012;
206. Mori A, Deola S, Xumerle L, Mijatovic V, Malerba G, Monsurrò V. Next generation
sequencing: New tools in immunology and hematology. Blood Res. 2013.
207. Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining
response. Adv Radiat Oncol [Internet]. Elsevier; 2018 [cited 2018 Nov 6];3:534–47.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/30370353
208. Ponomarev V. Advancing Immune and Cell-Based Therapies Through Imaging.

186
Mol Imaging Biol. 2017;
209. Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, et al. Rapid
PD-L1 detection in tumors with PET using a highly specific peptide. Biochem
Biophys Res Commun. 2017;
210. Bensch F, Veen E van der, Jorritsma A, Hooge ML, Boellaard R, Oosting S, et al.
Abstract CT017: First-in-human PET imaging with the PD-L1 antibody

89

Zr-

atezolizumab. Cancer Res. 2017;
211. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, et al. Human
biodistribution and radiation dosimetry of novel PET probes targeting the
deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011;
212. Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis
of 2’-Deoxy-2’-[18F]fluoro-9-β- DArabinofuranosylguanine: A novel agent for
imaging T-cell activation with PET. Mol Imaging Biol. 2011;
213. Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al.
An effective immuno-PET imaging method to monitor CD8-dependent responses
to immunotherapy. Cancer Res. 2016;76:73–82.
214. Tavare R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, et al.
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T
cells in vivo. Proc Natl Acad Sci. 2014;
215. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko C -w., Sridhara R, et al. FDA Drug
Approval Summary: Lapatinib in Combination with Capecitabine for Previously
Treated Metastatic Breast Cancer That Overexpresses HER-2. Oncologist
[Internet].

2008;13:1114–9.

Available

from:

187
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2008-0816
216. Hortobagyi GN. Trastuzumab in the Treatment of Breast Cancer. N Engl J Med
[Internet].

2005;353:1734–6.

Available

from:

http://www.nejm.org/doi/abs/10.1056/NEJMe058196
217. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance
to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007. page
1–22.
218. Muthuswamy SK. Trastuzumab resistance: All roads lead to SRC. Nat Med.
2011;17:416–8.
219. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib
in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias. N Engl J Med
[Internet].

2006;354:2531–41.

Available

from:

http://www.nejm.org/doi/abs/10.1056/NEJMoa055229
220. Seoane S, Montero JC, Ocaña A, Pandiella A. Effect of multikinase inhibitors on
caspase-independent cell death and DNA damage in HER2-overexpressing breast
cancer cells. J Natl Cancer Inst. 2010;102:1432–46.
221. Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, et al. A phase I
study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first
line therapy for patients with HER2-overexpressing advanced breast cancer.
GEICAM/2010-04

study.

Oncotarget

[Internet].

2017;

Available

from:

http://www.oncotarget.com/fulltext/17113
222. Boerner RJ, Kassel DB, Barker SC, Ellis B, DeLacy P, Knight WB. Correlation of
the phosphorylation states of pp60(c-Src) with tyrosine kinase activity: The

188
intramolecular pY530-SH2 complex retains significant activity if Y419 is
phosphorylated. Biochemistry. 1996;35:9519–25.
223. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical
implications. Ann N Y Acad Sci. 2005. page 70–5.
224. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice D a, Romney D a, Parsons
SJ. Src family kinases and HER2 interactions in human breast cancer cell growth
and

survival.

Oncogene

[Internet].

2001;20:1465–75.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/11313890
225. Peiró G, Ortiz-Martínez F, Gallardo A, Pérez-Balaguer A, Sánchez-Payá J, Ponce
JJ, et al. Src, a potential target for overcoming trastuzumab resistance in HER2positive breast carcinoma. Br J Cancer. 2014;111:689–95.
226. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek
C, et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
J Med Chem. 2007;50:5853–7.
227. Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Craig Jordan V. Modulating
therapeutic effects of the c-Src inhibitor via oestrogen receptor and human
epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer
[Internet]. Pergamon; 2012 [cited 2018 Jul 16];48:3488–98. Available from:
https://www.sciencedirect.com/science/article/pii/S0959804912003711
228. Massicano AVF, Marquez-Nostra B V., Lapi SE. Targeting HER2 in Nuclear
Medicine for Imaging and Therapy. Mol Imaging. 2018;17.
229. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al.
Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clin Cancer Res

189
[Internet].

2008

[cited

2018

Aug

3];14:8010–8.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/19088017
230. Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as
a potential therapeutic target in triple-negative breast cancer. Ann Oncol [Internet].
2009

[cited

2018

Aug

3];20:862–7.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/19150933
231. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al.
Identification of human triple-negative breast cancer subtypes and preclinical
models for selection of targeted therapies. J Clin Invest [Internet]. 2011 [cited 2018
Aug

3];121:2750–67.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/21633166
232. Nakai K, Hung M-C, Yamaguchi H. A perspective on anti-EGFR therapies targeting
triple-negative breast cancer. Am J Cancer Res [Internet]. e-Century Publishing
Corporation;

2016

[cited

2018

Aug

3];6:1609–23.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/27648353
233. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role
of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat
[Internet].

2012

[cited

2018

Aug

3];136:331–45.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/23073759
234. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triplenegative breast cancer: optimising therapeutic outcomes. Ann Oncol [Internet].
2012

[cited

2018

Aug

3];23:2223–34.

Available

from:

190
http://www.ncbi.nlm.nih.gov/pubmed/22517820
235. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor
signaling network and its role in cancer. Discov Med [Internet]. 2011 [cited 2018
Aug 3];12:419–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22127113
236. Han W, Lo H-W. Landscape of EGFR signaling network in human cancers: Biology
and therapeutic response in relation to receptor subcellular locations. Cancer Lett
[Internet].

2012

[cited

2018

Aug

3];318:124–34.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/22261334
237. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, et al. Nuclear EGFR
protein expression predicts poor survival in early stage non-small cell lung cancer.
Lung Cancer [Internet]. NIH Public Access; 2013 [cited 2018 Aug 3];81:138–41.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23628526
238. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: From
traditional signal transduction to direct nuclear translocalization. Breast Cancer
Res. Treat. 2006. page 211–8.
239. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, et al. Nuclear
epidermal growth factor receptor is a functional molecular target in triple-negative
breast cancer. Mol Cancer Ther [Internet]. NIH Public Access; 2014 [cited 2018
Aug

3];13:1356–68.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/24634415
240. Li C, Iida M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab- and radiationinduced nuclear translocation of the epidermal growth factor receptor in head and
neck squamous cell carcinoma. Radiother Oncol [Internet]. NIH Public Access;

191
2010

[cited

2018

Aug

3];97:330–7.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/20667610
241. van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, et al. PET
imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head
and neck and lung cancer. Radiother Oncol [Internet]. 2017 [cited 2018 Aug
3];122:267–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28012793
242. Even AJG, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJL, Heukelom J,
Tesselaar MET, et al. Quantitative assessment of Zirconium-89 labeled cetuximab
using PET/CT imaging in patients with advanced head and neck cancer: a
theragnostic approach. Oncotarget [Internet]. 2017 [cited 2018 Aug 3];8:3870–80.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/27965472
243. Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth
C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal
cancer.

Oncotarget

[Internet].

2015;6:30384–93.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/26309164%0Ahttp://www.pubmedcentral.nih
.gov/articlerender.fcgi?artid=PMC4745807
244. van Dijk LK, Boerman OC, Kaanders JHAM, Bussink J. PET Imaging in Head and
Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFRTargeted Imaging. Clin Cancer Res [Internet]. 2015 [cited 2018 Aug 3];21:3602–9.
Available

from:

http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-

0432.CCR-15-0348
245. Chekol R, Solomon VR, Alizadeh E, Bernhard W, Fisher D, Hill W, et al. 89Zrnimotuzumab for immunoPET imaging of epidermal growth factor receptor I.

192
Oncotarget [Internet]. Impact Journals, LLC; 2018 [cited 2018 Aug 3];9:17117–32.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29682209
246. Pool M, Kol A, Lub-de Hooge MN, Gerdes CA, de Jong S, de Vries EGE, et al.
Extracellular domain shedding influences specific tumor uptake and organ
distribution of the EGFR PET tracer 89Zr-imgatuzumab. Oncotarget [Internet].
Impact Journals, LLC; 2016 [cited 2018 Aug 3];7:68111–21. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27602494
247. Wei L, Shi J, Afari G, Bhattacharyya S. Preparation of clinical-grade 89Zrpanitumumab as a positron emission tomography biomarker for evaluating
epidermal growth factor receptor-targeted therapy. J Label Compd Radiopharm.
2014;57:25–35.
248. Aerts HJWL, Dubois L, Perk L, Vermaelen P, van Dongen GAMS, Wouters BG, et
al. Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab
Uptake Assessed with PET. J Nucl Med [Internet]. 2008 [cited 2018 Aug 7];50:123–
31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19091906
249. Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch H-J.
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and
Therapy. Pharmaceuticals (Basel) [Internet]. Multidisciplinary Digital Publishing
Institute

(MDPI); 2014 [cited 2018 Aug 7];7:311–38. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/24603603
250. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, et al. Nuclear
Epidermal Growth Factor Receptor Is a Functional Molecular Target in TripleNegative Breast Cancer. Mol Cancer Ther [Internet]. 2014 [cited 2018 Aug

193
3];13:1356–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24634415
251. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, et al. Nuclear
Epidermal Growth Factor Receptor Is a Functional Molecular Target in TripleNegative Breast Cancer. Mol Cancer Ther [Internet]. 2014 [cited 2018 Aug
3];13:1356–68. Available from: http://mct.aacrjournals.org/cgi/doi/10.1158/15357163.MCT-13-1021
252. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer:
Harnessing the T cell response. Nat. Rev. Immunol. 2012. page 269–81.
253. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapyinduced immunosurveillance in breast cancer. Nat. Med. 2015. page 1128–38.
254. Hoos A, Janetzki S, Britten CM. Advancing the field of cancer immunotherapy:
MIATA consensus guidelines become available to improve data reporting and
interpretation for T-cell immune monitoring. Oncoimmunology. 2012;1:1457–9.
255. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, et al. Novel
technologies and emerging biomarkers for personalized cancer immunotherapy. J.
Immunother. Cancer. 2016.
256. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of
immune signatures in longitudinal tumor samples yields insight into biomarkers of
response and mechanisms of resistance to immune checkpoint blockade. Cancer
Discov. 2016;6:827–37.
257. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion
Sequencing. N Engl J Med [Internet]. 2012;366:883–92. Available from:

194
http://www.nejm.org/doi/abs/10.1056/NEJMoa1113205
258. Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, et al.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring
of CD8 T cells. J Exp Med [Internet]. 2017;214:2243–55. Available from:
http://www.jem.org/lookup/doi/10.1084/jem.20161950
259. Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS. Novel Radiotracer
for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating
Lymphocytes. Bioconjug Chem. 2015;
260. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, et al. Imaging PD-L1
Expression with ImmunoPET. Bioconjug Chem. 2018;29:96–103.
261. Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, et al.
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal
antibody for assessing radiation-induced PD-L1 upregulation in head and neck
cancer and melanoma. Oncoimmunology [Internet]. 2017 [cited 2018 Jun
12];6:e1329071. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28811971
262. Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G. High-resolution
PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers.
Theranostics. 2016;
263. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and
adaptive immune responses. Adv. Immunol. 2007.
264. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic
inflammation: A magic bullet? Science (80-. ). 2013.
265. Li K, Baird M, Yang J, Jackson C, Ronchese F, Young S. Conditions for the

195
generation of cytotoxic CD4+ Th cells that enhance CD8+ CTL-mediated tumor
regression. Clin Transl Immunol. 2016;
266. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and
immunotherapy. Cancer Immunol. Immunother. 2005.
267. Xu X, Fu X, Plate J, Chong AS. IFN-y Induces Cell Growth Inhibition by Fasmediated Apoptosis : Requirement of STATI Protein for Up-Regulation of Fas and
FasL Expression1 Fas FasL ^. Cell. 1998;
268. Zaidi MR, Merlino G. The two faces of interferon-?? in cancer. Clin. Cancer Res.
2011.
269. Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, et al.
Noninvasive imaging of PSMA in prostate tumors with89Zr-Labeled huJ591
engineered antibody fragments: The faster alternatives. Mol Pharm. 2014;11:3965–
73.
270. Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, et al. Activity of DNA
vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Cell Immunol. 2006;
271. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al.
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in
mice. J Clin Invest. 2014;124:687–95.
272. Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond
WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination
reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl

196
Acad Sci. 2016;
273. Diodoro MG, Carlo E Di, Zappacosta R, Iezzi M, Coletti A, Modesti A, et al. Salivary
carcinoma in HER-2/neu transgenic male mice: An angiogenic switch is not
required for tumor onset and progression. Int J Cancer. 2000;
274. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, et al.
Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a
dominant regulatory T-cell self-tolerance. Cancer Res. 2006;66:7734–40.
275. Whittington PJ, Piechocki MP, Heng HH, Jacob JB, Jones RF, Back JB, et al. DNA
vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer
Res

[Internet].

2008

[cited

2018

Jun

12];68:7502–11.

Available

from:

http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-08-1489
276. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The
therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive
immunity. Cancer Cell [Internet]. 2010 [cited 2018 Jun 12];18:160–70. Available
from: http://linkinghub.elsevier.com/retrieve/pii/S1535610810002485
277. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in
breast cancer. J Immunother cancer [Internet]. 2016 [cited 2018 Jun 13];4:59.
Available from: http://jitc.biomedcentral.com/articles/10.1186/s40425-016-0165-6
278. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic
influence of tumour-infiltrating lymphocytes in cancer: a systematic review with
meta-analysis. Br J Cancer [Internet]. 2011 [cited 2018 Jun 13];105:93–103.
Available from: http://www.nature.com/articles/bjc2011189
279. Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying

197
baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
J. Immunother. Cancer. 2017.
280. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the
immunoreactive function of radiolabeled monoclonal antibodies by linear
extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–
89.
281. McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku
A, et al. Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A
(Duligotuzumab). Sci Rep [Internet]. Nature Publishing Group; 2018 [cited 2018 Jul
11];8:9043. Available from: http://www.nature.com/articles/s41598-018-27454-6
282. Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, et al.
Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.
Cancer Immunol Res [Internet]. 2015 [cited 2018 Jun 12];3:777–86. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25711535
283. Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, et al.
Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.
Cancer Immunol Res. 2015;3:777–86.
284. Zanardi E, Bregni G, de Braud F, Di Cosimo S. Better Together: Targeted
Combination Therapies in Breast Cancer. Semin Oncol [Internet]. 2015 [cited 2018
Jul 5];42:887–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26615133
285. Li Z, Qiu Y, Lu W, Jiang Y, Wang J. Immunotherapeutic interventions of Triple
Negative Breast Cancer. J Transl Med [Internet]. BioMed Central; 2018 [cited 2018
Jul

5];16:147.

Available

from:

https://translational-

198
medicine.biomedcentral.com/articles/10.1186/s12967-018-1514-7
286. Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. Novel immunotherapy
in the treatment of advanced non-small cell lung cancer. Expert Rev Clin Pharmacol
[Internet].

2016

[cited

2018

Jul

5];9:1571–81.

Available

from:

http://www.ncbi.nlm.nih.gov/pubmed/27623999
287. Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al.
Simultaneous blockade of programmed death 1 and vascular endothelial growth
factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp
Immunol [Internet]. 2013 [cited 2018 Jul 5];172:500–6. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23600839

199
ABSTRACT
UTILIZING IMMUNOPET TO MONITOR TUMOR RESPONSE TO TREATMENT IN
BREAST CANCER
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With a broad spectrum of therapies available for treating breast cancer, the need
for personalized medicine tailoring the cure according to phenotype is evident. Such an
approach may be fully realized with the development of quantitative imaging technologies
for disease detection, staging and diagnosis, without increasing patient burden. Immunopositron emission tomography (PET) combines the targeted specificity of antibodies with
the sensitivity of PET for whole body imaging by targeting molecular features amplified in
lesions. ImmunoPET probes targeting different antigens and their utility to measure
response to treatment were explored.

89Zr-trastuzumab

was employed as a surrogate

readout of Src inhibition after dasatinib treatment in HER2+ breast cancer. 89Zr-cetuximab
was also employed to measure cell-surface EGFR expression following dasatinib
treatment in triple negative breast cancer. Tumor infiltrating T-cells were measured using
89Zr-anti-CD3

and 89Zr-anti-IFNγ after vaccination in a murine model of breast cancer. All

studies utilized in vitro uptake assays, autoradiography, IHC, and western blots to validate
tracer specificity. PET scans were analyzed after treatment to determine changes in
tracer retention. In each study PET was able to detect tumor uptake changes which
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occurred early (within 1 week) of treatment. Through these projects I provide clinically
relevant imaging strategies to better predict treatment outcomes and aid clinicians in
cancer management.
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